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The major focus for the present study was to examine the effects of provider 
stigmatization on the medical care of HIV+ patients, by using an experimental paradigm 
and examining a conceptual framework to clarify the relationship between provider 
stigmatization and negative treatment outcomes. Initial qualitative findings from focus 
groups (n = 18) indicated that several key elements of stigmatizing treatment experiences 
included judgmental and condescending language, patient avoidance, increased physical 
distance between patient and provider during conversations and procedures, and use of 
extra, unnecessary precautions (e.g. use of extra gloves, masks). These provider 
behaviors were experimentally manipulated and incorporated into computerized vignettes 
containing audio and visual stimuli depicting “typical” medical appointments. In the 
experimental phase, participants (n = 90) were randomly assigned to view either a highly 
stigmatizing or a non-stigmatizing treatment vignette and then subsequently rate their 
willingness to engage in HIV care. Findings indicated that patients assigned to the highly 
stigmatizing condition were the most unwilling to engage in HIV care as demonstrated in 
lower intentions to remain in care, disclose sexual and substance use risk behaviors, and 
discuss medication adherence difficulties. As hypothesized, the effect of the experimental 
stigma condition on patients’ willingness to engage in care was mediated by patients’ 
feelings of comfort and their perceptions of stigma within the patient-provider 
interaction. Findings from the present study may help to inform the development of 
interventions to assist healthcare providers in creating more positive treatment 
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HIV-Related Stigmatization in Treatment Settings: Effects on Patient Comfort and 
Treatment Decisions 
 Over one million people in the United States are currently infected with HIV and 
global estimates indicate that 33 million are now living with HIV/AIDS worldwide 
(UNAIDS, 2007). With the advent of highly active antiretroviral therapy (HAART), 
many who are living with HIV can anticipate sustained viral suppression and much 
improved life expectancy relative to patients living with HIV earlier in the epidemic. 
Despite biomedical advances, HIV-infected individuals still face many challenges, 
prominent among which is the widespread social stigma associated with HIV disease. 
Stigmatization broadly refers to viewing a person, or a group of persons, as devalued, 
spoiled or flawed in the eyes of society, resulting in stereotyping, prejudice, status and 
power loss, social isolation, and discrimination (Crocker, Major, & Steele, 1998). 
Although negative attitudes toward HIV+ individuals have decreased somewhat in recent 
years, HIV-related stigmatization remains prevalent both in the United States and 
globally (Mahajan et al., 2008). Studies suggest that the persistence of HIV-related 
stigmatization is the result of a complex relationship of several interacting factors, 
including misconceptions about HIV being transmitted through casual contact, the 
symbolic association of HIV to homosexuality and drug use, and the belief that HIV+ 
persons are to blame for becoming infected (Pryor, Reeder, & Landau, 1999; Pryor, 
Reeder, Yeadon, & Hesson-McInnis, 2004).  
HIV+ individuals are cognizant of this stigmatization. In a recent clinic-based 
study of 221 HIV+ men and women, 42% indicated that others behaved negatively 
towards them because of their HIV status and 29% reported that people avoid being 
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around them because they are HIV+ (Vanable, Carey, Blair & Littlewood, 2006). Indeed, 
the effects of HIV-related stigma on persons living with HIV are significant and wide 
ranging. A significant proportion of HIV+ persons report experiencing physical violence, 
decreased social support, and job-related difficulties as a result of disclosing their HIV 
status (Berger, Ferrans, & Lashley, 2001; Rothenberg, Paskey, Reuland, Zimmerman, & 
North, 1995; Vara-Diaz, Serrano-Garcia, & Toro-Alfonso, 2005; Zierler et al., 2000). 
Stigma-related experiences also contribute to stress and adjustment difficulties in HIV+ 
individuals (Clark, Lindner, Armistead, & Austin, 2003; Lee, Kochman, & Sikkema, 
2002). In addition, research indicates that stigma interferes with disease management, 
inhibits disclosure of HIV status to sexual partners, and undermines HIV prevention 
efforts among at-risk populations (Chesney & Smith, 1999; Lindau et al., 2006; Vanable 
et al., 2006).  
Provider Stigmatization: A Focus on Patient Self Care and Transmission Risk 
Reduction 
The experience of stigmatization in health care settings may be particularly 
detrimental to the health and well being of persons living with HIV. Treatment advances 
and the advent of HAART have allowed many HIV+ individuals to live longer and 
healthier lives (Wood et al., 2003), but successful management of HIV requires strict 
adherence to demanding medication regimens, careful attention to diet and health 
behaviors, and vigilant efforts to control infections that can harm the immune system 
(Agne, Thompson, & Cusella, 2000; Bodenlos et al., 2007). Healthcare providers, 
including physicians, nurses, and medical students, play a critically important role in 
overseeing care for persons living with HIV. In so far as instances of negativity and 
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discomfort among providers likely contribute to poor patient-provider communication, 
provider stigma may reduce patients’ willingness to attend appointments, reduce 
serostatus disclosure to healthcare providers, and interfere with patient comprehension of 
important medical instructions (Bodenlos et al., 2007; Catz, Kelly, Bogart, Benotsch, & 
Mcauliffe, 2000; Heckman, Catz, Heckman, Miller, & Kalichman, 2004). Indeed, 
provider stigmatization may greatly impact the care received by HIV+ individuals, 
though few studies have examined this assertion. As such, the present study aims to fill 
this gap by examining the impact of provider stigmatization on several aspects of HIV 
medical care related to communication, patients’ psychological comfort, and the 
disclosure of behaviors that may compromise HIV+ patients’ health. 
Provider Stigmatization in the Context of Patient-Provider Interactions 
 Existing research suggests that the development and maintenance of positive 
patient-provider relationship plays an especially important role in predicting which 
patients will remain in care and openly discuss their risk behaviors and medication 
adherence difficulties (Mallinson, Rajabiun, & Coleman, 2007). For persons living with 
HIV, initial interactions with medical providers serve as a critical opportunity to develop 
positive patient-provider relationships. Instances of provider stigmatization, expressed 
through specific behaviors and overall demeanor, can presumably create barriers to the 
process of gaining the trust necessary for a strong working relationship between HIV+ 
individuals and their treatment providers. Qualitative reports from HIV+ individuals 
indicate that stigmatizing experiences at the time of disclosure can lead to decreased trust 
in current providers and also deter serostatus disclosures with future healthcare providers 
(Agne, Thompson, & Cusella, 2000). Indeed, unsatisfactory treatment experiences (in 
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general) have been found to negatively influence patients’ perceptions and expectations 
of their providers, with reduced trust in one’s provider predicting decreased adherence to 
HIV clinic appointments (Whetten, et al., 2006).  
 The CDC reports that 75% of HIV+ persons are aware of their diagnosis, and of 
those, approximately one third are not receiving HIV care (Glynn & Rhodes, 2005). 
Although attributable to a variety of causes, this statistic demonstrates that despite being 
aware of one’s HIV status, barriers exist which deter some HIV+ individuals from 
enrolling or remaining in HIV care. Demonstration of stigmatizing behaviors from a 
healthcare provider may be one of these barriers, with HIV+ persons’ decisions to enroll 
in treatment potentially being deterred by previous experiences with stigmatizing 
demeanor or actions of providers. The failure to enroll in HIV care not only poses a 
substantial health risk to HIV+ persons, but has also been found to contribute to increased 
HIV transmission, as HIV+ persons who forgo treatment often have been found to have 
higher viral loads and therefore pose a greater risk for infection to their sexual partners 
(Kalichman, Rompa, Luke, & Austin, 2002). Studies are needed which examine possible 
deterrents to enrollment in HIV care.   
 Open communication within a patient-provider relationship has perhaps become 
an even more important issue in recent years, as CDC guidelines now recommend that 
HIV care providers deliver HIV-prevention services to identify and reduce patients’ 
transmission related risk behaviors at routine medical visits (Grodensky, Golin, Boland, 
Patel, Quinlivan, & Price, 2008). Effective interventions necessitate the honest and 
accurate disclosure of one’s transmission related risk behaviors, which in turn requires a 
certain level of trust within the patient-provider relationship. These prevention efforts not 
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only serve to protect the health of HIV+ individuals’ sexual partners and the larger 
population, but also have the potential to protect HIV+ patients themselves in terms of 
becoming infected with other sexually transmitted diseases which may compromise their 
health further.  
 Positive patient-provider relationships are also a critical element in interventions 
with substance using HIV+ patients. HIV+ patients who perceive stronger relationships 
with their provider are more likely to discuss their substance use at medical visits 
(Metsch, et al., 2008). Subsequently, engaging in discussions of substance use with HIV+ 
care providers is associated with increased likelihood of entering into substance abuse 
treatment (Korthuis, et al., 2008). In this context, stigmatizing experiences may decrease 
HIV+ patients’ willingness to disclose risky substance use behaviors, thereby precluding 
any chances to effectively intervene with the patient.  
 Similar concerns pertain to sexual risk behaviors and medication adherence, such 
that providers demonstrating stigmatizing behaviors may decrease the chance of their 
patients being forthright about sexual risk-taking and adherence difficulties. Indeed, 
research points to an association between poor patient-provider relationships and reduced 
adherence to highly active antiretroviral therapies (HAART) regimens (Johnson, et al., 
2006; Schneider, Kaplan, Greenfield, Li, & Wilson, 2004). Without a strong sense of 
trust in their providers, patients may be less able to effectively manage the side-effects of 
HAART, the complexity of dosing schedules, and the special dietary instructions that 
make it difficult to maintain the level of adherence required to ensure complete viral 
suppression (Bangsberg, et al., 2001; Chesney, 2003; Trotta, et al., 2002). Thus, 
stigmatization among providers may serve as a significant barrier to high quality patient 
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care by way of its effects to the patient-provider relationship in general, and more 
specifically its effects to the areas of communication regarding disclosure of risk 
behavior and subsequent patient receptivity to risk reduction messages from providers. 
With provider-based intervention initiatives garnering more attention and support in HIV 
research, it is critical to undertake studies that increase our understanding of the 
mechanisms through which provider stigmatization may interfere with provider based 
efforts to promote sexual risk reduction, medication adherence, and related health 
behavior changes.  
 As medical providers continue to play a critical role in promoting the health and 
well-being of HIV+ individuals, it is important to understand if certain behaviors within 
the treatment settings may be perceived as stigmatizing by patients and hence detract 
from this process. Thus, the major focus for the present study was to examine the effects 
of provider stigmatization on several important aspects of HIV treatment. More 
specifically, the study uses both qualitative focus groups and an experimental paradigm 
to (1) identify key characteristics of stigmatizing treatment experiences and (2) 
characterize the association of HIV-related stigmatization to patients’ decisions to enroll 
in care, disclose risky sexual and substance use behaviors, discuss medication adherence 
difficulties, and their willingness to engage in conversations related to risk reduction and 
promotion of self care. The present study tests the hypothesis that the presence of 
stigmatization in patient provider interactions will decrease the willingness of HIV+ 
patients to engage in the above mentioned elements of HIV treatment related to intentions 
to enroll in care, intentions to openly communicate with their providers, and decisions to 
disclose sensitive health information related to sexual risk, substance use, and medication 
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adherence difficulties. By utilizing an experimental paradigm that assesses HIV+ 
patients’ reactions to hypothetical vignettes of stigmatizing and non-stigmatizing patient-
provider interactions and then their subsequent decisions to engage in various aspects of 
HIV care, the present study extends the limited field of research evaluating the impact of 
provider stigmatization. 
HIV-related Stigmatization within Treatment Settings  
 An important basis for conducting the present study lies in the fact that 
stigmatization within healthcare settings remains prevalent even today. Nearly 30 years 
into the epidemic, available data provides evidence to suggest that a significant subset of 
healthcare providers still harbor stigmatizing beliefs about HIV+ individuals and 
demonstrate behaviors detrimental to their medical care including patient avoidance, 
inadequate care, differential treatment, and to a lesser extent, refusal of treatment 
(Anderson, Vojir, & Johnson, 1997; Buseh & Stevens, 2006; Carter, Lantos, & Hughes, 
1996; Ladany, Stern, & Inman, 1998; McCann, 1999; McDaniel & Carlson, 1995).  
However, although recent literature has provided much description about the experience 
of HIV-related stigmatization in treatment settings, few studies have examined the impact 
that provider stigmatization may have on the medical care of HIV+ patients. To inform 
the present research examining the impact of provider stigmatization on HIV patients’ 
willingness to engage in care and communicate openly with their providers, it is 
important to first review the general literature surrounding provider specific, HIV-related 
stigmatization. Reviewed qualitative and quantitative findings describe the widespread 
nature of provider stigmatization as experienced by HIV+ patients, examining 
frequencies of specific provider behaviors and providing detailed accounts of 
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stigmatizing treatment experiences and the ways in which HIV+ patients’ perceive 
provider behaviors and demeanor. Studies examining the effects of provider stigma 
receive a more detailed examination. The review reports on studies occurring since 1995, 
as a thorough review of earlier studies was completed by Eldridge and St. Lawrence 
(1995). Broadly, earlier findings indicated a high occurrence of stigmatizing attitudes and 
behaviors from providers including blaming HIV+ individuals for their infection, 
unfounded fear of contagion, and frequent treatment refusals. For the current review, an 
emphasis was placed on identifying gaps and limitations in existing research, hence 
providing a basis for the importance of conducting the present study.     
 Provider behaviors indicative of stigmatization were categorized as those 
pertaining to (1) subtle indicators related to provider demeanor and (2) more overt 
indicators tied to specific aspects of provider care. Behaviors demonstrating a negative 
demeanor are those which are often perceived by a patient as stigmatizing, but the intent 
behind such behaviors is largely unknown (Rintamaki et al., 2007). They include 
nonverbal and verbal communication of negative affect, such as irritations or anger, 
nervousness, or fear at having to work with HIV+ individuals. In contrast, stigmatizing 
behaviors in the form of care provision are more overt and may directly compromise 
treatment (Rintamaki et al., 2007). As shown in Table 1, a total of 14 studies provide 
qualitative or quantitative data on stigmatizing behaviors of healthcare providers as 
reported by HIV+ patients. The table specifies each study’s sample size, participant 
characteristics, design, objectives, and major findings, while also summarizing the 
study’s limitations and method in which provider stigma was operationalized and 
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assessed. Table 2 provides a summary of the stigmatizing behaviors examined by each 
study. 
Stigmatizing Behavior Related to Demeanor  
 As the experimental paradigm of the present study utilizes vignettes incorporating 
both visual and audio elements to depict patient-provider interactions, the success of the 
study design relies heavily on the accurate depiction of both stigmatizing and non-
stigmatizing provider behaviors and treatment experiences. As such, it is important to 
understand precisely which behaviors HIV+ patients note as indicative of a stigmatizing 
treatment experience in terms of both subtle cues of a provider’s demeanor and attitude, 
as well as more overt behaviors. This first section of the review examines findings from 
studies that report data on negative demeanor among providers, as reported by HIV+ 
patients. Behaviors demonstrating a negative demeanor are those that are often perceived 
by a patient as stigmatizing, but the intent behind such behaviors is largely unknown 
including judgmental language, nonverbal behaviors, expression of discomfort, and 
negative affect. Though these demeanor-related actions may not have as obvious a 
detrimental impact as a refusal of treatment, they remain some of the most reported 
negative experiences of HIV+ patients, especially in more recent years.  
 Judgmental or deficient communication. Seven qualitative studies reported data 
on negative experiences within the realm of provider communication (see Table 2). Some 
of the most frequently reported negative experiences of HIV+ patients involved 
providers’ use of judgmental language. Language of this nature often pertains to making 
attributions about a patient’s acquisition of HIV, blaming the patient for their infection, 
and judging patients negatively based on their HIV+ status. Another complaint noted in 
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this literature pertained to the general lack of communication between the patient and 
provider as related to the HIV+ individuals’ health, medication, prevention, or other 
treatment details. In two studies focusing on the experiences of HIV+ mothers (Lindau et 
al., 2006; Marcenko & Samost, 1999), a subset of participants reported experiences in 
which nurses and physicians spoke to them in ways that indicated moral disapproval of 
their decision to become pregnant while HIV+. In Blake et al. (2008), a qualitative study 
focusing on HIV testing and care experiences, many of the HIV+ women in the sample 
(n=64) noted deficits in providers’ willingness to communicate with them about 
prevention strategies and treatment elements.  
 In three other qualitative studies (Buseh & Stevens, 2006; Rintamaki et al., 2007; 
Surlis & Hyde, 2001), patients described experiences in which providers made negative 
attributions about the route in which they became infected. For example, in a study 
conducted by Buseh and Stevens (2006), an African American woman reported that her 
physician assumed she became infected through intravenous drug use because of her 
ethnicity. More overt accounts of victim blaming were noted in Rintamaki et al.’s (2007) 
study of HIV+ veterans, with one participant reporting pain during a blood draw, upon 
which the nurse replied, “If you hadn’t done this to yourself, we wouldn’t have to be 
going through this!” (pp. 963). Similar accounts of blaming were noted by intravenous 
drug users in Surlis and Hyde’s (2001) qualitative study of HIV+ individuals receiving 
nursing care in a hospital setting. Thus, findings regarding judgmental communication 
appear to demonstrate a high frequency of patient blaming and negative judgment of 
HIV+ individuals. 
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 Nonverbal behaviors related to proximity, eye contact, and extra 
precautions. Three studies reported provider stigmatization as experienced through 
inadequate eye contact, increased distance between the patient and provider, or the use of 
seemingly unnecessary precautions during health visits (Blake et al., 2008; Lindau et al., 
2006; Rintamaki et al., 2007). All of these studies were qualitative in nature, with patients 
providing firsthand accounts of their treatment experiences. HIV+ patients reported 
“being stared at and watched” by providers (Blake et al., 2008), as well as receiving “the 
sort of looks” that denoted negative judgment (Lindau et al., 2006). HIV+ veterans 
(Rintamaki et al., 2007) reported perceiving stigma when providers demonstrated less 
than adequate amounts of eye contact and distanced themselves during treatment visits. 
Among veteran participants (N=50), some recounted experiences in which physicians 
placed themselves across the room, behind another patient’s bed, and even out in the 
hallway to discuss treatment or other AIDS-related issues (Rintamaki et al., 2007). Such 
behaviors not only risk injuring the patient emotionally, but also threaten their rights to 
confidentiality. In both Blake et al.’s (2008) qualitative study of HIV+ women and 
Rinktamaki et al.’s (2007) qualitative study of HIV+ veterans, patients reported the use of 
extra gloves in situations in which one pair of gloves was likely adequate. An additional 
account noted surgeons wearing protective suits and face shields during a discussion 
taking place well in advance of a patient’s surgery (Rintamaki et al., 2007). Patients 
reported a heightened sensitivity to the precautions taken by providers, as they had 
witnessed incidents in which the precautions taken with them were noticeably different 
than those taken with other patients. Although limited to only three qualitative studies, 
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these studies nonetheless provide narrative accounts of the way in which nonverbal 
behaviors of providers can be perceived as stigmatizing among HIV+ patients. 
 Expression of discomfort or negative affect. Four studies (1 qualitative and 3 
quantitative) reported stigmatizing experiences related to provider discomfort or 
expression of negative affect (see Table 2). HIV+ veteran patients in Rintamaki et al. 
(2007) reported many instances in which their providers were overtly nervous or fearful 
during treatment, as well as experiences where providers demonstrated hostility, 
irritation, and anger through their facial expressions, vocal tones, or other non-verbal 
mannerisms. Most apparent examples of such behavior occur when providers shifted their 
demeanor immediately after discovering the patient’s HIV+ status. For example, Kinsler 
et al. (2007) reported that 20% of the HIV+ participants they surveyed (N=223) reported 
that a healthcare provider had been uncomfortable with them since learning of their HIV 
diagnosis. Similarly in the quantitative study by Schuster et al. (2005), 20% of surveyed 
participants from a nationally representative sample of HIV+ individuals (N= 2466) 
reported the experience of being seen by a physician who appeared to be uncomfortable 
around them after learning that they were HIV+. Discomfort and negative affect were 
also assessed in a final quantitative study (Thrasher et al., 2008) that examined the 
relationship between discriminatory healthcare experiences and adherence to HAART. 
Though statistics for individual items were not listed, 41% of the HIV+ participants 
(N=1886) reported experiencing at least one of the six discriminatory healthcare 
experiences, two of which were associated with provider affect and discomfort. Thus 
findings across the four studies assessing provider discomfort suggest that a small but 
significant proportion of HIV+ patients perceive their providers to be uncomfortable 
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around them and note affective displays of negativity in the form of irritability, 
nervousness, or anger. 
Stigmatizing Behavior Related to Provision of Care 
 In contrast to above findings related to provider demeanor, stigmatizing behaviors 
in the form of care provision can be considered more overt stigma encounters which 
compromise the medical treatment of HIV+ individuals including patient avoidance, 
delayed treatment, lack of touch, differential or inadequate care, and treatment refusal. 
Though stigmatization of this nature occurs at a lessened frequency than compared to the 
start of the epidemic, HIV+ patients nonetheless continue to report experiencing these 
provider behaviors. As such, they are relevant to the present study and will inform the 
content of both the qualitative focus groups and the treatment vignettes of the 
experimental phase of the study. Stigmatization findings related to the provision of care 
are reviewed below. 
 Patient avoidance or delayed treatment. Eight studies (5 qualitative and 3 
quantitative) provided reports of experiences in which treatment was delayed or patients 
were avoided by their providers presumably because of their HIV status (see Table 2). In 
four qualitative studies, patients reported incidents in which their appointments were 
delayed for extended periods (Blake et al., 2008; Marcenko & Samost, 1999), staff would 
not bring them their food (Buseh & Stevens, 2006), and physicians would not 
acknowledge their presence in the room (Rintamaki et al., 2007). Indeed, quantitative 
survey data from Schuster et al. (2005) and Kinsler et al. (2007) indicated that between 
18% and 19% of HIV+ participants reported perceiving that some healthcare provider 
preferred to avoid them. As both Schuster et al. (2005) and Kinsler et al. (2007) utilized 
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the same item, “Since you have had HIV, has any health care provider preferred to avoid 
you?”, it is unclear what specific act of avoidance the participants might be reporting on 
(e.g. canceling appointments, avoiding touch, etc.). In the qualitative study by Surlis and 
Hyde (2001), hospital patients who had become infected with HIV through intravenous 
(IV) drug use were more likely to report that nurses ignored them as compared to those 
infected through homosexual activity. They believed they were avoided even more so 
because of the combination of their HIV status and their IV drug use. In sum, both 
qualitative and quantitative studies suggest that a significant minority of HIV+ patients 
report experiences in which they were avoided or felt ignored by their providers.  
 Lack of touch during treatment. A majority of health visits require providers to 
physically touch their patients to perform assessments (blood pressure, physicals) and 
procedures (dressing wounds, surgeries). As such, when providers decrease their level of 
touch, or refuse to do so altogether, treatment quality may decline. In two of the reviewed 
qualitative studies (Blake et al., 2008; Lindau et al., 2006), patients reported incidents in 
which their providers refused to touch them and perform physical examinations. In both 
studies focusing on HIV+ women, participants reported feeling subsequent shame (Blake 
et al., 2008) and threats to their safety, with one woman reporting that she had even been 
transported to another hospital by taxi because no one wanted to touch her (Lindau et al., 
2006). Though literature is limited, available qualitative reports denote that providers’ 
unwillingness or aversion to touching HIV+ individuals remains an important issue and 
concern for some patients. 
  Inadequate or differential treatment. Six studies (3 qualitative and 3 
quantitative) reported data concerning the question of whether HIV+ patients perceived 
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that they received differential or inadequate treatment based on their serostatus (see Table 
2). For example, veteran patients in Rintamaki et al.’s (2007) qualitative study reported 
that health providers sometimes spent inadequate time on their needs, leaving them to 
experience unnecessary pain during procedures. Irish hospital patients from another 
qualitative study (Surlis & Hyde, 2001) indicated that providers treated them 
differentially based on their mode of infection, with patients infected through IV drug use 
believing they received the poorest care.  
 Two quantitative studies also reported findings related to inadequate or 
differential treatment due to HIV status. In a survey study by Elford et al. (2008), 14% of 
HIV+ patients recruited from HIV outpatient clinics in London (N=1385) reported that 
they had been treated differently or unfairly by a healthcare provider because of their 
HIV status. Differential or unfair treatment was reported to occur most often from 
dentists (25%), followed by general practitioners (17%), with 5% noting unsatisfactory 
treatment by healthcare providers at HIV specialty clinics. In contrast, participants in 
Bodenlos et al.’s (2007) study of patients’ attitudes towards their healthcare providers in 
an HIV clinic setting reported high levels of satisfaction in terms of their providers’ 
treatment efforts and overall quality of care. Thus, findings regarding the quality of care 
HIV+ patients perceive they are receiving appear to be mixed, with two studies noting a 
high frequency of poor or differential care (Elford et al., 2008; Rintamaki et al., 2007) 
and another reporting high ratings of healthcare quality (Bodenlos et al., 2007). 
 Treatment refusal. Treatment refusal based on a person’s HIV status is the most 
overt form of stigmatization. Such experiences were noted in six of the reviewed studies 
of patient reports of provider stigmatization (see Table 2). Approximately 4% of African 
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American females sampled (N=366) in Wingwood et al.’s (2007) qualitative study 
reported being denied medical care as a result of being HIV+. Higher incidence of 
treatment refusals were noted in quantitative, survey-based studies by Schuster et al. 
(2005) and Kinsler et al. (2007), with 8% and 19% of patients reporting this experience 
respectively. In addition to an outright denial of care, treatment refusals can take the form 
of refusal to perform certain procedures or being referred to other providers. For 
example, in qualitative studies focusing on the treatment experiences of HIV+ veterans 
(Rintamaki et al., 2007) and HIV+ mothers (Lindau et al., 2006), participants provided 
accounts of nurses refusing to draw blood, dentists refusing to pull teeth, and incidents in 
which they presented with emergency needs and were transferred to other hospitals after 
providers learned of their serostatus. In sum, recent findings denote that a subset of HIV+ 
individuals still encounter refusals for medical treatment, though at a decreased frequency 
relative to studies carried out earlier in the epidemic (Weinberger, Conover, Samsa, & 
Greenberg, 1992). 
Summary 
 The reviewed studies of provider stigmatization provide information on the extent 
to which HIV+ patients continue to have stigmatizing experiences within medical care 
settings and validate the need for conducting the present study. Indeed, as provider 
stigma remains a concern for a subset of HIV+ patients, studies examining its impact are 
needed. Although differences in study methodologies and sampling strategies preclude 
definitive prevalence estimates, both qualitative and quantitative data from the review 
suggest that a significant minority of HIV+ patients continue to experience stigmatization 
in healthcare settings. Findings suggest that some HIV+ patients experience negativity 
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from health care providers, including judgmental communication, increased distance 
during treatment, lessened eye contact, the use of unnecessary precautions, and the 
expression of discomfort or negative affect. While stigmatization related to the direct 
markers of HIV care provisions (e.g., inadequate care, refusal of treatment) was noted to 
occur less frequently, such behaviors were nonetheless experienced by a subset of HIV+ 
patients sampled across studies. Indeed, patients reported multiple instances where 
providers (1) avoided, delayed, or refused treatment, (2) were uncomfortable with or 
avoided direct physical contact with patients, and (3) instances where treatment was 
inadequate or differential because of a patient’s HIV status. The reviewed literature 
describing experiences of provider stigmatization in the form of both negative demeanor 
and altered provision of care informs the design of the present study in terms of the 
content of the qualitative focus group interview guide as well as the development of the 
hypothetical treatment vignettes used in the experimental phase of the study.  Although 
existing studies provide a foundation for understanding which provider behaviors are 
perceived to be stigmatizing by HIV+ patients, qualitative focus groups will be helpful in 
informing on more recent experiences of provider stigmatization, as well as provider 
behaviors that have occurred most often specifically among the present study’s sample 
population. 
Impact of Provider Stigmatization on HIV Care 
 The studies reviewed thus far focus on providing descriptive data to characterize 
stigmatization as perceived by HIV+ patients. Several quantitative studies focus more 
broadly on the question of whether provider stigmatization is associated with markers of 
treatment access and self care, including appointment attendance, HAART adherence, 
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access to care, and perceived quality of care. A review of this literature provides a 
foundation for the present study, as the included studies are the few examples of 
correlational research examining the impact of provider stigmatization on HIV care. 
Although the present study focuses specifically on the impact of provider stigmatization 
on HIV+ patients’ decisions to engage in care and willingness to discuss sensitive topics 
like sexual and substance use risk behaviors and medication adherence, reviewed findings 
nonetheless offer initial data on the impact of stigmatization on aspects of HIV self care 
and patients’ perceptions of the care they receive.  
 Appointment attendance. Regular appointment attendance is integral to the 
successful management of HIV. During routine clinic visits, providers monitor disease 
status and immune functioning, make treatment adjustments, provide support for 
medication adherence, and strive to control infections that can harm immune systems. In 
Bodenlos et al. (2007), findings indicated that HIV clinic patients (N=109) who perceived 
less provider stigmatization reported better appointment attendance. Indeed, low 
stigmatization and a positive provider relationship, combined with having a large social 
support network and being on a HAART medication regimen accounted for 27% of the 
model’s variance in predicting appointment attendance. This finding is particularly 
relevant to the present study, as one of the outcomes of interest pertains to HIV+ patients’ 
intentions to remain in care following a stigmatizing treatment experience. Findings from 
Bodenlos et al. (2007), suggest that the experience of provider stigmatization does indeed 
play a role in predicting which patients are more likely to actively engage in care, as 
defined by consistent appointment attendance. 
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 Quality and access to care. Two studies examined the association between 
provider stigmatization and access to care, defined in terms of affordability, availability, 
convenience, and specialist accessibility. First, in Kinsler et al. (2007), 26% of a sample 
of HIV+ men and women recruited from medical centers, outreach programs, case 
management services, and HIV clinics in the Los Angeles area (N=223) endorsed at least 
one item indicating experiences of provider stigmatization (See Table 1). Fifty-eight 
percent of the sample also endorsed at least one of six items related to low access of care, 
with bivariate and multivariate analyses indicating that higher perceptions of provider 
stigmatization at baseline assessment were associated with lower access to care at the six 
month follow-up assessment (Kinsler et al., 2007). Second, Schuster et al. (2005) 
confirmed their hypothesis that higher perceptions of provider stigmatization would be 
related to lower access to care among their nationally representative sample of 2466 
HIV+ individuals, using the same measures utilized by Kinsler et al. (2007). The authors 
(Schuster et al., 2005) also found that patients reporting higher levels of stigmatization 
were more likely to report receiving a lower quality of medical and hospital care. Taken 
together, findings from these two studies denote that patients perceiving higher levels of 
stigmatization from their providers are more likely to report lower access to care and 
lower quality of care received. As two of the stigma items utilized in Kinsler et al. (2007) 
and Schuster et al. (2005) related to patient avoidance and treatment refusal, these 
findings suggest provider stigmatization may affect an HIV+ individual’s access to care 
by limiting the amount of available treatment centers they are able receive care at. In 
addition, after experiencing negative interactions with providers, patients may be 
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reluctant to return follow up appointments or seek out other treatment even when in great 
need (Kinsler et al., 2007).  
 HAART adherence. A study conducted by Thrasher et al., (2008) examined the 
association of healthcare discrimination and provider distrust to HAART adherence, with 
an emphasis on explaining potential disparities in adherence based on racial/ethnic 
differences. Discriminatory experiences directed towards HIV+ patients did not emerge 
as a predictor of adherence difficulties. Further, a hypothesized mediating path between 
ethnicity, provider stigmatization, and adherence was not supported. However, findings 
did indicate that discriminatory experiences were associated with provider distrust and 
weakened belief in the effectiveness of HAART, variables which subsequently predicted 
adherence difficulties. Thrasher et al.’s (2008) findings speak to importance of 
considering indirect pathways in understanding the effect of stigmatization on health and 
treatment outcomes by way of stigma’s effects to the patients’ perceptions of their 
providers. Drawing from this research, the present study has also considered patients’ 
perceptions of the provider and feelings within the treatment interaction as relevant 
factors to explaining the effect of stigmatization on HIV+ patients’ decisions to engage in 
care.  
Summary 
 Three studies provide data on the relationship of provider stigmatization to 
treatment outcomes of HIV+ patients. Taken together, they provide initial data on the 
impact of perceived stigmatization from healthcare providers on HIV care, both in terms 
of the treatments provided by healthcare workers and also in patients’ efforts regarding 
self care. These reviewed correlational studies provide initial evidence for a link between 
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provider stigmatization and detrimental effects to treatment in terms of lower perceived 
quality of care, lower access to care, decreased appointment attendance, and to a lesser 
extent, lower HAART adherence. Although additional research is needed to address 
methodological limitations, reviewed findings provide preliminary evidence to suggest 
that provider stigmatization negatively impacts the medical care of HIV+ individuals. 
Findings provide a strong basis for conducting the present study, which will contribute to 
the small literature that has examined the impact of provider stigmatization on aspects of 
HIV treatment and self care. The present study will also extend the literature by 
providing the first experimental examination of this area of study. 
Limitations of Existing Studies 
 The reviewed literature documents the existence of HIV-related stigmatization 
among healthcare providers and its potential effects to the medical treatment and self care 
of HIV+ patients. However, several inconsistencies and gaps in our understanding of 
provider stigmatization exist due to methodological limitations within the literature. 
Limitations of the present literature include a general lack of studies examining the 
impact of provider stigma, a lack of quality and consistency in the measures used to 
assess provider stigma, and a lack of studies utilizing experimental designs to examine 
the experience of provider stigmatization and its impact on various aspects of HIV care 
and HIV+ patients’ perceptions of their treatment experiences. Such limitations are 
discussed, with attention paid to how the present study addresses them through both its 




Lack of Studies Examining the Impact of Provider Stigma 
 Broadly, there is a need for studies that specifically aim to examine the effects of 
provider stigmatization on the medical care of HIV+ individuals. Although several 
qualitative studies provide anecdotal evidence for the link between provider 
stigmatization and poor treatment outcomes, there are relatively few empirically-based 
studies that examine such questions. Those that do exist are correlational in nature. A 
growing number of well-designed, theoretically informed studies have begun examining 
the impact of societal stigma on HIV+ individuals’ emotional and physical health. 
Indeed, experiencing HIV-related stigmatization (not provider-specific) negatively 
impacts mental health (Berger et al., 2001; Clark et al., 2003), as well as contributes to 
delays in entering into care, lapses in medication adherence, and fewer status disclosures 
to physicians (Chesney & Smith, 1999; Vanable et al., 2006). Research on provider-
specific stigmatization would benefit from a greater focus on empirically-based studies 
that seek to document the impact of stigma on the medical treatment of HIV+ individuals 
including engagement in care, patient-provider communication, and issues related to risk 
behavior and medication adherence. The present study helps to fill this gap in the 
literature, clarifying how provider stigmatization can affect the above mentioned HIV 
treatment and self care variables. 
Lack of Quality in the Conceptualization and Measurement of Provider-specific 
HIV Stigmatization 
 In stigmatization research, the operationalization and assessment of HIV-related 
stigmatization varies widely across studies. This lack of consistency in stigma 
measurement creates difficulties when trying to generalize and compare findings across 
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studies and over time (Eldridge & St. Lawrence, 1995; Mahajan et al., 2008; Nyblade, 
2006). For empirically-oriented studies involving patient self-report, measures are often 
restricted to small item sets and narrowly focused on extreme behavioral markers of 
stigmatization such as treatment refusal. Recent qualitative studies provide a richer 
understanding of the stigma experiences of HIV+ individuals within treatment settings, 
and future research would benefit from incorporating this information into the 
development of better tools to assess perceptions of provider stigma. The present study 
addresses this limitation, as its operationalization of provider stigma is multifaceted in 
nature. The study incorporates findings from previous literature and information gathered 
from qualitative focus groups to create detailed representations of provider stigma in 
vignettes depicting a range of provider behaviors related to both demeanor and the 
provision of care.  
 Reviewed studies also lacked time-sensitive language in their measures, often 
assessing instances of stigma since the time of diagnosis. This approach not only lacks 
the specificity required to capture current trends related to stigmatization in treatment 
settings, but is also prone to error associated with memory recall difficulties.  Needed are 
studies that capture more in-the-moment measures of patient perceptions of provider 
treatment behaviors.  The present study’s design addresses this limitation as well, 
requiring HIV+ patients to rate their level of psychological comfort (e.g. level of worry, 
nervousness, etc.) and beliefs about the patient-provider relationship immediately 
following the presentation of (potentially) stigmatizing behaviors in a hypothetical care 
visit via a computer program. This design indeed allows for time-sensitive assessments of 
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reactions to provider stigma and lessens the possibility of recall errors often found in 
traditional survey based studies.  
Lack of Experimental Study Designs  
 In the few existing studies that examine the impact of HIV+ patients’ perceptions 
of provider stigma, none have utilized an experimental design to examine stigma’s 
association with negative treatment outcomes. Indeed, past research has relied solely on 
self report measures of perceptions of provider stigma within the treatment setting and 
has been correlational in nature. A major limitation of these studies pertains to the 
potential risk of attributional biases. Indeed, all of the patient-based studies 
operationalized provider stigma as behaviors perceived by HIV+ patients to be 
stigmatizing, with no outside validation of the providers’ actual behaviors. Given the 
historically negative treatment of HIV+ individuals within our culture, HIV+ patients 
may be especially prone to perceiving threat or injustice in situations that may actually be 
benign (Chapman, 2002; Frable, Blackstone, & Scherbaum, 1990). As such, HIV+ 
persons may be more alert to potential threats, hyperaware of people’s treatment toward 
them, and potentially more likely to label neutral behavior as stigmatizing.  
 The use of an experimental paradigm, as utilized in the present study, has the 
potential to address these limitations and advance stigmatization research in several ways. 
First, relative to correlational studies, experimental designs allow for an examination of 
the causal effects of stigmatizing provider behaviors to HIV+ patients’ perceptions of 
treatment experiences and their decisions to engage in HIV care in terms of treatment 
enrollment, disclosure, and receptivity to risk reduction messages.  Secondly, an 
experimental design allows for the level of stigmatizing behaviors demonstrated by 
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providers to be controlled and manipulated across HIV+ patient subjects, thereby limiting 
the effects of attributional biases in the examination of stigma’s impact on HIV care. The 
vignette design of the present study allows for an examination of the potentially 
differential effects of having a highly stigmatizing treatment experience as compared to a 
treatment experience characterized by more neutral or positive provider behaviors while 
controlling for the exact stimuli being perceived by the patients (via the creation of the 
standardized vignettes). In this design, the patients’ perceptions of the provider behaviors 
are directly assessed through their self report, while the exact provider behaviors that are 
being experienced by the HIV+ patients are controlled in the standardized vignettes.  
Indeed, it is yet unknown which of the two, the behaviors or the perceptions of the 
behaviors, is more closely linked (if either) with treatment outcomes of HIV+ patients.  
 In sum, the existing literature pertaining to HIV-related, provider stigmatization 
informs the focus, content, and design of the present study. Limitations of previous 
research leave a gap in our understanding of the impact of provider stigmatization on the 
lives of HIV+ individuals. The present study begins to address these limitations and 
advances the current state of provider stigmatization research. 
Theoretical Considerations of the Present Study 
 The theoretical framework of the present study integrates findings from the 
provider stigmatization literature with the broader literature on patient-provider 
relationships to help explain the ways in which negative provider interactions may 
influence patients’ decisions to engage in medical care. The Interaction model of Client 
Health Behavior (IMCHB; Cox, 1982), described below, informs the mediational model 
utilized in the present study.  The mediational model of the present study is described in 
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detail, drawing reference from the IMCHB model while also elaborating on its own 
unique focus on the effects of provider stigmatization on HIV+ patients’ feelings of 
psychological comfort (e.g. level of worry, nervousness, etc.), intentions to enroll in care, 
intentions to openly communicate with the provider, and their disclosure of sensitive 
health information related to sexual risk behaviors, substance use, and lapses in 
medication adherence. 
The Interaction Model of Client Health Behavior  
 Although not specific to HIV care literature, the Interaction Model of Client 
Health Behavior (Cox, 1982) provides a useful framework for considering the role of 
patient-provider interactions in determining health outcomes. Indeed, this model captures 
the dynamic relationship between patient background characteristics, cognition, affect, 
and patient-provider interactions in predicting patient health outcomes, and has been used 
in its entirety or in parts as the guiding framework in studies predicting a range of health 
outcomes, including the use of prenatal care (Cox & Roghmann, 1984), engagement in 
self breast exams (Cox, Montgomery, Rai, McLaughlin, Steen, & Hudson, 2008), weight 
control behaviors (Troumbley & Lenz, 1992), children’s physical activity and diet 
(Robinson & Thomas, 2004), and satisfaction with medical care (Benkert, Hollie, 
Nordstrom, Wickson, & Bins-Emerick, 2009). The Interaction Model of Client Health 
Behavior (IMCHB) is multidimensional and dynamic, as illustrated in Figure 1. Of 
relevance to the present study, the IMCHB describes (1) individual patient characteristics 
(client singularity) and (2) patient-provider interactions as the elements of care most 
predictive of health outcomes. 
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 Individual patient characteristics. Individual patient characteristics include 
demographic background, availability of social supports, environmental constraints, 
previous experiences in healthcare, as well as their level of motivation to engage in 
healthcare. In addition, the IMCHB model also posits that each patient will differ from 
other patients in their cognitive appraisal of and affective response to their medical 
condition and treatment process. The model dictates that these aspects of client 
singularity have important effects on the subsequent patient behavior and treatment 
outcomes, such that the characteristics, cognitions, and emotions of an individual will 
first affect how they behave in patient-provider interaction, which will then affect health 
outcomes. Findings from Cox et al. (2008) and Troumbley and Lenz (1992) provide 
support for the importance of considering patient characteristics when predicting patient 
behavior and treatment outcomes. In both studies, participant background characteristics 
were found to be predictive of health behaviors, with findings from Troumbley and Lenz 
also demonstrating that patients with psychological distress are more likely to engage in 
risky health behaviors and have poorer health outcomes (e.g. risky driving, high blood 
pressure, experience illness, etc.). 
  Patient-provider relationship. According to Cox’s (1982) model, positive 
patient-provider interactions are defined in large part by the provider’s ability to 
demonstrate their competency, provide affective support, give the patient control in 
decisions, and provide health information in the proper amounts as based on the highly 
individualized needs of the patient. Failure of providers to correctly assess and 
subsequently meet the patient’s needs within the patient-provider interaction may 
negatively affect the patient health care decisions, behaviors, and treatment outcomes by 
 28 
lowering the patient’s level of motivation and self confidence and skewing their appraisal 
of their health status, treatment needs, and quality of care received (Cox, 1982).  For 
example, in Benkert et al.’s (2009) examination of the IMCHB model, findings 
demonstrated that the complex relationship between patients’ racial identity and their 
perceptions of the client-professional relationship had significant effects on patients’ 
satisfaction with primary care. The patient-provider interaction element included in the 
present study is more narrowly focused than that originally described in the IMCHB 
(Cox, 1982), using standardized vignettes to portray specific aspects of patient-provider 
relationships related to provider stigmatization. 
Model of the Present study 
 The present study adapts several aspects of the IMCHB model to examine the 
impact of provider stigmatization on HIV+ patients’ engagement in treatment. Both 
patient characteristics and treatment interactions were incorporated into the present 
study’s conceptualization of how provider stigmatization effects patients’ decisions to 
engage in treatment. Patient characteristics are operationalized as participant 
demographics and previous experiences with stigmatization in healthcare settings. 
Characteristics related to cognitive appraisal and affective response are operationalized in 
the present study as perceptions of stigmatization and their psychological comfort (level 
of worry, nervousness, etc.) within the patient-provider interaction respectively. For the 
present study, engagement in treatment is operationalized in terms of patients’ intentions 
to enroll in care, intentions to openly communicate with their provider, and the disclosure 
of sensitive health information related to sexual risk behaviors, substance use, and lapses 
in medication adherence. Specifically, the model posits that HIV+ patients’ perceptions 
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of stigmatization for a hypothetical patient-provider interaction and their feelings of 
psychological comfort with the provider will mediate the relationship between the 
experimental manipulation of provider stigmatization and HIV+ patients’ decisions to 
engage in treatment (See Figure 2). It is proposed that when providers engage in 
stigmatizing behaviors, HIV+ patients’ (1) perceive the devaluing nature of these 
behaviors, (2) their perceptions of the patient-provider relationship are harmed, and (3) 
their level of psychological comfort (e.g. level of worry, nervousness, etc.) within the 
treatment setting will decrease. A patient’s lowered sense of comfort, perceptions of 
stigmatization, and negative perceptions of the patient-provider relationship would then 
negatively influence their decisions to remain in care, disclose sensitive health 
information, and engage in discussions related to sexual risk behaviors, substance use, 
and medication adherence difficulties. 
 The role of motivational biases. In focusing specifically on outcome variables 
related to the disclosure of sensitive health information, the present study also considers 
the potential role of motivational biases in our conceptualization of the effects of provider 
stigmatization of patients’ disclosure of socially sensitive health behaviors.  In particular, 
it is believed that patients who experience stigmatization and negativity during a medical 
visit may be motivated to under-report socially sensitive behaviors because of concern 
about the possibility of experiencing further stigmatization from the provider.  
The literature on self-report accuracy for socially sensitive behaviors suggests that 
impression management and social desirability biases can lead to underreporting of 
behaviors that are seen as socially unacceptable (see e.g., Schroder, Carey, and Vanable, 
2003). Thus, research suggests that patients disclose higher rates of sexual risk behavior 
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when they are assured of anonymity relative to when they are asked about their past 
behaviors in a face to face interview (e.g., Des Jarlais, 1999; Metzger et al., 2000).  
Likewise, individuals are more likely to under-report substance use behaviors as the level 
of privacy afforded in the mode of assessment decreases (Moskowitz, 2004; Wright, 
Aquilino, Supple, 1998). Patients also vary in their degree of concern about impression 
management, and such differences help to explain under-reporting of substance use 
behaviors (e.g., Davis, Thake, and Vilhena, 2010). 
 Within the present study’s framework, motivational biases to under-report 
sensitive health behaviors are considered to be of potential relevance to the proposed 
mediational model. Put simply, when a HIV+ patient perceives that their provider is 
behaving in disrespectful or uncaring manner because of their HIV status, they may 
experience discomfort with the idea of communicating openly with the provider. In turn, 
patients may be reluctant to disclose socially sensitive behaviors because of fear that such 
disclosures will elicit increased negativity and judgment from the provider. That is, 
patients will likely underreport risky behaviors related to sexual behavior, substance use, 
and medication lapses in an effort to avoid further feelings of shame and to present 
oneself in a more positive light (e.g. “the good patient”). As such, the model posits that 
participants’ who engaged in the stigmatizing treatment interaction (vs. the non-
stigmatizing vignette) would be less likely to disclose accurate (and potentially 
embarrassing) information regarding their risk behaviors, as a function of their decreased 
feelings of comfort with the provider and their perceptions of being devalued by the 
provider because of their HIV status.  
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Summary of the Mediational Model 
 The present study tests the hypothesis that provider stigmatization within a 
medical visit will negatively impact HIV+ patients’ decisions to engage in treatment and 
openly communicate with the provider. It was predicted that patients’ perceptions of this 
stigmatization and discomfort with the hypothetical provider would mediate the 
relationship between the experimental manipulation of provider stigmatization and HIV+ 
patients’ decisions to engage in treatment. The mediational model of the present study 
draws upon several elements of the IMCHB (Cox, 1982) by incorporating both client 
characteristics (e.g. participant demographics, past stigma experiences, psychological 
comfort, and perceptions of stigma) and treatment interactions in its conceptualization of 
how provider stigmatization effects patients’ decision to openly communicate with 
providers and disclose sensitive information.  The model also draws upon the literature 
on self-report biases to support the hypothesized effects of stigmatization on disclosure of 
sensitive self-report data.  Indeed, the basic tenets of the IMCHB (i.e. client singularity 
and patient-provider interactions) are relevant in examining the effects of provider 
stigmatization on the health and treatment outcomes of HIV patients, in so much as 
negative provider attitudes and behaviors may be detrimental to the formation of the 
patient-provider relationship, impair a provider’s ability to provide needed emotional 
support, detract from the provision of health and treatment messages, decrease patients’ 
feelings of psychological comfort, and negatively affect patients’ perceptions of the care 
they receive. Within the framework of the present study, provider stigmatization was 
hypothesized to negatively impact health outcomes via its impact on patient-provider 
interactions and subsequent negative changes to patients’ level of motivation to engage in 
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care, their need to present themselves in a socially desirable fashion, and their trust in 
their provider. The present study examines this model, hypothesizing that the relationship 
between provider stigmatization and HIV+ patients’ decisions to engage in treatment (i.e. 
intentions to enroll in care, intentions to openly communicate with provider, disclosure of 
sensitive health information) would be mediated by HIV+ patients’ perceptions of 
stigmatization within the hypothetical patient-provider interaction and their comfort with 
the provider.  
Overview of the Present Study 
The major focus for the present study was to examine the effects of provider 
stigmatization on several important aspects of HIV treatment related to patients’ 
decisions to engage in care, including intentions to enroll in HIV care, intentions to 
engage in discussions related to risk behaviors, adherence challenges, and risk-reduction 
strategies, and the actual disclosure of sexual risk behavior, substance use, and lapses in 
medication adherence.  Although many recent studies have documented the existence of 
stigmatization in medical treatment settings, few have examined the impact of provider 
stigmatization on HIV+ patients’ decisions to engage in various aspects of HIV care,  and 
none have utilized experimental designs to address limitations inherent in survey based 
studies. The small existing literature supports an association between provider 
stigmatization and lower appointment attendance, lower access to care, and to a lesser 
extent, reduced HAART adherence, among HIV+ patients. However, conclusions are 
limited by the correlational nature of the findings. The present study addresses these 
limitations by not only exploring the extent to which HIV+ patients perceive 
stigmatization within the treatment setting, but also examining the effects these 
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perceptions of stigma have on their decisions to engage in important aspects of HIV care 
including issues related to disclosure, patients’ psychological comfort, and willingness to 
participate in risk reduction conversations.  
In using an experimental design, the present study utilizes a standardized and 
behaviorally oriented approach to assessing patient’s reactions to stigmatization in health 
care settings. In so doing, the present study advances a conceptual framework to clarify 
the relationship between provider stigmatization, patients’ feelings of psychological 
comfort and perceptions of stigma in the patient-provider interaction, and aspects of HIV 
care pertaining to HIV+ patients’ willingness to disclose risk behaviors, engage in risk 
reduction discussions, and enroll in care. Outcome variables as a whole are referred to as 
“engagement in care.” Specifically the model of the present study posits that the 
relationship between provider stigmatization and HIV+ patients’ engagement in care will 
be mediated by HIV+ patients’ perceptions of stigmatization within the hypothetical 
patient-provider interaction and their sense of psychological comfort (with regard to the 
provider in general and specifically in relation to engaging in conversations related to 
sexual risk behavior, substance use, and medication adherence).  
The present study also examines demographic characteristics and previous 
experiences of provider stigmatization as possible covariates or moderators for the 
proposed model. For example, the study explores whether differences in a participant’s 
degree of previous experiences with provider stigmatization alter the strength of the 
hypothesized causal relationship between the experimental stigmatization manipulation 
and participant’s subsequent decisions to engage in care. In the study’s experimental 
paradigm, HIV+ patients were randomized to provide ratings of either a highly 
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stigmatizing or a non-stigmatizing hypothetical treatment encounter with a physician 
described as very competent in treating HIV+ patients. Patients provided several ratings 
of general feelings of psychological comfort (e.g. level of worry, nervousness, etc.) with 
the provider while viewing the hypothetical treatment vignette and provided ratings 
regarding their comfort discussing risk behaviors with the provider, perceptions of 
stigmatization within the hypothetical patient-provider interaction, and their subsequent 
decisions to engage in various aspects of HIV care (e.g. intentions to enroll in care, 
disclose of sexual and substance use risk behaviors, and intentions to participate in 
medication adherence and risk reduction conversations) after the presentation of the 
vignette.  
By using an experimental paradigm and characterizing the mechanisms through 
which provider stigmatization affects HIV+ patients’ decisions to engage in care, the 
present research fills an important gap in the literature. An understanding of the 
mechanisms underlying the patients’ decisions to engage in care and openly 
communicate with their providers will help to highlight areas where changes to provider 
demeanor, language, or behaviors may be especially helpful. As such, the current 
research may inform the development of interventions to assist healthcare providers in 
creating more positive treatment experiences for their HIV+ patients to improve 
implementation of self care and reduction of risk behaviors. Qualitative focus groups 
informed the development of the hypothetical treatment vignettes of the experimental 
phase of the present study. Hypotheses for this between-subjects study were tested using 
an experimental paradigm assessing HIV+ patients’ reactions to medical treatment 
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scenarios that vary in their degree of provider stigmatization, as depicted using visual 
representations and audio recordings of the hypothetical patient/provider interactions.  
Aims and Hypotheses of the Present Study  
  Utilizing both qualitative focus groups and an experimental paradigm, the present 
study aims to: (1) identify key characteristics of stigmatizing treatment experiences 
among men and women receiving HIV treatment, (2) validate vignettes depicting 
stigmatizing and non-stigmatizing treatment interactions, and (3) characterize the 
association of HIV-related stigmatization to patients’ decisions to enroll in care, disclose 
risky sexual and substance use behaviors, discuss medication adherence difficulties, and 
their willingness to engage in conversations related to risk reduction and promotion of 
self care. The present study utilizes a between-subjects experimental design, randomizing 
participants into “stigma” and “non-stigma” vignette conditions. Vignette conditions 
depicting hypothetical patient-provider interactions varied based on the visual stimuli and 
audio recordings presented to the HIV+ participants using a computer program developed 
with MediaLab software (Jarvis, 2006). HIV+ participants were asked to imagine that 
they were the patient depicted in the hypothetical treatment vignette and then rated their 
feelings of psychological comfort, perceptions stigmatization within the patient-provider 
relationship, and decisions to engage in various aspects of HIV care.  
 The randomized stigma vignette condition serves as the study’s independent 
variable of interest. The mediational variables of the present study include HIV+ patients’ 
perceptions of stigmatization within the hypothetical patient-provider interaction and 
ratings of the patients’ psychological comfort with the provider (generally and in relation 
to discussing sensitive sexual, substance use, and adherence-related information) assessed 
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after individual, potentially stigmatizing provider behaviors are displayed. The dependent 
variables include several treatment outcomes pertaining to HIV+ patients’ decisions to 
engage in care. Specifically, the present study focuses on patient’s intentions to remain in 
care, intentions to discuss risk behaviors and risk reduction strategies, and actual 
disclosure of sexual risk behaviors, substance use, and lapses in medication adherence to 
the provider described in the hypothetical vignettes. What follows is a summary of the 
aims and the major study hypotheses.  
 Aim 1: To conduct qualitative research that will help to identify key 
characteristics of stigmatizing treatment experiences. The first aim of the present 
study was achieved through the use of three qualitative focus groups, totaling 18 HIV+ 
men and women, with the aim of determining what elements of patient-provider 
interactions were perceived to be most stigmatizing. These responses informed the 
development of vignettes to be used during the validation and experimental phases of the 
present study. 
 Aim 2: Validate vignettes depicting stigmatizing and non-stigmatizing 
treatment interactions. The second aim of the present study was achieved by 
conducting a small pilot study to examine the validity of the vignettes as depictions of 
stigmatizing and non-stigmatizing treatment interactions. HIV+ patients (n = 20) viewed 
both of the computerized vignettes, rated their level of psychological comfort (e.g. level 
of worry, nervousness, etc.) with the featured providers, rated their perceptions of the 
stigmatizing nature of the vignettes, and also provided verbal feedback to the research 
assistant about suggestions for improving the vignettes. Revisions to the vignettes would 
have been based on a lack of statistical differences in psychological comfort and 
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stigmatization ratings provided for the two vignette conditions, though such revisions 
were not necessary. 
 Aim 3: To characterize the association of HIV-related stigmatization to 
patients’ decisions to engage in medical care. A major goal of the present study was to 
determine whether stigmatization within medical treatment settings affects HIV+ 
patients’ decisions to enroll in HIV care, intentions to communicate openly with their 
providers about risk and self-care behaviors, and the self-reported disclosure of risky 
sexual behavior, substance use, and lapses in medication adherence. This aim was 
achieved by assessing HIV+ patients’ reactions to medical treatment vignettes depicting 
either high levels of provider stigmatization or no stigmatization and their subsequent 
decisions to engage in various aspects of HIV care. Reactions to the vignette were 
operationalized as participants’ perceptions of stigmatization within the hypothetical 
patient-provider interaction and their ratings of psychological comfort with the 
hypothetical provider (generally and in relation to disclosure of sensitive sexual, 
substance use, and adherence-related information) following the presentation of the 
patient-provider interaction. Following the presentation of the vignette, participants rated 
their intentions to enroll in care, and their intentions to engage in conversations related to 
risk behaviors and self care. Participants were also asked to disclose personal risk 
behaviors related to sexuality, substance use, and lapses in medication adherence. The 
vignette and all study measures were administered via a computer program designed 
using MediaLab software (Jarvis, 2006).   
 Hypothesis 1: Impact of provider stigmatization on patient comfort and 
perceptions of stigmatization within the patient-provider interaction. It was 
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hypothesized that the presence of provider stigma would lead to lower ratings of patient 
psychological comfort and higher perceptions of stigmatization within the patient-
provider interaction. Specifically, it was hypothesized that patients assigned to the 
“stigma” treatment vignette would report lower levels of comfort with the provider and 
increased perceptions of stigmatization within the patient-provider interaction following 
exposure to stimuli demonstrating various provider behaviors (e.g. eye contact, level of 
touch, etc.) as compared to those in “non-stigma” condition.  
 Hypothesis 2: Effects of provider stigmatization on patient engagement in 
care. It was hypothesized that the presence of provider stigma would lead to lower 
engagement in HIV medical care. Specifically, it was hypothesized that patients assigned 
to the “stigma” treatment vignette would report lower intentions to engage in care as 
compared to those in “non-stigma” conditions.  This would be demonstrated by lower 
intentions to enroll in care and lower intentions to engage in conversations related to 
risky sexual behaviors, substance use, and medication adherence difficulties. In addition, 
it was predicted that participants in the “stigma” group would report lower rates of 
disclosure of actual sexual risk behavior, substance use, and lapses in medication 
adherence.  
 Hypothesis 3: Mediating effects of patient comfort and perceptions of 
stigmatization on engagement in care. It was hypothesized that lower ratings of 
psychological comfort and higher perceptions of stigma within the patient-provider 
interaction would lead to lower engagement in HIV medical care.  In particular, it was 
hypothesized that patients reporting lower levels of comfort and higher perceptions of 
stigma within the patient-provider interaction featured in the vignette would also report 
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lower willingness to enroll in care, engage in conversations related to risky sexual and 
substance-related behaviors, discuss medication adherence difficulties, and disclose 
personal risk behaviors to the provider from their vignettes. Further, it was hypothesized 
that participants’ feelings of comfort and perceptions of stigmatization within the patient-
provider interaction would mediate the effect of stigmatization (as operationalized as 
“stigma” and “non-stigma” randomized conditions) on patients’ decisions to engage in 
care. 
Exploratory Aim 1: Examine the impact of previous experiences of provider 
stigmatization on participants’ feelings of psychological comfort, their perceptions 
of stigmatization within the treatment vignettes, and their decisions to engage in 
care. An exploratory aim of the study was to test whether participants’ previous 
experiences with provider stigmatization influenced the strength of the relationship 
between provider stigmatization and participants’ subsequent decisions to engage in care. 
In particular, the present study seeks to clarify whether past negative experiences impact 
patients’ psychological comfort in a treatment setting (as tested using the vignette 
methodology), their perceptions of patient-provider interactions, and their future 
decisions to engage in care.  
Orientation to Methods, Results, and Discussion Sections 
 The presentation of the methodology, results, and discussion sections of the 
present study are organized according to the three phases of the protocol: qualitative 
focus groups, validation sub-study, and the experimental phase. Hence, descriptions of 
the major aims, participants, measures, procedures, analytic strategy, results, and 
discussion are first presented for Phase 1, followed by separate methodology and 
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results/discussion sections for Phase 2, and finally those for Phase 3. Detailed recruiting 
procedures are noted in the description of Phase 1. 
Phase 1: Qualitative Focus Groups 
  The major aim of Phase 1 was to conduct qualitative research that would help to 
identify key characteristics of stigmatizing treatment experiences. Participant responses 
would inform the development of vignettes to be used during the validation and 
experimental phases of the present study. 
Methods 
 Participants. Eighteen HIV+ male and female adults were recruited during 
outpatient medical visits at the University Hospital Outpatient Infectious Disease (ID) 
Clinic, a teaching hospital affiliated with State University of New York (SUNY) Upstate 
Medical University. University Hospital is a Designated AIDS Care center providing 
outpatient and inpatient medical care for HIV infected people from the 15 county Central 
New York area, with an active outpatient population of approximately 785 HIV+ 
patients. Women and individuals from minority groups were included in this study. One 
third of the sample (n=6) was comprised of women, 61% were African American, 22% 
were Caucasian, and among men, 66% identified as men who have sex with men (MSM). 
Three focus groups (6 participants each) were conducted. 
 Measures. 
 Background characteristics and health history. Demographic and medical 
history data were collected to characterize the sample (See Appendix A). Demographic 
questions were assessed using standard questions developed in previous research with the 
population. Because health-related factors may relate to participants’ willingness to 
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engage in HIV care, patients also reported on several health indicator variables including 
viral load and CD4+ counts at last clinic visit, presence of AIDS diagnosis, time since 
HIV infection, and current medications. 
  Qualitative interview. A qualitative interview guide was utilized to facilitate 
discussion for three focus groups. Each focus group lasted approximately two hours. 
Focus group content pertained to participants’ experiences of HIV-related stigmatization 
within healthcare settings, positive experiences with providers, and suggestions for 
improving HIV-related healthcare experiences. Further details of the interview process 
are included in the procedures section.  
 Procedures.  
 Recruitment. For all phases of the study, the principal investigator (PI) worked in 
collaboration with staff at the Infectious Disease Clinic to recruit HIV+ patients during 
routine visits. A designated health care provider (e.g., triage nurse) informed patients 
about the opportunity to participate in the study and obtained verbal assent from patients 
regarding their willingness to be introduced to the PI. Patients who provided oral assent 
(to meet with the research staff) were then introduced to the PI or research assistant who 
provided a description of the study. The study description stated that the purpose of the 
research was to identify what medical provider behaviors are perceived as stigmatizing 
by HIV+ patients and to gain a better understanding of how providers’ behaviors  can 
affect the care of HIV+ patients. Eligibility for the all phases of the study was limited to 
those who were HIV+, at least 18 years of age, English-speaking, and physically and 
psychologically capable of providing informed consent as determined by treatment 
providers.  
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 Study protocol. After the initial meeting with the PI, qualitative focus group 
participants were informed of the time, date, and location of the focus groups and 
scheduled accordingly. Upon arriving for the focus group, participants were again given a 
thorough description of the requirements, risks, benefits, and confidentiality protections 
of the study, as outlined in the qualitative interview protocol (See Appendix C).  
Participants were then asked to sign consent forms (See Appendix D), complete a brief 
demographics sheet (See Appendix A), and participate in a two-hour discussion group.  
After the completion of the group, participants were compensated $20 for their time, and 
signed a receipt (Appendix E) before leaving the lab.  
 Data collection. At the time of the focus group, the facilitator first provided an 
overview of the focus group procedures and provided an overview of the consent form. 
After participants provided informed consent, they completed a brief demographics 
survey. Then, the focus group began with initial introductions of group members and the 
facilitators (PI and additional graduate student assistant).  
 Next, the facilitator initiated the focus group by asking a series of questions 
designed to prompt a discussion about both stigmatizing experiences in medical treatment 
settings, as well as  and positive experiences interactions with medical providers (See 
Appendix B). Participants were first asked about any negative experiences they have had 
in medical care, with respect to the providers’ behaviors, the participant’s subsequent 
feelings, and their perceptions about why they were treated poorly. After this introduction 
to negative treatment experiences, participants were asked more specifically about 
experiences of provider stigmatization. They were questioned about what they perceive 
stigmatization to be and also given a definition consistent with how it has been previously 
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defined in research to help direct discussions. Initial questions were open-ended, asking 
participants to report on treatment experiences (early and more recent) they found to be 
stigmatizing. Facilitators asked follow-up questions to clarify (1) what aspects of the 
provider interaction were stigmatizing and (2) how the participant came to attribute the 
negative behaviors to HIV-related stigmatization (vs. racial stigma, poor social skills, 
poor medical skills, etc.). Following the open discussion of stigmatizing and positive 
provider interactions, facilitators inquired about provider behaviors reported by HIV+ 
individuals in previous studies but not yet mentioned by the present study’s participants 
(e.g. eye contact, distance, etc.). Subsequent questions prompted discussions surrounding 
HIV+ participants’ perceptions of the emotional, social, and treatment-related effects of 
experiencing stigmatization from a healthcare provider. Closing discussions explored 
participants’ ideas for improved interactions with medical providers and obtain feedback 
about their participation in the focus group. 
 Qualitative data synthesis. Each focus group was audio-taped and reviewed 
several times by the principal investigator, with extensive notes taken upon each review. 
The process of data synthesis entailed the PI completing an open-coding of the detailed 
notes to capture maximum detail and complexity in the data. The focus group interview 
guide topics served as the initial framework upon which the coding classification scheme 
was derived, with additional topics pertinent to stigmatizing treatment experiences that 
emerged during the focus groups being added to the classification scheme. Coding was 
structured to differentiate stigmatizing treatment experiences related to provider’s overt 
behaviors, treatment practices, demeanor, and language, as well as document the 
commonality of patient experiences and the relative frequency of which they occurred.  
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Results and Discussion 
 Focus group participants reported a variety of stigmatizing experiences, including 
those related to provider demeanor, as well as more serious instances of stigmatization 
related to provision of care. As shown in Table 3, the most frequently reported 
experiences of provider stigmatization were related to judgmental language and 
avoidance and distancing within the exam room, with 56% and 44% of focus group 
participants (n = 18) reporting such instances respectively. In one instance, a female 
participant who had sought treatment for chest pain reported that upon disclosure of her 
HIV status to a hospital nurse, “Her demeanor changed. She was less friendly and 
ignored me. I was left hooked up to an EKG machine for three hours. My boyfriend had 
to search the hospital to get someone to help me.” Participants frequently reported being 
blamed for their HIV infection, with providers also making assumptions about the way 
they became infected and speaking to them in condescending manners. One female 
participant noted that when she disclosed her status, a nurse responded, “Well, you 
shouldn’t be out on the street messing around.” Many participants also reported instances 
in which their providers stood far away from them in the exam room and also tried to 
touch them as little as possible during examination procedures like taking blood pressure, 
using a stethoscope, and taking their temperature. Approximately one-third of 
participants (28%) also reported that their providers demonstrated awkward, 
uncomfortable, or nervous body language while treating them or upon finding out that 
they were HIV+.  For example, one participant noted that upon disclosing his status, his 
provider appeared “more cold and standoffish,” adding that “he couldn’t maintain eye 
contact with me.” 
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 Though noted less frequently, participants also reported instances in which 
providers took unnecessary precautions while treating them (22%), provided a lower 
standard of care because of the participants’ HIV status (22%), ignored the patients’ 
symptoms because they were HIV+ (22%), and demonstrated a lack of knowledge in 
HIV-related treatment issues (22%). For example, several participants reported providers 
wearing masks in the exam room during routine check-ups, with one participant reporting 
that his physician put on two pairs of gloves to examine him when he presented with leg 
pain. Two participants reported instances of being denied care entirely.  
 Based on these qualitative data, salient and commonly occurring stigmatizing 
behaviors of providers were identified to inform the development of the treatment 
vignette content utilized in the validity and experimental phases of the protocol. Audio 
and visual stimuli were created based on these identified experiences with consideration 
for the frequency of such occurrences and the capabilities of reproducing such 
experiences via the audio and visual design of the study’s experimental manipulation.  
Phase 2: Validation Sub-study 
The major goal of this small validity sub-study was to validate the present study’s 
treatment vignettes depicting stigmatizing and non-stigmatizing patient provider 
interactions. This goal was accomplished by first creating the vignettes and then 
completing a small pilot study to confirm whether they were believable and adequately 
depicted stigmatizing and non-stigmatizing treatment experiences. 
 A second goal of the validity sub-study was to examine the feasibility and utility 
of using a “short-form” vs. a “long-form” version of the computerized questionnaire. In 
the “short- form” version, the four segments (audio and associated pictures) of the 
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treatment vignettes were presented together, with each segment being presented 
immediately following the preceding segment. Measures of patient comfort and 
perceptions of stigma were presented once following the presentation of the final vignette 
segment. In the “long-form” version, the four segments of the treatment segments were 
presented individually (one at a time), with measures of patient comfort and perceptions 
of stigma being presented after each vignette segment for a total of four presentations of 
such items. Statistical analyses were conducted to determine whether there were 
significant differences in comfort and stigma ratings between short and long form 
versions. If no differences emerged, this would provide justification for using the time-
efficient “short-form” presentation. 
Methods 
 Participants. Twenty HIV+ male and female adults were recruited during 
outpatient medical visits at the University Hospital Outpatient Infectious Disease (ID) 
Clinic for the validity sub-study phase of the present research. Seventy percent of the 
sample was male, 55% identified as Caucasian, 35% identified as African American, 
70% were unemployed, 30% had an AIDS diagnosis, and 85% were on a HAART 
medication regimen. 
 Measures.  
 Background characteristics and health history. Demographic and medical 
history data were collected in order to characterize our sample (See Appendix A). 
Demographic questions were assessed using standard questions developed in previous 
research with the population. Because health-related factors may relate to participants’ 
willingness to engage in HIV care, patients also reported on several health indicator 
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variables including viral load and CD4+ counts at last clinic visit, presence of AIDS 
diagnosis, time since HIV infection, and current medications. 
  Patient comfort. HIV+ patients’ level of psychological comfort within the 
hypothetical treatment interaction was assessed by a brief measure of psychological 
patient comfort developed by Spake et al. (2003). This eight item measure has good 
internal consistency and has previously been used to predict patients’ intentions to remain 
in care with their physicians (Spake & Bishop, 2009). Alpha in the current sample was 
approximately .95 across the experimental “stigma” and “non-stigma” vignettes and short 
and long form versions of the validity study questionnaire program. Participants were 
asked to rate their feelings within the patient-provider relationship depicted in the 
vignette along eight related dimensions, including discomfort-comfort, uneasiness-at 
ease, tense-relaxed, worried-worry free. Although the original measure was rated on a 10-
point dimensional scale, the present study utilized a 7-point dimensional scale to be 
consistent with other study measures (See Appendix F).  In addition, a more specific 
assessment of comfort related to engaging in conversations about sexual risk behaviors, 
substance use, and adherence difficulties was completed at the close of the vignette 
presentation (See Appendix F). Participants were asked (via ACASI) to imagine 
themselves as the patient depicted in the vignette and respond to the psychological 
comfort items. For example: “Please imagine that you are the patient portrayed in this 
vignette. Now rate how you feel interacting with this provider in terms of feeling 
comfortable. Now rate how you feel interacting with this provider in terms of feeling 
worried.”  
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  Responses were rated using a 7-point Likert scale ranging from 1 (extremely 
uncomfortable, extremely worried) to 7 (extremely comfortable, extremely worry free). 
These items were presented to participants completing the “long-form” version four 
times, immediately following the presentation of each of the four segments of the 
hypothetical medical visit. Participants completing the “short-form” version completed 
this measure once following the presentation of the final vignette segment. Each segment 
of the treatment vignette featured one or two provider behaviors being manipulated 
across the two stigma conditions (e.g. eye contact, lack of touch, judgmental language). 
After the vignette presentation, participants completing both the short and long form 
version responded to three additional comfort items pertaining specifically to comfort in 
engaging in conversations with the vignette provider about (1) sexual risk behaviors, (2) 
substance use, and (3) medication adherence-related issues. For the purposes of the 
present validation study, summed psychological comfort ratings (Spake et al., 2003) and 
ratings on individual conversation-related comfort items were treated as separate 
dependent variables. 
 Perceptions of provider devaluation. HIV+ patients’ perceptions of the 
stigmatizing and devaluing nature of the hypothetical treatment interaction were assessed 
following their ratings of psychological comfort (See Appendix F). These items were 
presented to the participants completing the “long-form” version four times, immediately 
following the presentation of each of the four segments of the hypothetical medical visit. 
Participants completing the “short-form” version completed this measure once following 
the presentation of the final vignette segment. Nine items were created by the PI to reflect 
reactions to and perceptions of the treatment interaction as related to the experience of 
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being devalued (a defining characteristic of stigmatization). As defined by Crocker, 
Major, and Steele (1998), a stigmatized person is one whose social identity calls into 
question their humanity, such that the person is devalued, spoiled or flawed in the eyes of 
society. In essence, people who are stigmatized are no longer viewed as individuals, but 
as mere representatives of a particular socially identified and devalued group, and, 
consequently, are assumed to possess many or all of the characteristics associated with 
that group. Items created by the PI reflect these concepts.  
 Participants were asked to imagine that they were the patient in the vignette and 
respond via ACASI to such items as: “I felt devalued by this provider,” “I believe this 
provider made negative judgments about me,” and “I believe this provider was 
comfortable treating me.” Scale ratings reflect a 7-point Likert scale ranging from 1 
(strongly disagree) to 7 (strongly agree). For the purposes of the validation study, the sum 
score of devaluation ratings were treated as the dependent variables of interest. The 
psychometric properties of this measure were examined in terms of its internal 
consistency, with the measure having an alpha of approximately .75 across the 
experimental “stigma” and “non-stigma” vignettes and short and long form versions of 
the validity study questionnaire program. 
  Procedures. 
 Recruitment. Recruitment procedures are described in Phase 1 methodology. 
 Experimental manipulation of provider stigmatization: Patient-provider 
interaction vignettes. A description of the present study’s vignettes depicting 
stigmatizing and non-stigmatizing patient-provider interaction is outlined in the following 
subsections, detailing the technology utilized to present the vignettes, the content of the 
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vignettes, and the format of the vignettes in terms of how they were presented to the 
participants.  
 Technology utilized. MediaLab software (Jarvis, 2006) was used to create a 
computer program that (1) presented the visual and audio elements of the patient-provider 
interaction vignettes, as well as (2) provided a computerized assessment of the study’s 
independent and outcome measures of interest. MediaLab offers a flexible programming 
framework for integrating assessments and experimental content from a variety of media 
formats (e.g., video, audio, PowerPoint, questionnaires). The PI is experienced in 
MediaLab software (Jarvis, 2006) programming, having completed prior research 
utilizing a computerized, hypothetical vignette design (Heath & Vanable, 2009).   
 Vignette content. Creation of the treatment vignettes for the validation and 
experimental phase of the study was informed by the qualitative focus groups that were 
tasked with identifying key elements of provider behaviors that have been experienced by 
HIV+ patients and were considered to be stigmatizing. Based on these findings, and a 
thorough review of prior qualitative and quantitative provider stigmatization research, 
medical visit vignettes incorporated varying levels of the provider’s use of judgmental 
language, spatial proximity, eye contact, negative affect and discomfort, lack of touch, 
respect for confidentiality, and avoidance. The PI also consulted with providers (mostly 
nurse practitioners) at the Infectious Disease Clinic for additional input regarding the 
structure and content of typical, first-time medical appointments (e.g. questions asked, 
procedures completed, length of interactions, etc.).  
 Prior to the presentation of the vignettes, participants were instructed (via audio 
recordings presented on the computer) to imagine that they were the patient depicted in 
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the interaction on the screen. They were asked to take in their surroundings, imagine 
themselves sitting on the exam table, and focus on the thoughts and feelings that they 
might be having. They were informed of the premise of the medical appointment, which 
was described as involving a first time appointment following a move to a new city. They 
were told that although the doctor has the patient’s previous treatment records, he or she 
plans to discuss some of the information for verification and clarification of certain 
details. They were informed that the doctor was very competent in treating HIV+ patients 
and had been practicing at the clinic for several years. After this preliminary information 
was presented to the participants, the presentation of the vignette began.  
 The basic elements of the medical appointment scenario proceeded as follows: (1) 
provider enters room and greets patient, (2) provider chooses a location in the room to sit, 
(3) provider asks about general health and well-being, (4) provider refers to patient’s 
chart and asks about information related to means of transmission (e.g. male-to-male 
sexual contact, male-to-female sexual contact, IV drug use, etc.), recent illnesses and 
procedures, and HIV status indicators (CD4 count, viral load), (5) patient and provider 
discuss medication options, (6) provider does brief physical exam on patient (checks 
heart beat and breathing, examines ears and throat, etc.), (7) provider discusses recent 
headache symptoms with patient, (8) provider summarizes findings to patient and 
outlines treatment plan, (9) provider exits room and returns with headache medications, 
(10) provider returns and alerts patient that they will be asked several questions related to 
sexual risk behaviors and substance use. 
 Throughout the hypothetical treatment visit, specific elements related to provider 
demeanor and behaviors were manipulated, so as to be presented in either stigmatizing or 
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non-stigmatizing ways. This was accomplished through modifying the provider’s use of 
judgmental language, spatial proximity, eye contact, negative affect and discomfort, lack 
of touch, respect for confidentiality, and avoidance. In order to maintain a high level of 
experimental control, the vignettes were standardized so that (1) the credentials of the 
provider described in the vignette were the same (i.e. highly competent), (2) the same 
actors were portrayed in all visual depictions, (3) the same actor’s voice was used to 
portray the provider across conditions, and (4) the flow and content of the treatment visits 
(e.g. greeting, conversations, procedures) was consistent across conditions. The 
presentation of the vignette took approximately ten minutes.   
 Vignette format. Vignettes incorporated photographs of a hypothetical medical 
provider and audio voice recordings to demonstrate varying levels of stigmatization 
within the treatment visit. Photographs and audio recordings for stigmatizing and non-
stigmatizing treatment vignettes differed  in terms of the provider’s use of judgmental 
language, spatial proximity, eye contact, negative affect and discomfort, lack of touch, 
respect for confidentiality, and avoidance. Audio recordings were also used to narrate the 
hypothetical patient-provider interactions, providing step-by-step descriptions of the 
providers’ behaviors throughout the medical visit. Additional audio recordings were used 
to simulate patient-provider discussions, with actors portraying the voices of the patient 
and the provider. Voices for the narrator were provided by the PI, with voices for the 
patient and provider provided by several student actors chosen based on their 
appropriateness for the roles. Both male and female patient versions were created to 
increase participants’ ability to identify with hypothetical patient. Photographs of the 
manipulated provider behaviors were taken by the PI using a high quality digital camera. 
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 Photos of an older student actor (age 30 or older) were used for the vignettes. 
Photos depicted a hypothetical provider engaging in various aspects of the outlined 
vignette scenario in an actual medical examination room to increase believability of the 
interactions. Photographs were presented simultaneously with the corresponding audio 
description of the treatment visit to provide visual representations of the potentially 
stigmatizing provider actions.   
 The treatment vignettes of the patient-provider interactions within the medical 
care visit were presented in four segments, with each segment presenting one or two 
provider behaviors such as eye contact (or lack thereof), judgmental language regarding 
HIV status (or more non-judgmental statements), and placing oneself across the room 
from the patient (as compared to choosing the seat nearest them). Figures 3, 4, 5, and 6 
provide illustrative examples of how the “stigma” and “non-stigma” vignette segments 
were arranged in the long and short form versions of the program.  Though these figures 
are not meant to be exact representations of the visual or audio content of the actual study 
vignettes, they provide an example of the intended general layout and nature of the 
treatment vignettes. The “stigma” condition featured stigmatizing behaviors in all four 
segments and the “non-stigma” condition featured no stigmatizing behaviors in all of the 
segments.  
 Study protocol. After the initial meeting with the PI, validity phase participants 
either followed the investigator to the assigned lab space and immediately completed the 
study protocol (after clinic visit) or were informed of available times and dates and 
scheduled accordingly. Upon arriving for the validity phase of the study, participants 
were greeted by the PI who followed protocol procedures (See Appendix G) and 
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provided a thorough description of the study via the informed consent procedures (See 
Appendix H). The validity phase stimuli and questionnaire battery were administered 
using audio computer-assisted self-interviewing (ACASI) on a desktop computer. Before 
beginning, the PI introduced the computerized study protocol and described how the 
computer program works. The PI answered questions the participant had and confirmed 
the participant’s ability to successfully interact with the computer program.  For 
participants with limited computer exposure, the PI provided additional instruction on the 
use of the mouse and keyboard as necessary.  Participants were also instructed that if they 
had any difficulties with the computer program to ring a bell on the desk and the PI 
would assist them.  
 After completing consent procedures and filling out a brief demographics 
questionnaire (see Appendix A), participants viewed both the “stigma” and “non-stigma” 
vignettes on a computer. The ordering of the vignettes was randomized. Participants in 
the “long form” version of the survey rated their level of comfort (e.g. level of worry, 
nervousness, etc.) with the provider and how stigmatizing they perceived the vignette 
interaction to be after each of the four segments of a vignette, via a questionnaire 
presented on the computer (See Appendix F). Participants completing the “short-form” 
version provided ratings for comfort and perceptions of stigmatization once, immediately 
following the presentation of the fourth vignette segment. Following the presentation of 
both vignettes, participants engaged in a brief discussion with the PI regarding their 
reactions to the vignettes. The discussion assessed whether the “stigma” vignette 
segments were perceived to be adequately stigmatizing by the participant and if they 
were distinguishable enough from the “non-stigma” vignette segments. Suggestions for 
 55 
improving the vignettes were elicited from the participants. After completing this 
protocol, participants were compensated $10.  
 Analytic strategy. Analyses for the validity sub-study consisted of both between-
subjects and within-subjects t-tests to evaluate differences between ratings for the 
“stigma” and “non-stigma” vignettes. Between-subjects t-tests evaluated potential 
differences in psychological comfort and stigmatization ratings between persons viewing 
the “stigma” vignette first and persons viewing the “non-stigma” vignette first. Within-
subjects t-tests evaluated participants’ ratings of comfort and perceptions of 
stigmatization on the “stigma” vignette as compared to their ratings on the “non-stigma” 
vignette. The potential effect of presentation order of the vignettes was also examined. 
All analyses were performed on averaged comfort and stigmatization ratings, with “long-
form” responses averaged across vignette segments to compare with “short-form” 
responses. There was an expectation of significant differences in psychological comfort 
and stigmatization ratings between the stigmatizing and non-stigmatizing manipulations. 
It was also expected that there would not be any statistical differences between comfort 
and stigma scores between short and long form versions.  
Results and Discussion 
 Significant differences in perceptions of stigmatization and comfort ratings were 
found when comparing participant responses to the “stigma” and “non-stigma” vignettes 
when using both the short and long form survey formats (see Table 3). Results from t-
tests also indicated no significant order effects of the presentation of the vignettes, nor 
any significant differences between stigma and comfort ratings when comparing long and 
short form versions of the survey (see Table 3). These latter results provide support for 
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the use of the more time-efficient and participant-favored (via verbal feedback) “short 
form” survey protocol in the experimental phase of this study. Overall, findings support 
the use of the vignettes as a valid experimental manipulation of HIV-related 
stigmatization within a medical treatment setting, as the provider in the “stigma” vignette 
was rated as more stigmatizing/devaluing of his patients and found to induce lower 
feelings of comfort within the treatment setting. As such, no changes were made to the 
content of the vignettes for the experimental phase of the study. 
Phase 3: Experimental Study  
  The major goal of the experimental phase of the present study was to determine 
whether stigmatization within medical treatment settings affects HIV+ patients’ decisions 
to engage in HIV care and communicate openly with their providers about risk and self-
care behaviors such as unprotected sex, drug use, and medication adherence. This goal 
was achieved by assessing HIV+ patients’ reactions to medical treatment vignettes 
depicting either high levels of provider stigmatization or no stigmatization and their 
subsequent decisions to engage in various aspects of HIV care. 
Methods 
 Participants. Ninety HIV+ male and female adults were recruited during 
outpatient medical visits at the University Hospital Outpatient Infectious Disease (ID) 
Clinic for the experimental phase of the present research. Cell sizes between conditions 
were equal, with 45 participants randomized to the “stigma” condition (29 males, 16 
females) and 45 participants randomized to the “non-stigma” condition (29 males, 16 
females). Of the experimental phase participants, 34.4% were female, 69% of males 
identified as MSM, 52% were African American, 71% were unemployed, 22.2% held an 
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AIDS diagnosis, and 83.3% were on a HAART medication regimen. The complete 
demographic characteristics of the experimental sample can be found in Table 5.  
Measures. 
 Background characteristics and health history. Demographic questions were 
assessed using standard questions developed in previous research with the population 
(See Appendix A). Because health-related factors may relate to participants’ willingness 
to engage in HIV care, patients also reported on several health indicator variables, 
including viral load and CD4+ counts at last clinic visit, presence of AIDS diagnosis, 
time since HIV infection, and current medications. 
 Previous HIV-related stigmatization experiences. Past research suggests that 
HIV+ persons may be more alert to potential threats, hyperaware of people’s treatment 
toward them, and potentially more likely to label neutral behavior as stigmatizing 
(Chapman, 2002; Frable, Blackstone, & Scherbaum, 1990). It stands to reason that the 
risk of these appraisals may be heightened if an HIV+ individual has experienced 
previous instances of stigmatization in a healthcare setting. As such, an original measure 
assessing previous experiences with provider HIV-related stigmatization was included in 
the present study to include as a possible covariate or moderator in the model (See 
Appendix I). Fifteen items assessed the number of times the participant had experienced 
various types of stigmatizing experiences while in a healthcare treatment setting. The 
measure contains items related to more demeanor-based aspects of HIV-related 
stigmatization (e.g. lessened eye contact, judgmental language, discomfort), as well as 
stigmatizing behaviors related to the provision of care (e.g. avoidance, differential care, 
refusal of treatment). This measure was presented at the end of the study, and participants 
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reported how many times they have experienced each stigma item as based on a five 
point rating scale ranging from 0 (never) to 4 (more than 10 times). The measure was 
created following a review of the relevant qualitative and quantitative provider 
stigmatization literature and was evaluated in terms of internal consistency (Chronbach’s 
alpha), individual item performance, and factor structure (via exploratory factor analyses) 
following data collection. Factor analyses indicated that the scale performed well as a 
single factor measure, with the model accounting for 57% of the variance explained. This 
measure also demonstrated strong internal consistency with an alpha of .91.   
 Patient comfort. HIV+ patients’ level of psychological comfort was assessed 
following the presentation of the vignette by a measure of psychological patient comfort 
developed by Spake et al. (2003). Further detail about this eight item measure is provided 
in the validity phase methodology. Participants were asked (via ACASI) to imagine 
themselves as the patient depicted in the vignette and respond to the comfort items. These 
items were presented to the participants once, immediately following the presentation of 
the final segment of the hypothetical medical visit. Factor analyses indicated that the 
scale performed well as a single factor measure, with the model accounting for 89% of 
the variance explained. This measure also demonstrated strong internal consistency with 
an alpha of .95. In addition, a more specific assessment of comfort related to engaging in 
conversations about sexual risk behaviors, substance use, and adherence difficulties was 
also completed at the close of the vignette presentation. For the purposes of the 
experimental study, both a composite score of comfort ratings (Spake et al., 2003) and 
individual conversation-related (sexual behavior, substance use, adherence difficulties) 
comfort items were examined as mediator variables of interest. 
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 Perceptions of stigmatization within the patient-provider interaction. 
Perceptions of stigmatization within the hypothetical treatment interaction were assessed 
in two ways (See Appendix K). First, the measure of devaluation that was developed for 
the validity phase of the present study was used (see validity phase methodology for 
detailed description). As described earlier, this subscale consists of nine items (rated on 
7-point Likert scale) created to reflect reactions to and perceptions of the treatment 
interaction as related to the specific experience of being devalued (a defining 
characteristic of stigmatization). Participants were asked to imagine that they are the 
patient in the vignette and respond to the items via ACASI.  
 The second way that perceptions of stigmatization was assessed was through an 
adaptation of the 13-item Engagement with Health Care Providers scale (Bakken, et al., 
2000), with modifications to accommodate the experimental nature of the present study. 
Items from this subscale focus on participants’ perceptions of the patient-provider 
relationship. The original scale has strong internal consistency and has been successfully 
used with HIV+ patient populations (Bakken, et al., 2000; Metsch, et al., 2008). Items 
were modified to assess participants’ beliefs about the future actions of the hypothetical 
providers and nature of the patient-provider relationship presented in the vignettes (e.g. “I 
believe this provider would involve me in treatment decisions.”), rather than assess the 
current nature of their patient-provider interactions (e.g. “My provider involves me in 
treatment decisions.”) as indicated in the original scale. Examples of additional items 
include: “I believe this provider would respect me,” “I believe this provider would care 
about me,” and “I believe this provider would see me when I ask.” Scale ratings reflect a 
7-point Likert scale ranging from 1 (strongly disagree) to 7 (strongly agree). 
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 The psychometric properties of the entire perceptions of stigmatization measure 
were examined in terms of its internal consistency (e.g. Chronbach’s alpha) and factor 
structure via exploratory factor analyses. The factor structure of the entire perceptions of 
stigmatization measure was examined to determine whether the measure in its entirety or 
its potential subscales should be treated as mediator variables in the planned analyses. 
Contrary to original expectations, factor analyses indicated that the scale performed well 
as a single factor measure, with the model accounting for 77% of the variance explained. 
This measure also demonstrated strong internal consistency with an alpha of .96.  
 Engagement in care. HIV+ patients’ engagement in care was assessed using 
several brief measures created specifically for this study (See Appendix L). Engagement 
in care measures served as the primary dependent variables of interest and were assessed 
using two types of items: (1) those that assessed a participant’s intentions to engage in 
various aspects of care, and items that assessed (2) participants’ disclosure of actual risk 
behaviors. Participants’ intentions to engage in care were operationalized as participants’ 
intentions to (1) remain in care with the provider portrayed in the vignette, (2) discuss 
sexual risk behaviors with the provider, (3) discuss substance use with the provider, and 
(4) discuss medication adherence difficulties with the provider. These items were worded 
to assess the likelihood of participants engaging in these various treatment activities and 
will be rated on a 7-point Likert scale ranging from 1 (extremely unlikely) to 7 
(extremely likely). Assessment of actual patient disclosure included nine items pertaining 
to (1) sexual risk behavior, (2) substance use, and (3) lapses in medication adherence. 
Items required participants to report the frequency in which they have actually engaged in 
various risk behaviors.  
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 An assessment approach based on patients’ intentions to engage in care and 
openly communicate with their providers about risky behaviors was utilized to allow for 
a larger pool of responses from the sample. As some participants may not engage in the 
various risk behaviors assessed in the present study, items were worded in terms of their 
intentions to disclose in the hypothetical event that these behaviors had occurred (e.g. “In 
the event that you happened to engage in X, how likely is it that you would disclose this 
to the provider?). Although the more direct assessment of disclosure (e.g. having the 
participant choose whether to actually disclose their own risky behavior to the 
hypothetical provider) has greater external validity, such an approach could potentially be 
limited by the number of participants in the sample who had actually engaged in the 
behavior of interest. As such, it was deemed important to include both an intentions-
based measure of disclosure and a more direct assessment of patient disclosure following 
a potentially stigmatizing treatment experience. The psychometric properties of all 
engagement in care measures were examined to assure their internal consistency (e.g. 
Chronbach’s alpha). 
 Intentions to remain in care. Participants’ intentions to remain in care with the 
provider shown in the vignette was assessed with the single item, “How likely is it that 
you would remain in care with this provider?” and measured on a 7-point Likert scale.  
 Intentions to discuss sexual risk behaviors. Intentions to discuss sexual risk 
behaviors included items related to disclosing unprotected anal/vaginal sex with a steady 
partner of HIV- or unknown serostatus (historically vs. occurrences within the past three 
months), disclosing unprotected anal/vaginal sex with a casual partner of HIV- or 
unknown serostatus (historically vs. occurrences within the past three months), and also 
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initiating a conversation about difficulties achieving and maintaining safer sex practices. 
The decision to use the three month point as the cut off for “recent” sexual experiences is 
based on several findings supporting the reliability of self reports of sexual risk behaviors 
measured at this time frame (Carey et al., 2001; Jaccard et al., 2002; Kauth, St. Lawrence, 
& Kelly, 1991).  As actual sexual risk behaviors were assessed later in the study, items 
assessing intentions to disclose sexual behaviors were also based on the three month time 
frame for the purpose of item consistency. Items were worded in terms of their 
willingness to disclose as based on the hypothetical event that these behaviors had 
occurred (e.g. “In the event that you happened to have unprotected anal sex, how likely is 
it that you would disclose this to the provider?). These items were rated on a 7-point 
Likert scale ranging from 1 (extremely unlikely) to 7 (extremely likely). This measure 
demonstrated strong internal consistency with an alpha of .95. 
 Intentions to discuss substance use risk behaviors. Intentions to discuss substance 
use risk behaviors included items related to disclosing substance abuse and dependence 
(historical vs. recent, alcohol vs. other drugs), disclosing needle sharing, and initiating 
conversations about seeking substance use treatment. Similar to the sexual risk items, 
intentions to disclose substance use were based on a three month time frame to 
distinguish intentions to disclose “recent” vs. “historical” occurrences of risk behavior. 
As some participants may not have engaged in these substance use risk behaviors, items 
were worded in terms of their intentions to disclose based on the hypothetical event that 
these behaviors had occurred (e.g. “In the event that you happened to have shared needles 
during drug use, how likely is it that you would disclose this to the provider?). These 
items will be rated on a 7-point Likert scale ranging from 1 (extremely unlikely) to 7 
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(extremely likely). This measure demonstrated strong internal consistency with an alpha 
of .97. 
 Intentions to discuss medication adherence difficulties. Intentions to discuss 
medication adherence difficulties included items related to disclosure of unintentional 
non-adherence to HAART (e.g. forgetting, misplacing medications, sleeping through 
doses), disclosure of intentional non-adherence to HAART (e.g. purposely skipping 
doses, medication vacations, taking meds not as prescribed), and initiating conversations 
related to difficulties with medication adherence. Similar to the other risk items, 
intentions to disclose adherence difficulties were based on a three month time frame to 
distinguish willingness to disclose “recent” vs. “historical” lapses in medication 
adherence. Items were worded in terms of their intentions to disclose, presuming that 
these behaviors had occurred (e.g. “In the event that you happened to skip taking your 
medications, how likely is it that you would disclose this to the provider?). These items 
will be rated on a 7-point Likert scale ranging from 1 (extremely unlikely) to 7 
(extremely likely). This measure demonstrated strong internal consistency with an alpha 
of .96. 
 Disclosure of health risk behaviors. In contrast to the aforementioned outcome 
variables, items assessing disclosure of health risk behavior assessed the participants’ 
willingness to disclose their actual sexual and substance use related risk behaviors, as 
well as lapses in medication adherence. This measurement domain included nine items 
that assessed the participants’ history of risk behaviors and was designed to closely 
represent the types of risk assessment questions that a provider typically asks during a 
routine medical treatment visit in terms of content, specificity, and quantity (See 
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Appendix L). Items were read to the participants in the voice of the provider (neutral 
tone) in order to mimic as closely as possible what it would be like to disclose sensitive 
information to the provider they viewed in the treatment vignette.  
 Three items assessed history of sexual risk behavior, including number of lifetime 
sexual partners, number of partners in past three months, and percentage of time in which 
condoms were used in the past three months.  
 Four items assessed history of substance use, including two alcohol use items 
assessing quantity and frequency of use in past three months (Quantity Frequency 
method), one item providing a basic assessment of lifetime drug use, and one item 
assessing frequency of drug use in the past three months.  
 Two items were used to assess lapses in HIV medication adherence, with one 
item assessing how long ago a dose of medication was purposely skipped, and another 
item assessing the total percentage of HAART doses taken in the previous week.  
 Other than items related to sexual partner history, disclosure items provided 
participants with categorical, ordered response choices to identify frequency of condom 
use, alcoholic consumption, and missed medication doses, typically on a five point scale. 
The rationale for using a categorical response format was to control for participant error 
in item interpretation, subsequent errors when entering responses, and to eliminate the 
need to handle extreme outlier responses in data analyses. As some items assessed for 
typical behaviors across a time period, categorical responses allow participants to report 
ranges of behaviors, that may be more accurate representations of their activities (vs. 
having to choose one number). Although participants will not see the assigned score of 
their response (e.g. 3-4 alcoholic drinks in one week = 2, more than 6 drinks in one week 
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= 4), these scores were used to describe a basic, relative level of risk present in their 
behaviors. Sexual behavior items related to lifetime and recent number of sexual partners 
were presented in open-response format to allow for the large range of sexual partner 
experiences expected in the clinical participant population, rather than estimate and 
determine meaningful cutoffs for categorical responses.  
 Responses to personal disclosure items were examined individually rather than 
via composite variables after discovering the poor internal consistency of the potential 
subscales. Higher scores on all items were conceptualized to represent increased 
willingness to disclose risk behaviors, rather than actual differences in risk behaviors 
between the stigma and non-stigma experimental groups. This conceptualization was 
based on the assumption that randomization would control for behavioral differences 
between the experimental groups, thus allowing any significant differences in the 
quantity or frequency of reported risk behaviors between groups to be attributed to the 
effects of stigmatization on participants’ willingness to disclose sensitive information . All 
measures assessing HIV+ patients’ decisions to engage in care were presented via 
ACASI, following the complete presentation of the treatment vignettes and the measures 
of patient psychological comfort and perceptions of the patient-provider relationship. 
 Procedures.  
 Recruitment. Recruitment procedures are described in Phase 1 methodology.  
 Experimental manipulation of provider stigmatization. Provider stigmatization 
was operationalized as varying levels of stigmatizing demeanor and treatment behaviors 
presented to HIV+ participants through the use of hypothetical vignettes. Vignettes of 
hypothetical HIV medical care visits incorporated visual and audio stimuli and were 
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presented to participants via a computer screen (for further description of vignettes, refer 
to validity sub-study methodology). Patient-provider interactions in the vignettes were 
manipulated to portray two experimental conditions: “stigma” and “no stigma.” As noted 
previously, the vignettes used in the experimental phase of the present study were 
reviewed by HIV+ patients in the validity sub-study and found to accurately depict 
stigmatizing and non-stigmatizing patient-provider interactions. Scripts for these 
vignettes can be found in Appendix M. As a between-subjects study, participants in the 
experimental phase were randomized to a condition and viewed only one treatment 
vignette. To maintain a high level of experimental control, the vignettes (stigma and no 
stigma conditions) were standardized so that (1) the credentials of the provider described 
in the vignette were the same (i.e. highly competent), (2) the same actor was portrayed in 
all visual depictions, (3) the same actor’s voice was used to portray the provider across 
conditions, and (4) the flow and content of the treatment visits (e.g. greeting, 
conversations, procedures) was consistent across conditions. The “stigma” condition 
featured stigmatizing behaviors in all four segments and the “non-stigma” condition 
featured zero stigmatizing behaviors in all of the segments. For further illustration of the 
presentation of the vignette segments, see Figures 3, 4, 5 and 6.  
 Study protocol. After the initial meeting with the PI, experimental phase 
participants either followed the investigator to the assigned lab space and immediately 
complete the study protocol (after clinic visit) or were informed of available times and 
dates and scheduled accordingly. Upon arrival, participants were greeted by the PI who 
followed protocol procedures (See Appendix N) and provided a thorough description of 
the study via the informed consent procedures (See Appendix O). The experimental 
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stimuli and questionnaire battery were administered using audio computer-assisted self-
interviewing (ACASI) on a desktop computer. Because ACASI affords greater privacy 
over traditional paper and pencil questionnaires and interviewer administered surveys, 
ACASI may have enhanced participants’ willingness to disclose sensitive information 
(Schroder, Carey, & Vanable, 2003). Similar to the validity sub-study, the PI first 
introduced the computerized study protocol, described how the computer program works, 
answered any questions the participant had, and ensured the participant’s ability to 
successfully interact with the computer program.  For participants with limited computer 
exposure, the PI provided additional instruction on the use of the mouse and keyboard as 
necessary.  Participants were also instructed that if they had any difficulties with the 
computer program to ring a bell on the desk and the PI would assist them. Participants 
then completed the small battery of self-report assessments (e.g. demographics, health-
related variables) and responded to one treatment vignette as depicted on the computer 
through visual and audio components. The ordering of the protocol was as follows: (1) 
reporting of background and health information, (2) presentation of the treatment vignette 
with, (3) ratings of psychological comfort, (4) ratings of perceptions of stigmatization 
within the hypothetical patient-provider interaction, (5) ratings on measures assessing 
decisions to engage in care, and (6) ratings on the Experiences of HIV-related 
Stigmatization in Healthcare Settings measure. After completing this protocol, 
participants were compensated $20 for approximately 45 minutes to one hour of their 




Experimental phase analyses.  
 Descriptive and preliminary analyses. The full sample was described using 
summary statistics (frequency, mean, standard deviation) obtained from self-reported 
demographic information, health status variables (i.e., AIDS diagnosis, HIV-related 
hospitalizations), medical history variables (initiation of HAART, time elapsed since 
diagnosis), and past experiences of HIV-related stigmatization in healthcare settings. 
Summary statistics were also generated for the proposed mediating and outcome 
variables of interest (i.e., perceptions of patient-provider relationship, psychological 
comfort, intentions to enroll in care, intentions to disclose sexual and substance use risk 
behaviors, intentions to discuss medication adherence difficulties, and actual disclosure 
of personal risk behaviors). Finally, analyses pertaining to measure reliability and factor 
structure were performed to ensure strong internal consistency of the proposed mediators 
and dependent variables, with particular attention paid to the newly created measures.  
Equivalency between study conditions. To assess for equivalence between the 
“stigma” and “non-stigma” vignette conditions, separate ANOVA and Chi-square 
analyses were performed on demographic variables, health status variables, and the 
measure of past stigmatizing experiences reported during the experimental phase 
protocol. Non-significant findings would indicate that the randomization procedure was 
successful.  Any significant differences in demographic, health status, or past stigma 
characteristics between the conditions would be considered as additional covariates in 
analyses examining primary study hypotheses.  
 Analyses for aim 3: To characterize the association of HIV-related 
stigmatization to patients’ decisions to engage in medical care. First, bivariate analyses 
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were conducted to identify the association between mediators (perceptions of patient-
provider relationship and level of comfort), dependent variables (treatment engagement 
measures), and relevant demographic, health status, past stigma experiences, and medical 
history variables to identify potential covariates and moderators for the mediational 
model. To examine study hypotheses, regression equations were conducted using an 
SPSS macro designed to examine multiple mediator models (Preacher & Hayes, 2008) 
using the product-of-coefficients mediation approach and bootstrapping statistical 
methods. This macro also allows for the statistical control of covariates and comparisons 
between indirect effects in mediation analyses. Separate regression analyses were 
performed for the intentions and disclosure outcome variables representing engagement 
in care: (1) intentions to remain in care, (2) intentions to discuss sexual risk behaviors, (3) 
intentions to discuss substance use, (4) intentions to discuss medication adherence 
difficulties, and (5) disclosure of personal risk behaviors (nine items examined in 
separate regression equations). Stigma condition (stigma vs. no stigma) served as the 
models’ independent variable of interest, with patients’ perceptions of stigmatization 
within the hypothetical patient-provider interaction and levels of psychological comfort 
within the treatment setting serving as the models’ proposed mediators.  
 Support for study hypotheses would be provided by significant unstandardized 
regression coefficients for the direct effect of stigma level on engagement in care 
outcome variables reaching significance at the conventional .05 level. This was similarly 
expected for the regression paths between stigma level and the mediating variables 
regarding perceptions of stigmatization within the patient-provider interaction and 
psychological comfort. Finally, in examining the mediation hypothesis, it was expected 
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that Sobel’s test of the models’ total indirect effects would be significant, demonstrating 
that the effects of stigma on engagement of care are either partially or fully mediated by 
the effects of patient perceptions of stigmatization within the patient-provider interaction 
and patients’ psychological comfort.  
Results 
 Equivalency between study conditions. T-test and Chi-square analyses revealed 
few differences between participants randomized to the “stigma” and “non-stigma” 
conditions on demographic variables, health status variables, and the measure of past 
stigmatizing experiences reported during the experimental phase protocol. As noted in 
Table 5, the only significant difference noted was for paid work hours, with participants 
in the “stigma” condition reporting significantly more work hours than those in the “non-
stigma” condition, t(23) = -2.07, p = .05. However, as only 24 participants were included 
in this analyses (due to high rates of unemployment among participants) and work hours 
was not significantly related to study outcome measures, it was not selected as a covariate 
in subsequent analyses. These largely non-significant findings indicate that the 
randomization procedure was successful.  
 Descriptive findings. In performing initial descriptive analyses, all mediating and 
“intentions-based” outcome variables were found to have normal distributions, with no 
signs of significant skew or kurtosis. In contrast, seven of the nine disclosure-based 
outcome variables presented with non-normal distributions as a function of significant 
skew, and in some cases, the presence of extreme outliers (lifetime and recent sexual 
behavior items). Such outcome variables were transformed using log transformations to 
correct for skew, with extreme outliers also truncated to three standard deviations away 
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from the mean. All analyses were performed using both original and transformed 
versions of variables, with no significant differences in outcome noted. Statistics 
presented within the text and associated tables and figures report findings from analyses 
performed with the transformed variables.  
 As shown in Table 6.1, significant correlations were noted between the mediating 
variables of the present study (perceptions of stigma, general comfort, and specific 
disclosure comfort measures), between the intention-based outcome variables, and finally 
between the mediators and the intentional outcome variables. Correlations were in the 
expected direction, with perceptions of stigma being significantly (negatively) correlated 
with comfort measures (other mediating variables) and intention-based outcome 
measures assessing intentions to a) remain in care, b) disclose sexual risk behavior, c) 
disclose substance-related risk behavior, and d) disclosure medication adherence 
difficulties. In contrast, comfort-based mediating variables were positively correlated 
with intention-based outcome variables, such that higher levels of comfort were 
associated with greater likelihood to remain in care and disclose risk activities.  
 Only two significant associations were noted for mediators and disclosure-based 
outcome variables. As noted in Table 6.2, the only significant correlations were found 
between general patient comfort and report of number of sexual partners in the past three 
months (r = -.22, p < .05) and also between comfort related to discussion of sexual risk 
and report of lifetime number of sexual partners (r = -.23, p < .05).  Contrary to study 
hypotheses, both of these significant negative correlations suggest that increased patient 
comfort was associated with decreased reporting of sexual risk. Perceptions of stigma and 
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patient comfort were not related to participants’ reports of any of the other sexual, 
substance-related, and medication adherence risk behaviors.  
 Bivariate examination of effects of stigma condition on engagement in care. 
Summary statistics in Table 7 present mean values for mediating and outcome variables 
for both experimental conditions, with significant differences reported via t-test statistics. 
As noted, participants in the “non-stigma” condition reported significantly lower 
perceptions of stigma, higher levels of comfort (general and disclosure related), and 
greater intentions to remain in care and to disclose risk behaviors than those in the 
“stigma” condition (see Table 7).  
 Two trends (p < .10) were noted among disclosure-based outcome variables (see 
Table 7). First, participants in the “non-stigma” condition reported missing doses of their 
HAART medications more recently than did participants in the “stigma” condition. 
Second, participants in the “non-stigma” condition reported using condoms less 
frequently than participants in the “stigma” condition.  No differences between the 
groups were found for number of lifetime and recent sexual partners, alcohol 
consumption, or lifetime and recent drug use variables. Such outcomes may suggest 
greater disclosure of risk behaviors from participants in the “non-stigma” condition.  
  Exploratory Aim: Impact of previous experiences of provider stigmatization.  
Correlational analyses were used to examine the relevance of previous experiences of 
provider stigmatization as a covariate or moderator of the proposed mediational model. 
As no significant associations were noted between previous experiences of stigmatization 
and the mediating and outcome measures of the present study (see Tables 6.1 and 6.2), it 
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was not selected as a covariate in subsequent analyses regarding primary study 
hypotheses. 
 Primary study hypotheses: Mediational model of the association of HIV-
related stigmatization to patients’ decisions to engage in medical care. Regression 
equations predicting intention-based and disclosure-based outcomes were conducted 
using an SPSS macro designed to test multiple mediator models (Preacher & Hayes, 
2008). The macro relies upon the product-of-coefficients mediation approach and 
bootstrapping statistical methods. Results are first described in terms of the overall fit of 
the mediational models (see Table 8), indicating the extent to which provider 
stigmatization accounted for a significant percentage of the variance in the engagement in 
care outcome measures. Results are secondarily described using illustrative figures of 
separate a (IV to mediator), b (mediator to DV), c (full direct effect of IV on DV), and c' 
(remaining direct effect of IV on DV after accounting for indirect effects via mediators) 
paths. Although Sobel’s test and bootstrapping procedures do not rely on examining the 
statistical significance of separate a and b paths (e.g. Baron and Kenny’s causal steps 
mediation approach), these figures provide useful information about the relationships 
between the individual variables in the model. Lastly, results are described in terms of the 
significance of their unstandardized coefficients from Sobel’s test of the indirect effects 
of provider stigmatization (experimental IV) on engagement in care via the mediating 
pathways (ab paths) of the model. Confidence intervals (CI) pertaining to the coefficients 
were created via bootstrapping resampling procedures and are also provided in Tables 
9.1-9.4 and Tables 10.1-10.9. 
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 Intention-based mediation models. In focusing on the intention-based mediation 
models, it was hypothesized that participants’ feelings of comfort and perceptions of 
stigmatization within the patient-provider interaction would mediate the effect of 
stigmatization (as operationalized as “stigma” and “non-stigma” randomized conditions) 
on participants’ decisions to engage in care and openly engage in conversations about 
risk behaviors regarding sexuality, substance use, and medication non-adherence. Results 
described below outline the performance of the proposed mediator models, noting overall 
model fit, as well as providing information about the specific individual associations 
(model paths) between all of the included variables in the models (e.g. IVs, mediators, 
DVs).  
 Mediational model fit. Findings related to overall model fit provided support for 
the present study’s primary mediational hypotheses, such that the negative effects of 
provider stigmatization (experimental manipulation) on engagement in care were 
significant and these effects were mediated through the IV’s negative effects to 
participants’ perceptions of stigmatization and feelings of comfort. As shown in Tables 
9.1 to 9.4, the total direct and indirect effects of provider stigmatization accounted for a 
significant proportion of the variance in participants’ intentions to remain in care, F(3, 86) 
= 122.90, p < .001, R2 = .80, disclose risky sexual behavior, F(4, 85) = 26.69, p < .001, R2 = 
.54, disclose substance-related behaviors, F(4, 85) = 23.69, p < .001, R2 = .51, and disclose 
medication adherence difficulties, F(4, 85) = 10.90, p < .001, R2 = .31.  
 Individual a and b pathways. Pathways from the IV to the mediating variables 
(a1-a3) were all significant with unstandardized path coefficients ranging from -3.67 to 
3.23 (all ps < .001), demonstrating the negative effects of provider stigmatization 
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(experimental manipulation) on participants’ perceptions of stigmatization and feelings of 
comfort. Differences were noted among intention-based outcome models with regards to 
the significance of b paths from mediating variables to DVs, such that perceptions of 
stigma, general patient comfort, and specific comfort measures related to disclosure did 
not yield significant regression paths to every intentions outcome measure. These 
findings suggest that participants’ perceptions of stigmatization and feelings of comfort 
did not consistently predict participants’ intentions to remain in care and open engage in 
conversations related to risk behaviors, such that the performance of each mediator was 
unique to the outcome variable examined. As noted in Figures 7.1-7.4, perceptions of 
stigma yielded a significant b path in models predicting intentions to remain in care (B = 
-.57, p < .001), intentions to disclose sexual risk behaviors (B = -.44, p < .01), and 
intentions to disclose medication adherence difficulties (B = -.41, p < .05), with a trend 
noted for intentions to disclose substance-related risk behavior (B = -.30, p < .1). The 
path coefficients for general patient comfort were only significant for models predicting 
intentions to remain in care (B = .55, p < .001) and intentions to disclose sexual risk 
behavior (B = .47, p < .05), with specific disclosure-related comfort measures being 
significantly associated only with intentions to disclose substance-related risk behavior 
(B = .37, p < .1).   
 Direct c and c' pathways. As noted in Figures 7.1-7.4, direct effects, as indicated 
in c pathways from the IV to the DV, were all significant with unstandardized path 
coefficients ranging from -1.61 to -3.40 (all ps < .001), indicating that the experimental 
stigma condition was predictive of participants’ intentions to remain in care, disclose 
sexual risk behavior, disclosure substance-related risk behaviors, and disclosure 
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medication adherence difficulties. When indirect effects of the IV via the mediating 
variables were accounted for, remaining direct effects (c' path coefficients) of the 
experimental stigma condition (IV) on intentions-based outcome variables were found to 
be non-significant, indicating the presence of mediation (see Figures 7.1-7.4). The latter 
finding supports the hypothesis that the negative effects of provider stigmatization on 
patients’ intentions to engage in care are mediated by HIV+ patients’ ability to perceive 
the stigmatization within the patient-provider relationship and also their experience of 
lower levels of comfort. 
 Sobel’s test of indirect effects and bootstrapping resampling analyses. Results 
from Sobel’s test of indirect effects and additional bootstrapping analytical procedures of 
the macro (Preacher & Hayes, 2008) provide a final source of support for the present 
study’s primary mediational hypotheses regarding the effects of provider stigmatization 
(experimental manipulation) on engagement in care being mediated through the IV’s 
effects to participants’ perceptions of stigmatization and feelings of comfort. Indeed, 
findings from Sobel’s tests and bootstrapping procedures supported all intentions-based 
mediation models, such that the total indirect effects of the experimental stigma condition 
(IV) on the intent-based DVs (remain in care, disclose risk behaviors) via participants’ 
perceptions of stigma and reports of comfort were significant at the p < .001 level for 
each model (see Tables 9.1-9.4). Similarly, percentile based and bias corrected and 
accelerated 95% CI ranges did not include a value of zero for any of the models, 
providing further support for the significance of the models’ total indirect effects, as 
obtained through bootstrapping resampling procedures. As shown in Tables 9.1-9.4, there 
were differences among the “intentions-based” models with regard to the significance of 
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individual mediating ab paths, such that all mediating pathways (e.g. perceptions of 
stigma, general comfort, disclosure specific comfort) were not significant in every model. 
These findings suggest that although all individual mediating paths (e.g. stigma 
comfort  intent to disclose substance-related risk behaviors) did not significantly 
predict every outcome variable, the composite of all the mediational paths of the model 
(i.e. stigma  perceptions of stigma, comfort, disclosure comfort  intentions outcome) 
were successful in predicting HIV+ participants intentions to remain in care and disclose 
risk behavior related to sexual activity, substance use, and medication non-adherence. 
 Significant mediating pathways for the “intent to remain in care” model included 
perceptions of stigma (B = -1.86, p < .001) and general patient comfort (B = -1.71, p < 
.001). The “intentions to disclose sexual risk behavior” model included the same 
mediating pathways, with the perceptions of stigma (B = -1.86, p < .001) and general 
patient comfort (B = -1.71, p < .001) paths both having significant path coefficients, 
while the path for the sexual disclosure comfort measure did not reach significance. The 
comfort measure concerning substance-related disclosure was the only significant 
mediating pathway (B = -1.11, p = .007) for the “intent to disclose substance-related risk 
behavior” model, with a trend noted for the perceptions of stigma path (B = -.98, p = .08). 
Finally, for the “intent to disclose HAART non-adherence” model, Sobel’s test of indirect 
effects indicated that perceptions of stigma was a significant mediating pathway (B = -
1.31, p = .04). However, confidence interval ranges obtained through bootstrapping 
resampling procedures contained a value of zero for both percentile and bias corrected 
and accelerated CIs, suggesting that mediating pathway coefficient may not statistically 
differ from zero. 
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 Disclosure-based mediation models. In focusing on the disclosure-based 
mediation models, it was hypothesized that participants’ feelings of comfort and 
perceptions of stigmatization within the patient-provider interaction would mediate the 
effect of stigmatization (as operationalized as “stigma” and “non-stigma” randomized 
conditions) on participants’ decisions to disclose sensitive information about their actual 
sexual behavior, substance use, and medication adherence practices. Results described 
below outline the performance of the proposed mediator models, noting overall model fit, 
as well as providing information about the specific individual associations (model paths) 
between all of the included variables in the models (e.g. IVs, mediators, DVs). 
 Mediational model fit. Findings related to overall model fit failed to provide 
support for the present study’s primary mediational hypotheses, such that the effects of 
provider stigmatization (experimental manipulation) on disclosure were non-significant 
and these effects were not mediated through participants’ perceptions of stigmatization 
and feelings of comfort. As shown in Table 8, the total direct and indirect effects of 
provider stigmatization did not account for a significant proportion of the variance in any 
of the disclosure-based outcome models. This is largely expected given that no 
significant differences between the groups were found during bivariate analysis (t-tests) 
on any of the disclosure-based outcome variables, leaving very little between group 
variance to be explained. The few significant findings from mediational analyses are 
reported with the understanding that groups did not significantly differ from each other. 
A trend was noted for the “disclosure of lifetime sexual partners” model, with the 
manipulation of provider stigmatization accounting for 7% of the variance in the number 
of lifetime sexual partners reported by participants, F(4, 72) = 2.46, p < .10, R2 = .07. The 
 79 
direction of this effect was unexpected, as the presence of stigma was associated with 
disclosure of greater number of lifetime sexual partners. Further discussion of results for 
the disclosure-based outcomes is completed with consideration of the poor fit of the 
mediational models.   
 Individual a and b pathways. As with “intentions-based” outcomes, pathways 
from the IV to the mediating variables (a1-a3) were all significant with unstandardized 
path coefficients ranging from -3.67 to 3.23 (all ps < .001), demonstrating the negative 
effects of provider stigmatization (experimental manipulation) on participants’ 
perceptions of stigmatization and feelings of comfort.  Few significant findings were 
noted among disclosure-based outcome models with regards to the significance of b paths 
from mediating variables to DVs, such that perceptions of stigma, general patient 
comfort, and specific comfort measures related to disclosure did not yield significant 
regression paths for many of the disclosure outcome measures. Such findings suggest that 
participants’ perceptions of stigmatization and feelings of comfort were largely not 
associated with participants’ decisions to disclose risky behaviors. As noted in Figures 
8.1-8.9, perceptions of stigma did not yield any significant b path in the disclosure-based 
models. The b path coefficients for general patient comfort were only significant for 
models predicting disclosure of lifetime drug use (B = -.32, p < .05), frequency of drug 
use in past three months (B = -.06, p < .05), with specific disclosure-related comfort 
measures being significantly associated with disclosure of lifetime sexual partners (B = -
.23, p < .01).  
 Direct c and c' pathways. In examining the direct relationship between 
stigmatization and patients’ disclosure of risk behavior, findings largely failed to provide 
 80 
support for the present study’s primary hypotheses. As noted in Figures 8.1-8.9, direct 
effects, as indicated in c pathways from the IV to the DV, were non-significant for seven 
of the nine disclosure-based models, indicating that the experimental stigma condition 
was largely not predictive of participants’ actual disclosure of sexual risk behavior, 
substance use, and HAART non-adherence. Trends were noted for the direct path for 
recent condom use and recency of missed HAART doses (see Figures 8.3 & 8.8), such 
that the presence of provider stigmatization (experimental manipulation) was associated 
with lower disclosure of failure to use condoms and missing recent doses of HAART. 
When indirect effects of the IV via the mediating variables were accounted for, remaining 
direct effects (c' path coefficients) of the experimental stigma condition (IV) on condom 
use remained at a trend level, while effects to recency of missed HAART doses were 
found to be non-significant, providing initial support for the presence of mediation in this 
model. 
 Sobel’s test of indirect effects and bootstrapping resampling analyses. Results 
from Sobel’s test of indirect effects and additional bootstrapping analytical procedures of 
the macro (Preacher & Hayes, 2008) failed to provide strong support for any of the 
proposed disclosure-based mediation models. Indeed, the total indirect effects of the 
experimental stigma condition (IV) on the disclosure based DVs (disclosure of risk 
behaviors) via participants’ perceptions of stigma and reports of comfort were non-
significant for all the disclosure-based models (see Tables 10.1-10.9). Similarly, 
percentile based and bias corrected and accelerated 95% CI ranges included values of 
zero for all of the models, providing further support for the non-significance of the 
models’ total indirect effects, as obtained through bootstrapping resampling procedures. 
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Additionally, as shown in Tables 10.1-10.9, very few models possessed any individually 
significant mediating pathways (e.g. perceptions of stigma, general comfort, disclosure 
specific comfort). 
 Perceptions of stigma did not account for significant mediating pathways in any 
of the disclosure-based models. Sobel’s test of indirect effects indicated that generalized 
patient comfort provided a significant mediating pathway for disclosure of recent drug 
use (B = .20, p < .05) and disclosure of lifetime drug use (B = 1.00, p < .05). However, 
confidence interval ranges pertaining to disclosure of lifetime drug use contained a value 
of zero for bias corrected and accelerated CIs, suggesting that mediating pathway 
coefficient may not statistically differ from zero. The mediating pathway through 
disclosure specific comfort measures was found to be significant for only the “disclosure 
of lifetime sexual partners model” (B = .70, p < .01). Based on these findings, alternative 
single mediator models were examined. These post hoc analyses revealed that stigma 
condition accounted for a significant amount of variance in the disclosure of lifetime 
sexual partners when disclosure-specific comfort was entered as the sole mediating 
pathway (see Tables 11.1 & 11.2). No significant improvements were noted in overall 
model fits for lifetime and recent drug use models (see Tables 11.1, 11.3, 11.4).  
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Discussion 
Summary of major findings. HIV remains a highly stigmatized illness and is 
associated with a number of adverse consequences among HIV+ individuals (Lee, 
Kochman, & Sikkema, 2002; Vanable et al., 2006).The experience of stigmatization in 
health care settings may be particularly detrimental to the health and well being of 
persons living with HIV. Although many recent studies have documented the existence of 
stigmatization in medical treatment settings, few have examined the impact of provider 
stigmatization on HIV+ patients’ decisions to engage in various aspects of HIV care. The 
present study used an experimental design and a behaviorally oriented approach to assess 
patients’ reactions to medical treatment scenarios in order to examine the impact of 
stigmatization on health care engagement. It was hypothesized that participants’ 
perceptions of stigmatization and feelings of comfort within the patient-provider 
relationship would mediate the effects of provider stigmatization (experimentally 
manipulated) on participants’ intentions to remain in care and openly engage in risk 
reduction conversations, as well as their decisions to disclose actual risk behaviors. 
Hypotheses were tested using an experimental design that randomized participants into 
“stigma” and “non-stigma” vignette conditions in which HIV+ participants were 
presented with visual stimuli and audio recordings depicting hypothetical patient-
provider interactions. Stigmatizing and non-stigmatizing vignettes differed in terms of 
distancing, avoidance, use of extra precautions, negative demeanor, and judgmental 
language. Primary study analyses were conducted within the framework of multiple 
mediator models based on the product-of-coefficients approach and bootstrapping 
analytical techniques.   
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Two important findings emerged from the study. The first major finding pertains 
to the negative impact provider stigmatization can have on HIV+ patients’ sense of 
comfort, their perceptions of the patient provider relationship, and ultimately their 
decisions related to care and sharing sensitive, health-related information with their 
healthcare providers. Findings from bivariate and mediational analyses confirmed that 
when the provider behaved in stigmatizing ways, HIV+ participants reported higher 
perceptions of stigmatization, more discomfort, and lower intentions to engage in care. 
Thus, participants were impacted in terms of their cognitive appraisal of the interaction, 
their emotional responses, and subsequent intentions to engage openly with the provider. 
Indeed, exposure to the “stigmatizing” provider lead to greater feelings of being 
devalued, more negative perceptions of the patient-provider relationship, and greater 
discomfort. Additionally, participants randomized to the “stigma” condition also reported 
having significantly lower intentions to remain in care and disclose sensitive health 
information regarding sexual risk activity, substance use, and medication non-adherence 
to the provider viewed in the vignette.  
In contrast to the “intentions-based” findings, no significant differences were 
noted for outcomes that focused on actual disclosure of risky sexual, substance, and non-
adherence related behaviors, with the presence of provider stigmatization having little 
effect on participants’ willingness to disclose sensitive information on the computerized 
survey. Indeed, participants randomized to the “stigma” and “non-stigma” conditions 
reported similar numbers of sexual partners, alcohol and drug use habits and histories, 
and medication adherence behaviors. Trend-level differences were noted for reports of 
condom use and disclosure of the recency of missed HAART doses, with participants 
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exposed to the “non-stigmatizing” provider being more likely to report instances of 
unprotected sex and lapses in medication adherence. These trend-level differences 
suggest that provider stigmatization may influence HIV+ patients’ decisions to be 
forthcoming about potentially risky sexual behaviors and less-than-perfect medication 
adherence. Additional research is warranted to explore these intriguing, yet inconclusive, 
trends in the data.   
The second major finding of this study pertains to the mediating pathways 
through which provider stigmatization negatively impacted patients’ intentions to openly 
communicate with their providers and effectively engage in their care. As hypothesized, 
findings from mediational analyses demonstrated that the effects of provider 
stigmatization (e.g. the experimental manipulation) on intention-based outcome measures 
were mediated by patients’ perceptions of stigmatization within the patient provider 
interaction and their feelings of comfort. Indeed, models containing stigma condition 
(IV), patient perceptions of stigmatization (mediator), general patient comfort (mediator), 
and measures of disclosure-specific comfort (mediator) performed very well in predicting 
participants’ intentions to remain in care and disclose risky sexual, substance use, and 
medication non-adherence behaviors with models explaining 30-80% of the variance in 
these intention-based outcome measures.  For all of these models, the direct effect of 
stigma condition became non-significant after accounting for the total indirect effects of 
the mediating pathways, an indication of the presence of mediation. To elaborate on these 
findings, when the provider engaged in stigmatizing behaviors, HIV+ patients’ (1) 
perceived the devaluing nature of these behaviors, (2) their perceptions of the patient-
provider relationship were harmed, and (3) their level of psychological comfort within 
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the treatment interaction decreased. Subsequently, these negative cognitive appraisals and 
affective responses to the stigmatizing interaction influenced their decisions to decline 
future treatment with the provider and lessened their willingness to disclose sensitive 
information about their health behaviors and engage in discussions related to sexual risk 
behaviors, substance use, and medication adherence difficulties.  
As noted, provider stigmatization (as experimentally manipulated) was not 
associated with significant differences in actual disclosure of risk behaviors among study 
participants in the “stigma” and “non-stigma” groups. Largely due to this lack of 
significant group differences and associated lack of between group variance, mediational 
models aimed at explaining the effect of stigma on patient disclosure performed poorly. 
Additionally, seven of the nine disclosure-based outcome variables required 
transformations due to non-normal distributions (e.g. extreme outliers regarding sexual 
partner numbers, skew due to low frequency use of drugs and alcohol) with several of the 
variables still not adhering to what could be considered preferred standards of skew and 
kurtosis even after the transformations were performed (though they were greatly 
improved). Indeed, variance explained through these mediational models ranged from 
.3% to 7% (a trend level effect for prediction of lifetime sexual partners). Examination of 
mediating paths suggests that even though participants exposed to stigmatizing provider 
behaviors reported perceiving more stigmatization and feeling less comfortable with the 
provider (IV to mediator paths), these perceptions and feelings did not influence the 
degree to which patients disclosed sensitive personal information on the computerized 
survey (mediator to DV paths).  
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Study strengths, limitations, and future directions. This present study is the 
first to utilize an experimental design to examine the detrimental effects of provider 
stigmatization on HIV+ patients’ treatment decisions and intentions to disclose sensitive 
health information. The strength of this design is that it provides evidence of a causal 
relationship between provider stigmatization and patient response.  
A second strength of the present study concerns the use of a multidimensional 
operationalization of HIV-related provider stigmatization. Stigma measures from 
previous empirical studies involving patient self-report are often restricted to small item 
sets that focus on extreme behavioral markers of stigmatization such as treatment refusal. 
The present study addressed this limitation by carefully constructing detailed 
representations of provider stigma in vignettes depicting a range of provider behaviors 
related to both demeanor and the provision of care. In addition, the present study allowed 
for time-sensitive assessments of immediate reactions to provider stigma, thereby 
lessening the possibility of recall errors. Finally, use of a computerized design likely 
increased patients’ perceptions of confidentiality, thus decreasing the chances of socially 
desirable responding often found in traditional survey based studies.  
 One limitation of the present study concerns the use of a dichotomized 
experimental manipulation of stigma, with one condition being highly stigmatizing and 
the other containing no elements of a stigmatizing interaction. In focusing on the highly 
stigmatizing interaction, the vignette was created to contain numerous examples of 
stigmatizing behaviors to characterize what a “stigmatizing provider” might look like. In 
reality, it may be unlikely that a provider would demonstrate this entire spectrum of 
stigmatizing behaviors, and if they did, such behaviors would probably not take place in 
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the span of a single treatment visit.  Given that this study was the first of its kind to 
experimentally examine the impact of provider stigma on medical care decisions, it was 
deemed important to first get a clear picture of the effects of HIV-stigmatization in a very 
apparent form. Future experimental research should examine the effects of stigmatization 
as operationalized on a continuum, either in the level of extremity, the quantity, or the 
types (e.g. verbal, non-verbal) of stigmatizing behaviors patients are exposed to.  
A second limitation of the present study concerns the use of hypothetical 
vignettes. Vignettes were developed to provide a realistic depiction of stigmatizing and 
non-stigmatizing medical appointments. Further, participants were encouraged to imagine 
themselves in the situation that was depicted in the vignette, “as if they were the patient.” 
By participant report, these efforts were largely successful. HIV+ patients in the validity 
study indicated that the behavior of the provider in the stigmatizing vignette was indeed 
stigmatizing and realistic, offering validity to the content of the vignettes. However, even 
the most carefully constructed vignettes are only modest approximations of what patients 
experience during an actual provider visit. The lack of significant findings for disclosure 
of actual sexual behavior, substance use, and adherence difficulties may be due to 
inherent design limitations associated with using vignettes as a mode of delivery for an 
experimental manipulation of an interaction. Though these items were read to the 
participants in the voice of the provider to mimic as closely as possible what it would be 
like to disclose sensitive information to the provider, this approximation may not have 
been a powerful enough mode of delivery to influence participants’ comfort with 
disclosing health behavior lapses. In sum, although the content of the vignettes may have 
been powerful in eliciting reactions from participants, the mode of delivery may have 
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been too weak of an approximation to affect participants’ actual disclosure of risk 
behaviors. 
A final limitation of the present study is the presence of high overlap between 
variables as indicated by the high correlations among the study’s mediating variables. 
Although the multiple mediator statistical design of the present study allowed for 
correlations between the included mediator variables, future studies would benefit from 
conceptualizing and/or operationalizing patients’ reports of comfort and perceptions of 
stigma in ways that better allow for more distinct comparisons of the effects of these 
variables. In addition, to further extend the findings from the present study, future 
experimental designs should include participant randomization to realistic stigmatizing 
and non-stigmatizing healthcare care experiences taking place within real medical 
facilities and portrayed by live “actors.” In so doing, research could provide additional 
insight into the impact of provider stigmatization on patient behavior. Ultimately, studies 
that utilize experimental manipulations of stigmatization will help to provide a more 
comprehensive understanding of the ways in which provider stigma effects HIV+ 
patients’ decisions to communicate openly with their provider and effectively engage in 
their care. This is important within the context of healthcare not just within the United 
States, but globally as well. In looking to future research, the present study provides a 
step-by-step research framework (qualitative interviews, vignette development and 
testing, experimental procedures) for identifying the content of stigmatizing behavior 
within treatment settings and understanding its impact on HIV+ patients. The portability 
of this protocol allows for the examination of provider stigmatization across many 
cultures and treatment settings. With future research and intervention efforts, it is the 
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hope that provider stigmatization will eventually be examined, understood, and decreased 
on a global scale. 
 Implications for the IMCHB model and practical applications. Findings from 
the present study provide support to Cox’s (1982) IMCHB model, emphasizing the 
impact of patient-provider relationships on treatment decisions and patient behaviors. As 
discussed, findings demonstrated that the effects of provider stigmatization were 
mediated by patients’ feelings of comfort within the treatment interaction, patients’ 
abilities to perceive the presence of devaluing nature of the stigmatizing behaviors, and 
their negative views of the quality of the patient-provider relationship (with the latter two 
comprising the study’s perceptions of stigma measure). As dictated in Cox’s (1982) 
IMCHB model, positive patient-provider interactions are defined in large part by the 
provider’s ability to demonstrate their competency, provide affective support, give the 
patient control in treatment decisions, and provide health information in the proper 
amounts as based on the highly individualized needs of the patient. Provider 
stigmatization likely inhibits the development of positive patient-provider relationship, as 
patients are left feeling devalued, disrespected, emotionally unsupported, uncomfortable, 
and vulnerable due to the behaviors of the persons responsible for their medical care. As 
a function of stigmatization, providers may fail to form positive working relationships 
with their HIV+ patients. In failing to achieve a sense of comfort and  trust with their 
providers, patients’ may be less willing to disclose important information about their 
health and health behaviors in fear of further negative judgment and emotional pain. 
Without such patient honesty, physicians are not able to obtain a complete picture of their 
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patients’ lives and health conditions and, consequently, are limited in their ability to 
provide high quality health care.  
 In focusing on practical implications, findings from the present study suggest that 
instances of provider stigmatization, expressed through specific behaviors and overall 
demeanor, play an important role in predicting which patients will likely remain in care 
and openly discuss their risk behaviors and medication adherence difficulties. As 
demonstrated in the present study, the process of evaluating the quality of the patient-
provider relationship and making decisions about disclosure can begin as early as the first 
appointment with the provider. Thus, it is important for medical care providers to 
understand how certain protocols (e.g. use of gloves, frequent assessments of sexual 
behavior, etc.), language, and behaviors within the treatment settings may be perceived as 
stigmatizing by patients and hence detract from this process.  
  Routine training programs for health care providers would benefit from focusing 
on practical steps to prevent HIV-related stigmatization within treatment settings. Such 
trainings should aim to help professionals in the health care field gain an awareness of 
how even the subtlest of their behaviors may be interpreted by the HIV+ patients they 
treat. A first step in developing such trainings would be to undertake future research to 
pinpoint the “hot-button” provider behaviors noticed most frequently by HIV+ patients 
and found to cause the most damage to the patient-provider relationship. Identifying a 
few key areas for behavioral intervention would allow for the fairly quick training of a 
large number of providers, with a chance for maximum recall and dissemination of 
learned skills. It is also suggested that providers be exposed to HIV care settings and to 
HIV+ patients multiple times throughout their medical training to increase their skill, 
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confidence, and comfort in developing working relationships with this patient population. 
By teaching providers to focus on and potentially reshape certain aspects of their 
demeanors, language, and nonverbal behaviors, it is the hope that positive patient-
provider relationships can be formed and the overall quality of patient experiences within 
HIV care could be increased.   
Conclusions 
 In summary, the present study provided initial evidence regarding the negative 
effects of provider stigma on HIV+ patients’ willingness to openly communicate about 
risk behaviors and make decisions about the future of their care. Compared to patients 
who were not exposed to provider stigmatization, patients exposed to stigmatizing 
language and behaviors from the healthcare provider were less willing to remain in care 
and less willing to disclose sexual and substance use related risk behaviors and 
medication adherence difficulties. These effects were mediated by patients’ perceptions 
of the degree of stigmatization present within the patient provider relationship and their 
feelings of comfort throughout the medical appointment. Future explorations of the 
impact of provider stigmatization on HIV+ patient’s healthcare decisions and health 
outcomes are needed in order to inform the development of stigma reduction 
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Table 2. Summary of Patient Reported Provider Stigmatization Studies 
  
Stigmatizing Behavior related to Demeanor 
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Bodenlos 
(2007) 













































Stigmatizing Behavior related to Demeanor 
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Total 7 3 2 4 8 2 6 6 
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Table 3. Frequency of Provider Stigmatization Instances-Qualitative Focus Groups 
 
Stigmatizing Behavior % of Participants (n=18) 
 
Judgmental Language (blame, assumptions about 
transmission, condescension)  56% 
Avoidance or Distancing 44%  
Body Language (discomfort) 28% 
Demeanor Shifts 22%  
Extra Precautions (gloves, masks, etc.) 22% 
Non-competence in Treating HIV 22%  
Provided Differential Care because HIV+ 22% 
Problems ignored because HIV+ 22% 
Confidentiality Issues 17% 
Rushing Appointments or not Listening to Patient 17% 
Lack of Physical Contact 11% 
Refusal of Care 11% 
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Table 4. Validity Sub-study: Vignette Comparisons 
 
 T 
Perceptions of Stigma  
Stigma vs. No Stigma (long form)       3.26**  
Stigma vs. No Stigma (short form)         7.16*** 
Long Form vs. Short Form (stigma vignette) -1.70 
Long Form vs. Short Form (no stigma vignette)    .18 
  
Comfort Ratings  
Stigma vs. No Stigma (long form)       -3.78** 
Stigma vs. No Stigma (short form)         -7.19*** 
Long Form vs. Short Form (stigma vignette)     2.09 
































Note: Ɨ  trend at p < .1, * p < .05, **  p < .01, *** p < .001 
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Table 5. Demographic Characteristics of Experimental Phase Sample 






 M (SD) % M (SD) % M (SD) % 
Age 
 
45.2 (11.1)  45.7 (11.5)  44.6 (10.9)  
Gender 
  Male 
  Female 













  2% 
Hispanic/Latino 
 
 9%  7%  11% 
Race 
  African 
American 













 29%  38%  20% 
Paid Hours of 
Work/Week  
33 (14.6)  37.2 (13.7)*  25.4 (13.8)*  
 
Have  Primary 
Relationship 
Partner 









11.5 (7.6)  11 (7.5)  12 (7.2)  
 
AIDS Diagnosis 















 4.29 (8.43)  2.93 (4.26)  







Table 6.1. Correlation Table: Association of Mediators and Intention Outcome Variables 
 
 1 2 3 4 5 6 7 8 9 10 
1 1          
2 -.88*** 1         
3 -.84*** .93*** 1        
4 -.82*** .86*** .89*** 1       
5 -.89*** .92*** .91*** .88*** 1      
6 .10 -.17 -.20 -.17 -.18 1     
7 -.71*** .72*** .67*** .70*** .66*** -.172 1    
8 -.68*** .67*** .63*** .70*** .63*** -.128 .85*** 1   
9 -.57*** .55*** .48*** .57*** .52*** -.103 .74*** .80 1  
10 -.87*** .87*** .81*** .75*** .85*** -.096 .65*** .63*** .52*** 1 
 
Legend:  
1 (Perceptions of Stigma) 
2 (Comfort-general) 
3 (Comfort-sexual behavior) 
4 (Comfort-substance use) 
5 (Comfort-med adherence) 
6 (Previous Experiences of Stigma) 
7 (Intention to Disclose Sexual Risk Behaviors) 
8 (Intention to Disclose Substance Use Risk Behaviors) 
9 (Intentions to Disclose Medication Adherence Difficulties 























































.061 .138 -.082 -.025 .010 .046 -.048 -.160 .016 
Comfort-
general 
























Note: Ɨ  trend at p < .1, * p < .05, ** p < .01, *** p < .001
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 M (SD) M (SD) T 
Mediators    
Perceptions of Stigma 2.00 (.82) 5.23 (1.52) -12.54*** 
Comfort-general 5.55 (1.11) 2.44 (1.69) 10.33*** 
Comfort-sexual behavior 5.42 (1.11) 2.11 (1.77)  9.64*** 
Comfort-substance use 5.64 (1.43) 2.69 (1.82) 8.56*** 
Comfort-adherence 6.00 (1.33) 2.33 (1.72) 11.31*** 
    
Intentions Outcome Variables    
Intention to Remain in Care 5.96 (1.45) 2.44 (1.69) 9.29*** 
Intention to Disclose Sexual Risk 
Behaviors 
4.89 (1.45) 2.90 (1.88) 5.70*** 
Intention to Disclose Substance Use 
Risk Behaviors 
5.05 (1.50) 2.97 (1.88) 5.82*** 
Intentions to Disclose Medication 
Adherence Difficulties 
5.33 (1.43) 3.72 (1.87) 4.50*** 
    
Disclosure Outcome Variables    
Number of Lifetime Sexual Partners
a
 76.18 (296.82) 101.89 (244.99) .28 
Number of Recent Sexual Partners
a
 1.49 (2.90) 1.73 (2.90) .55 
Recent Condom Use Neglect 3.333 (1.78) 2.67 (1.65) 1.84
 Ɨ
 
Recent Alcohol Use Frequency
a
 1.53 (.79) 1.49 (.94) .62 
Recent Alcohol Use Quantity
a
 1.53 (.97) 1.51 (.843) -.09 
Extent of Lifetime Drug Use 2.36 (1.23) 2.40 (1.20 -.17 
Frequency of Recent Drug Use
a
 1.69 (1.13) 1.53(1.06) .76 
Recency of Missed HAART Doses
a
















Note: a Means and standard deviations presented are based on non-transformed variables 
for ease of viewing potential differences between groups. However, T-tests were 
performed on Log transformed versions of these variables. 
 Ɨ  
trend at p < .1, * p < .05, ** 
p < .01, *** p < .001   
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Table 8. Summary Table of Mediational Model Fits 
 
Dependent Variables           Model Summary 
 Adjusted R
2
 df F 
Intention DVs    
    
Intention to Remain in Care .804 (3, 86) 122.90*** 
Intention to Disclose Sexual Risk Behaviors .536 (4, 85) 26.69*** 
Intention to Disclose Substance Use Risk 
Behaviors 
.505 (4, 85) 23.69*** 
Intentions to Disclose Medication 
Adherence Difficulties 
.308 (4,85) 10.90*** 
    
Disclosure DVs    
    
Disclosure of Lifetime Sexual Partners
a
 .071 (4, 72) 2.46
Ɨ
 
Disclosure of Recent Sexual Partners
a
 .012 (4, 84) 1.26 
Disclosure of Recent Condom Use .014 (4, 85) 1.31 
Disclosure of Alcohol Use Frequency
a
 .029 (4, 85) .37 
Disclosure of Alcohol Use Quantity
a
 .020 (4, 85) .56 
Disclosure of Lifetime Drug Use .027 (4, 85) 1.62 
Disclosure of Recent Drug Use
a
 .030 (4, 85) 1.69 




.003 (4, 85) .93 
Disclosure of Overall HAART Adherence
a




















Note: a Analyses performed on Log transformations of these outcome measures. Ɨ  trend at 








Table 9.1. Mediation Model: The Effect of HIV Stigma on Intentions to Remain in Care through Patients’ Feelings of Comfort and 
their Perceptions of Stigmatization within the Patient Provider Relationship. 
 
  





Bias Corr. & Accel. 95% CI 
Path 
Point 
Estimate SE Z p Lower Upper Lower Upper 
         
Direct         
Stigma Condition .16 .38 .42 (t) .674     
         
Indirect         
Stigma Perceptions -1.86 .45 -4.16 <.001 -2.81 -1.00 -2.80 -1.09 
Patient Comfort: Gen. -1.71 .38 -4.45 <.001 -2.62 -.89 -2.61 -.90 










Table 9.2. Mediation Model: The Effect of HIV Stigma on Intentions to Disclose Sexual Risk Behavior through Patients’ Feelings of 
Comfort and their Perceptions of Stigmatization within the Patient Provider Relationship. 
  





Bias Corr. & Accel. 95% CI 
Path 
Point 
Estimate SE Z p Lower Upper Lower Upper 
         
Direct         
Stigma Condition .69 .47 1.48 (t) .143     
         
Indirect         
Stigma Perceptions -1.41 .53 -2.66 .008 -2.59 -.10 -2.41 -.09 
Patient Comfort: Gen. -1.46 .62 -2.36 .018 -2.86 -.16 -2.82 -.23 
Patient Comfort: Sex .18 .52 .34 .734 -1.06 1.41 -1.00 1.50 










Table 9.3. Mediation Model: The Effect of HIV Stigma on Intentions to Disclose Substance Use Related Risk Behavior through 
Patients’ Feelings of Comfort and their Perceptions of Stigmatization within the Patient Provider Relationship.  
  





Bias Corr. & Accel. 95% CI 
Path 
Point 
Estimate SE Z p Lower Upper Lower Upper 
         
Direct         
Stigma Condition .28 .50 .56 (t) .575     
         
Indirect         
Stigma Perceptions -.98 .56 -1.74 .083 -2.24 .53 -2.35 .50 
Patient Comfort: Gen. -.27 .53 -.52 .61 -1.82 .99 -1.73 1.19 
Patient Comfort: Subs. -1.11 .52 -2.68 .007 -2.01 -.30 -1.93 -.23 









Table 9.4. Mediation Model: The Effect of HIV Stigma on Intentions to Disclose HAART Non-adherence through Patients’ Feelings 
of Comfort and their Perceptions of Stigmatization within the Patient Provider Relationship.  
  





Bias Corr. & Accel. 95% CI 
Path 
Point 
Estimate SE Z p Lower Upper Lower Upper 
         
Direct         
Stigma Condition .19 .55 .34 .74     
         
Indirect         
Stigma Perceptions -1.31 .64 -2.03 .042 -2.72 .26 -2.82 .04 
Patient Comfort: Gen. -.92 .64 -1.45 .148 -2.52 .37 -2.49 .47 
Patient Comfort: Med .43 .70 .62 .54 -1.52 1.83 -1.34 2.00 








Table 10.1. Mediation Model: The Effect of HIV Stigma on Disclosure of Lifetime Sexual Partners through Patients’ Feelings of 
Comfort and their Perceptions of Stigmatization within the Patient Provider Relationship. (LOG)  
  





Bias Corr. & Accel. 95% CI 
Path 
Point 
Estimate SE Z p Lower Upper Lower Upper 
         
Direct         
Stigma Condition -.11 .24 -.47 (t) .64     
         
Indirect         
Stigma Perceptions -.28 .26 -1.05 .292 -.83 .30 -.88 .26 
Patient Comfort: Gen. -.28 .29 -.97 .33 -.95 .33 -1.00 .32 
Patient Comfort: Sex .70 .26 2.66 .008 .26 1.32 .26 1.38 









Table 10.2. Mediation Model: The Effect of HIV Stigma on Disclosure of Sexual Partners in Past Three Months through Patients’ 
Feelings of Comfort and their Perceptions of Stigmatization within the Patient Provider Relationship. (LOG) 
  





Bias Corr. & Accel. 95% CI 
Path 
Point 
Estimate SE Z p Lower Upper Lower Upper 
         
Direct         
Stigma Condition -.03 .10 -.33 (t) .74     
         
Indirect         
Stigma Perceptions -.08 .11 -.72 .469 -.34 .26 -.35 .31 
Patient Comfort: Gen. .12 .12 1.00 .319 -.16 .42 -.15 .47 
Patient Comfort: Sex .04 .10 .40 .692 -.20 .26 -.24 .24 










Table 10.3. Mediation Model: The Effect of HIV Stigma on Disclosure of Recent Condom Use Neglect through Patients’ Feelings of 
Comfort and their Perceptions of Stigmatization within the Patient Provider Relationship.  
  





Bias Corr. & Accel. 95% CI 
Path 
Point 
Estimate SE Z p Lower Upper Lower Upper 
         
Direct         
Stigma Condition -.67 .36 -1.84 (t) .069     
         
Indirect         
Stigma Perceptions .86 .68 1.25 .210 -.53 2.37 -.58 2.16 
Patient Comfort: Gen. .06 .79 .08 .940 -1.58 1.67 -1.77 1.79 
Patient Comfort: Sex -.42 .69 -.61 .540 -1.88 1.08 -1.88 .98 









Table 10.4. Mediation Model: The Effect of HIV Stigma Disclosure of Frequency of Alcohol Use through Patients’ Feelings of 
Comfort and their Perceptions of Stigmatization within the Patient Provider Relationship. (LOG) 
  





Bias Corr. & Accel. 95% CI 
Path 
Point 
Estimate SE Z p Lower Upper Lower Upper 
         
Direct         
Stigma Condition -.05 .07 -.68 (t) .500     
         
Indirect         
Stigma Perceptions .01 .08 .19 .848 -.18 .19 -.15 .21 
Patient Comfort: Gen. -.05 .07 -.63 .531 -.18 .10 -.20 .09 
Patient Comfort: Subs. .05 .05 .96 .338 -.05 .16 -.07 .16 










Table 10.5. Mediation Model: The Effect of HIV Stigma Disclosure of Quantity of Alcohol Use through Patients’ Feelings of Comfort 
and their Perceptions of Stigmatization within the Patient Provider Relationship. (LOG)  
  





Bias Corr. & Accel. 95% CI 
Path 
Point 
Estimate SE Z p Lower Upper Lower Upper 
         
Direct         
Stigma Condition .004 .04 .09 (t) .962     
         
Indirect         
Stigma Perceptions -.02 .08 -.29 .774 -.17 .12 -.16 .13 
Patient Comfort: Gen. -.06 .08 -.83 .409 -.23 .12 -.24 .10 
Patient Comfort: Subs. .09 .06 1.50 .134 -.07 .24 -.06 .23 









Table 10.6. Mediation Model: The Effect of HIV Stigma Disclosure of Lifetime Drug Use through Patients’ Feelings of Comfort and 
their Perceptions of Stigmatization within the Patient Provider Relationship. 
  





Bias Corr. & Accel. 95% CI 
Path 
Point 
Estimate SE Z p Lower Upper Lower Upper 
         
Direct         
Stigma Condition -.26 .42 -.62 (t) .537     
         
Indirect         
Stigma Perceptions -.65 .48 -1.36 .174 -1.71 .35 -1.65 .36 
Patient Comfort: Gen. 1.00 .46 2.19 .028  .01 2.23 -.12 2.09 
Patient Comfort: Subs. -.05 .34 -.14 .893 -.71 .66 -.76 .63 








Table 10.7. Mediation Model: The Effect of HIV Stigma Disclosure of Drug Use in Past Three Months through Patients’ Feelings of 
Comfort and their Perceptions of Stigmatization within the Patient Provider Relationship. (LOG)  
  





Bias Corr. & Accel. 95% CI 
Path 
Point 
Estimate SE Z p Lower Upper Lower Upper 
         
Direct         
Stigma Condition -.08 .08 -.99 (t) .323     
         
Indirect         
Stigma Perceptions -.12 .09 -1.33 .184 -.28 .04 -.31 .05 
Patient Comfort: Gen. .20 .08 2.36 .018 .05 .39 .05 .38 
Patient Comfort: Subs. -.04 .06 -.67 .502 -.06 .14 -.19 .11 










Table 10.8. Mediation Model: The Effect of HIV Stigma Disclosure of Recency of Missed HAART Doses through Patients’ Feelings 
of Comfort and their Perceptions of Stigmatization within the Patient Provider Relationship. (LOG)  
  





Bias Corr. & Accel. 95% CI 
Path 
Point 
Estimate SE Z p Lower Upper Lower Upper 
         
Direct         
Stigma Condition -.08 .08 -1.06 (t) .293     
         
Indirect         
Stigma Perceptions -.01 .09 -.06 .949 -.14 .13 -.13 .13 
Patient Comfort: Gen. .04 .09 .47 .639 -.14 .25 -.13 .25 
Patient Comfort: Med -.04 .10 -.40 .693 -.21 .20 -.23 .18 








Table 10.9. Mediation Model: The Effect of HIV Stigma Disclosure of HAART Non-Adherence through Patients’ Feelings of 
Comfort and their Perceptions of Stigmatization within the Patient Provider Relationship. (LOG) 
  





Bias Corr. & Accel. 95% CI 
Path 
Point 
Estimate SE Z p Lower Upper Lower Upper 
         
Direct         
Stigma Condition -.05 .14 -.35 (t) .731     
         
Indirect         
Stigma Perceptions .07 .16 .42 .677 -.23 .39 -.24 .36 
Patient Comfort: Gen. -.26 .16 -1.62 .105 -.58 .06 -.63 0.00 
Patient Comfort: Med .24 .18 1.34 .180 -.27 .59 -.15 .62 








Table 11.1 Alternate Single Mediator Models for Disclosure Outcomes-Model Fit Summary 
Dependent Variables Model Summary 
 Adjusted R
2
 df F 
Disclosure of Lifetime Sexual Partners
a
 .058 (2, 74) 3.32
*
 
Disclosure of Lifetime Drug Use .027 (2, 87) 2.25 
Disclosure of Recent Drug Use
a
 .030 (2, 85) 1.69 
Note: 
a




Table 11.2 Alternate Single Mediator Model: The Effect of HIV Stigma on Disclosure of Lifetime Sexual Partners through Patients’ 
Feelings of Disclosure-Specific Comfort. (LOG) 
  





Bias Corr. & Accel. 95% CI 
Path 
Point 
Estimate SE Z p Lower Upper Lower Upper 
Direct         
Stigma Condition -.32 .20 -1.57 (t) .12     
         
Indirect         
Patient Comfort: Sex .35 .14 2.47 .01 .14 .6 .12 .61 









Table 11.3 Alternate Single Mediator Model: The Effect of HIV Stigma Disclosure of Lifetime Drug Use through Patients’ Feelings 
of General Comfort. 
  





Bias Corr. & Accel. 95% CI 
Path 
Point 
Estimate SE Z p Lower Upper Lower Upper 
Direct         
Stigma Condition -.54 .37 -1.44 (t) .15     
         
Indirect         










Table 11.4 Alternate Single Mediator Model: The Effect of HIV Stigma Disclosure of Recent Drug Use through Patients’ Feelings  of 
General Comfort. (LOG) 
  





Bias Corr. & Accel. 95% CI 
Path 
Point 
Estimate SE Z p Lower Upper Lower Upper 
Direct         
Stigma Condition -.13 .07 -1.90 (t) .06     
         
Indirect         
Patient Comfort: Gen. .09 .05 1.86 .06 .01 .19 .01 .19 





Figure 1. Interactional Model of Client Health Behavior 
Figure 2. Mediation Model of Provider Stigma’s Effects to HIV+ Patients’ Engagement  
in Care  
Figure 3. Characterization of the “Non-Stigma” Treatment Vignette-Long Version 
Figure 4. Characterization of the “Stigma” Treatment Vignette-Long Version 
Figure 5. Characterization of the “Non-Stigma” Treatment Vignette-Short Version 
Figure 6. Characterization of the “Stigma” Treatment Vignette-Short Version 
Figures 7.1-7.4. Intention-Based Mediation Models 
 
Figures 8.1-8.9. Disclosure-Based Mediation Models 
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*Note: Specific diagram representation from Mathews, Secrest, & Muirhead (2008).






Figure 2. Mediation Model of Provider Stigma’s Effects to HIV+ Patients’ Engagement  
in Care 
 
Predictor Variable      Mediation Variables    Dependent Variables 




















1. general feeling of 
psychological comfort 
with the provider 
 
2. feelings of comfort 
regarding having 
conversations related 
to sexual behavior, 






1. perceptions of being 
devalued by provider 
 
2. perceptions of the 












































1.     2.          *3.                   *4.  
Order of Computerized Protocol: 
1. “non-stigma” Segment 1 Audio: (Narrator) Dr. Smith knocked on the door before entering into the room. She approached Mr.  
Johnson and shook his hand while introducing herself. Looking him in the eye, she asked, “How are you doing today?” (Actor)  
 Manipulated Independent Variables: touch (handshake), eye contact (maintained) 
  
Comfort Measure: Imagine that you are the patient portrayed in this vignette. Now please rate you feelings of . . . comfort . . . worry 
 
2. “non-stigma” Segment 2 Audio: (Narrator) Dr. Smith takes a seat in a chair a few feet away from the exam table where Mr. Johnson 
is sitting and begins reviewing his chart. She says (Actor: calm, pleasant tone), “Mr. Johnson I would like to confirm a few 
things in your medical history to make sure I have the most correct and current information. It says that you tested positive for 
HIV five years ago, most likely from sexual activity with men.” Mr. Johnson replied, “Yeah, that’s the story.” Dr. Smith 
(Actor: same calm, pleasant tone): “Ok, and it says that you began taking anti-retroviral medications pretty soon after the 
diagnosis.” Mr. Johnson replied: “Yeah it was within a few months.”  
 Manipulated Independent Variables: proximity in room (close), language and tone (non-judgmental) 
 
Comfort Measure: Imagine that you are the patient portrayed in this vignette. Now please rate you feelings of . . . comfort . . . worry .   
 
* Segments 3 and 4 proceed in similar fashion with comfort ratings following each segment. 
























1.     2.          *3.                   *4.  
Order of Computerized Protocol: 
1. “stigma” Segment 1 Audio: (Narrator) Dr. Smith knocked on the door before entering into the room. She took a few steps into the 
room while introducing herself. While looking at the medical chart, she asked, “How are you doing today? (Actor)”.  
 Manipulated Independent Variables: touch (no handshake), eye contact (lacking) 
  
Comfort Measure: Imagine that you are the patient portrayed in this vignette. Now please rate you feelings of . . . comfort . . . worry .   
2. “stigma” Segment 2 Audio: (Narrator) Dr. Smith takes a seat in a chair across the room from the exam table where Mr. Johnson is 
sitting and begins reviewing his chart. She says (Actor: calm, unpleasant tone), “Mr. Johnson I would like to confirm a few 
things in your medical history to make sure I have the most correct and current information. It says that you tested positive for 
HIV five years ago, having gotten infected because you were sleeping with other men.” Mr. Johnson replied, “Yeah, that’s the 
story.” Dr. Smith (Actor: sarcastic tone): “Not surprising. It also says that you began taking anti-retroviral medications pretty 
soon after the diagnosis.” Mr. Johnson replied: “Yeah, it was within a few months.” 
 Manipulated Independent Variables: proximity in room (far), language and tone (judgmental) 
 
Comfort Measure: Imagine that you are the patient portrayed in this vignette. Now please rate you feelings of . . . comfort . . . worry .   
 


























   1.       2.          *3.     *4.  
Order of Computerized Protocol: 
1. “non-stigma” Segment 1 Audio: (Narrator) Dr. Smith knocked on the door before entering into the room. She approached Mr. 
Johnson and shook his hand while introducing herself. Looking him in the eye, she asked, “How are you doing today?” (Actor)  
 Manipulated Independent Variables: touch (handshake), eye contact (maintained) 
  
2. “non-stigma” Segment 2 Audio: (Narrator) Dr. Smith takes a seat in a chair a few feet away from the exam table where Mr. Johnson 
is sitting and begins reviewing his chart. She says (Actor: calm, pleasant tone), “Mr. Johnson I would like to confirm a few 
things in your medical history to make sure I have the most correct and current information. It says that you tested positive for 
HIV five years ago, most likely from sexual activity with men.” Mr. Johnson replied, “Yeah, that’s the story.” Dr. Smith 
(Actor: same calm, pleasant tone): “Ok, and it says that you began taking anti-retroviral medications pretty soon after the 
diagnosis.” Mr. Johnson replied: “Yeah it was within a few months.”  
 Manipulated Independent Variables: proximity in room (close), language and tone (non-judgmental) 
 
* Segments 3 and 4 proceed in similar fashion. 
 
Comfort Measure: Imagine that you are the patient portrayed in this vignette. Now please rate you feelings of . . . comfort . . . worry .   
 
















   1.       2.          *3.     *4.  
Order of Computerized Protocol: 
1. “stigma” Segment 1 Audio: (Narrator) Dr. Smith knocked on the door before entering into the room. She took a few steps into the 
room while introducing herself. While looking at the medical chart, she asked, “How are you doing today? (Actor)”.  
 Manipulated Independent Variables: touch (no handshake), eye contact (lacking) 
  
2. “stigma” Segment 2 Audio: (Narrator) Dr. Smith takes a seat in a chair across the room from the exam table where Mr. Johnson is 
sitting and begins reviewing his chart. She says (Actor: calm, unpleasant tone), “Mr. Johnson I would like to confirm a few 
things in your medical history to make sure I have the most correct and current information. It says that you tested positive for 
HIV five years ago, having gotten infected because you were sleeping with other men.” Mr. Johnson replied, “Yeah, that’s the 
story.” Dr. Smith (Actor: sarcastic tone): “Not surprising. It also says that you began taking anti-retroviral medications pretty 
soon after the diagnosis.” Mr. Johnson replied: “Yeah, it was within a few months.” 
 Manipulated Independent Variables: proximity in room (far), language and tone (judgmental) 
 
 
* Segments 3 and 4 proceed in similar fashion. 
 
Comfort Measure: Imagine that you are the patient portrayed in this vignette. Now please rate you feelings of . . . comfort . . . worry  
 













B = -3.40*** 
Path a1: 
B = 3.23*** 
Path b1: 
B = -.57*** 
Path c’: 
B = .16 
Path a2: 
B = -3.12*** 
Path b2: 
B = .55*** 
Figure 7.1. Mediation Model: The Effect of HIV Stigma on Intentions to Remain in Care 
through Patients’ Feelings of Comfort and their Perceptions of Stigmatization within the 
Patient Provider Relationship. 
 




































Remain in Care 




B = -2.00*** 
Path a1: 
B = 3.23*** 
Path b1: 
B = -.44** 
Path c’: 
B = .69 
Path a2: 
B = -3.12*** 
Path b2: 
B = .47* 
Path b3: 
B = -.05 
Path a3: 
B = -3.31*** 
Figure 7.2. Mediation Model: The Effect of HIV Stigma on Intentions to Disclose Sexual 
Risk Behavior through Patients’ Feelings of Comfort and their Perceptions of 
Stigmatization within the Patient Provider Relationship. 
 















































B = -2.08*** 
Path a1: 






B = .28 
Path a2: 
B = -3.12*** 
Path b2: 
B = .09 
Path b3: 
B = .37** 
Path a3: 
B = -2.96*** 
Figure 7.3. Mediation Model: The Effect of HIV Stigma on Intentions to Disclose 
Substance Use Related Risk Behavior through Patients’ Feelings of Comfort and their 
Perceptions of Stigmatization within the Patient Provider Relationship. 
 

















































B = -1.61*** 
Path a1: 
B = 3.23*** 
Path b1: 
B = -.41* 
Path c’: 
B = .19 
Path a2: 
B = -3.12*** 
Path b2: 
B = .30 
Path b3: 
B = -.12 
Path a3: 
B = -3.67*** 
Figure 7.4. Mediation Model: The Effect of HIV Stigma on Intentions to Disclose 
HAART Non-Adherence through Patients’ Feelings of Comfort and their Perceptions of 
Stigmatization within the Patient Provider Relationship. 
 
















































B = .03 
Path a1: 
B = 3.16*** 
Path b1: 
B = -.09 
Path c’: 
B = -.11 
Path a2: 
B = -2.92*** 
Path b2: 
B = .10 
Path b3: 
B = -.23** 
Path a3: 
B = -3.11*** 
Figure 8.1. Mediation Model: The Effect of HIV Stigma on Disclosure of Lifetime 
Sexual Partners through Patients’ Feelings of Comfort and their Perceptions of 
Stigmatization within the Patient Provider Relationship. (LOG) 
 














































B = -.06 
Path a1: 
B = 3.23*** 
Path b1: 
B = -.02 
Path c’: 
B = .03 
Path a2: 
B = -3.08*** 
Path b2: 
B = -.04 
Path b3: 
B = -.01 
Path a3: 
B = -3.29*** 
Figure 8.2. Mediation Model: The Effect of HIV Stigma on Disclosure of Sexual Partners 
in Past Three Months through Patients’ Feelings of Comfort and their Perceptions of 
Stigmatization within the Patient Provider Relationship. (LOG) 
 


















































B = 3.23*** 
Path b1: 







B = -3.12*** 
Path b2: 
B = -.02 
Path b3: 
B = .13 
Path a3: 
B = -3.67*** 
Figure 8.3. Mediation Model: The Effect of HIV Stigma on Disclosure of Recent 
Condom Use Neglect through Patients’ Feelings of Comfort and their Perceptions of 
Stigmatization within the Patient Provider Relationship. 
 














































B = -.02 
Path a1: 
B = 3.23*** 
Path b1: 
B = .005 
Path c’: 
B = -.05 
Path a2: 
B = -3.12*** 
Path b2: 
B = .01 
Path b3: 
B = -.02 
Path a3: 
B = -2.96*** 
Figure 8.4. Mediation Model: The Effect of HIV Stigma Disclosure of Frequency of 
Alcohol Use through Patients’ Feelings of Comfort and their Perceptions of 
Stigmatization within the Patient Provider Relationship. (LOG) 
 















































B = .004 
Path a1: 
B = 3.23*** 
Path b1: 
B = -.007 
Path c’: 
B = .003 
Path a2: 
B = -3.12*** 
Path b2: 
B = .02 
Path b3: 
B = -.03 
Path a3: 
B = -2.96*** 
Figure 8.5. Mediation Model: The Effect of HIV Stigma Disclosure of Quantity of 
Alcohol Use through Patients’ Feelings of Comfort and their Perceptions of 
Stigmatization within the Patient Provider Relationship. (LOG) 
 
















































B = .04 
Path a1: 
B = 3.23*** 
Path b1: 
B = -.20 
Path c’: 
B = -.26 
Path a2: 
B = -3.12*** 
Path b2: 
B = -.32* 
Path b3: 
B = .02 
Path a3: 
B = -2.96*** 
Figure 8.6. Mediation Model: The Effect of HIV Stigma Disclosure of Lifetime Drug Use 
through Patients’ Feelings of Comfort and their Perceptions of Stigmatization within the 
Patient Provider Relationship. 
 








































Lifetime Drug Use 




B = -.04 
Path a1: 
B = 3.23*** 
Path b1: 
B = -.04 
Path c’: 
B = -.08 
Path a2: 
B = -3.12*** 
Path b2: 
B = -.06* 
Path b3: 
B = .01 
Path a3: 
B = -2.96*** 
Figure 8.7. Mediation Model: The Effect of HIV Stigma Disclosure of Drug Use in Past 
Three Months through Patients’ Feelings of Comfort and their Perceptions of 
Stigmatization within the Patient Provider Relationship. (LOG) 
 
 







































Recent Drug Use 








B = 3.23*** 
Path b1: 
B = -.002 
Path c’: 
B = -.08 
Path a2: 
B = -3.12*** 
Path b2: 
B = -.01 
Path b3: 
B = .01 
Path a3: 
B = -3.67*** 
Figure 8.8. Mediation Model: The Effect of HIV Stigma Disclosure of Recency of 
Missed HAART Doses through Patients’ Feelings of Comfort and their Perceptions of 
Stigmatization within the Patient Provider Relationship. (LOG) 
 












































Recency of Missed 
HAART Doses 




B = -.004 
Path a1: 
B = 3.23*** 
Path b1: 
B = .02 
Path c’: 
B = -.05 
Path a2: 
B = -3.12*** 
Path b2: 
B = .08 
Path b3: 
B = -.06 
Path a3: 
B = -3.67*** 
Figure 8.9. Mediation Model: The Effect of HIV Stigma Disclosure of HAART Non-
Adherence through Patients’ Feelings of Comfort and their Perceptions of Stigmatization 
within the Patient Provider Relationship. (LOG) 
 
 












































  147    
 
Appendices
  148    
 
List of Appendices 
Appendix A-Demographics and Medical Information 
Appendix B-Qualitative Interview Guide 
Appendix C-Draft of Qualitative Focus Group Protocol 
Appendix D-Draft of Qualitative Focus Group Informed Consent Form 
Appendix E-Study Receipt 
Appendix F-Validity Sub-study Questionnaire 
Appendix G-Draft of Validity Phase Protocol 
Appendix H-Draft of Validity Phase Informed Consent Form 
Appendix I-Experiences of HIV-related Stigmatization in Healthcare  
Appendix J-Patient Comfort Measure 
Appendix K- Perceptions of Stigmatization within the Patient-Provider Interaction 
Appendix L-Engagement in Care Measures 
Appendix M-Vignette Scripts 
Appendix N-Draft of Experimental Phase Protocol 
Appendix O-Draft of Experimental Phase Informed Consent Form 
 




Demographics and Medical Information 




These questions ask about your background.  Please remember that all information 
you provide is completely confidential.  Do no put your name on this form. 
 
1.  What is the highest grade in school that you have ever completed?  (circle correct 
number below) 
 
1   2   3   4   5   6   7   8   9   10   11   12   (12 = high school degree) 
 
13   14   15   16(= bachelors’ degree)   17   18(= masters’ degree)   19   
 20(=doctoral degree) 
2.  What is your current age? ______   
 
3. What is your Date of Birth ____ / ____ / ____ 
 
4.  Do you consider yourself to be Hispanic/Latina/Latino? No  Yes 
 
5.  Which of the following best describes your racial/ethnic background? Is it…    
 1   African-American or Black 4   American Indian or Alaska Native 
 2   White or Caucasian  5    Mixed or Multiracial 
 3    Asian or Pacific Islander 6   Other 
6.  Do you identify as:  
  1   2   3 
 female  male  transgender 
 
7.  Do you identify as  
 1  gay/homosexual    2  heterosexual/straight  
 3  bisexual     4  other 
8.  Based on your past behavior, which of the following statements applies best to you? 
1   I have sex with men only.    
2   I have sex mostly with men.  
 3   I have sex with men and women equally. 
 4  I have sex mostly with women. 
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9.  Are you currently employed? 
no    
 
yes   10.  How many hours per week do you work? _______ 
    
 
11.   Which best describes your current relationship status? 
 1  I have a main or primary partner, and we live together 
 2  I have a main or primary partner, but we live separately 
 3  I don’t currently have a primary partner 
  
12.  Is English your first language?         No    Yes 
                                                                                        
13. Where do you live?  
 
1   My own apartment 
2   My own home 
3   My family’s house or apartment 
4   Someone else’s house or apartment(not family) 
5    A rooming house or single room hotel 
6    A shelter 
7   A group home or halfway house 
8  Other: please specify other: _______________  
 
 
14. Approximately how much money do you have to live off of in an average month? 
This includes money that goes toward paying your rent, utilities, and other 
monthly bills.  $ ________  
 
15. How old were you when you first learned that you were HIV+?   ______ years old.  
 
16. When were you first diagnosed?   ______   _______ 
     month   year  
                 
17.  Have you ever been hospitalized for an HIV-related illness? 
no   yes 
      17a.  How many times?   __________ 
  (go to next  question)     
 
18.  Have you been diagnosed with AIDS?  
     no      yes   
      18a. What was the approximate date?______ 
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19. What was your CD4 or helper t-cell count in your MOST RECENT test report? (If 
you are unsure of the exact number, please make as close an approximation as you 
can.)  
 
CD4 count ______  I don’t know 
 
20. What was your MOST RECENT HIV viral load?  
    1   2   3 
 Undetectable Don’t know Number:___________ 
 
21. Are you currently taking HIV medication(s)?  
    no      yes 
     21a. When did you start taking HIV meds? _______ 
 
22. Approximately how many medical appointments at the Infectious Disease Clinic have 
you missed in the past year? _________ 
 
 
23. What is the most likely way that you became infected with HIV? 
 1  Sex with a man who was HIV+ 
 2  Sex with a woman who was HIV+ 
 3  Blood Transfusion 
 4  Sharing Needles 
 5  Other  
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Appendix B 
Qualitative Interview Guide 
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Qualitative Focus Group 
Interview Guide 
 
Introduction and Consent 
 
Facilitator will introduce herself and review the major points of the consent form with the 
group as mentioned in the protocol: 
 
 WHO:  The project directors for this study are Jessie Heath, M.S., a clinical 
psychology doctoral student at Syracuse University and Dr. Peter Vanable, an 
associate professor of psychology at Syracuse University and an adjunct assistant 
professor of medicine at SUNY Upstate Medical University. 
 
  PURPOSE & PROCEDURE:  You are being asked to participate in a research 
study designed to learn more about effects of positive and negative treatment 
experiences of persons living with HIV. Our goal is to identify what medical 
provider behaviors are viewed as stigmatizing by HIV+ patients and gain a better 
understanding of how stigmatizing behaviors of medical care providers can affect 
the HIV+ patients they treat. We will use the information obtained in this study to 
inform the development of strategies to reduce the stigmatization of HIV+ 
patients in medical care settings.  
 
 TIME & COMPENSATION:  Your participation involves a group discussion and 
filling out a short questionnaire, a total of 2 hours. You will receive $20 for you 
time. 
 
 RISKS/BENEFITS:   
o Embarrassment or discomfort:  Some of the things we will talk about in 
the group discussion involved sensitive, private information.  You are 
invited to share as much or as little information as you desire, you can 
refuse to answer any question you feel is too personal. 
o Breach of confidentiality:  Because we will be meeting in a group, there is 
the potential for other group members to tell other people what you say 
during the discussion.  We will try to prevent this from happening by 
asking group members to keep everything that is said in the group 
discussion confidential.   
o Benefits:  You may learn more about your feelings and become aware of 
how your medical treatment experiences have affected you.  In addition, 
because the information you provide assists in the development of stigma 















To start out, I’d like you to tell me a little about yourself. 
 
 What was your experience like learning your have HIV?  When were you 
diagnosed?   
 Have you participated in research before?  What do you think about research? 
What do you think about involving people with HIV?   
 
I.  Negative Experiences in Medical Care 
 
I’d like to start by asking you a few questions about your experiences with in medical 
care.  
 
 In thinking specifically about medical care, what have been some of your most 
negative experiences with providers like doctors, nurses, med students?  
 Can you tell me about those experiences (what the provider specifically did or 
said, how you felt, when it occurred)? 
 Why do you think they behaved that way towards you?  
 
 
II. Stigmatization in Medical Care 
 
Now I would like to talk to you about a specific kind of negative experience in medical 
care that HIV+ patients like yourself have reported in the past, namely stigmatization or 
stigma. 
 
 When I say the word “stigma” or “stigmatization”, what comes to mind? How 
would you explain it to someone? 
 If not reported: Other HIV+ patients have reported these stigmatizing experiences 
in medical care (e.g. poor eye contact, increased distance, etc.). Have you?  
 How did you know that those experiences were related to being HIV+ vs. an 
alternative explanation like having a bad doctor or being treated poorly based on 
racial identity? 




III. Effects of Provider Stigmatization 
 
We’ve talked about your experiences with stigmatization in medical care.  I’d now like to 
ask you about how you think those experiences have affected you. 
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 How do you think provider stigmatization affects you (physical health, mental 
health, relationships, etc.)? 
 Do you think stigmatization affects your HIV disease progression? 
 Do you think stigmatization affects your relationship with the provider? How? 
 How does stigmatization affect your perceptions of your provider and your care? 
 Have your experiences of provider stigmatization had any lasting effects in your 
life? 
 If it weren’t for my experiences of provider stigmatization, I would have . . .? 
 
IV. Positive Treatment Experiences and Suggestions for Improved Care 
 
Given that we’ve talked about your negative experiences with medical care, I would also 
like to know about your positive experiences with providers.   
 
 Tell me about some of the most positive experiences you’ve have with medical 
providers. 
 How did the providers talk to you, behave, and make you feel?  
 What are some signs that your provider is not going to treat you in a stigmatizing 
way? 
 How have providers gotten you to feel comfortable enough to open up about 
sensitive information like sexual risk behaviors, substance use, and medication 
non-adherence? 





I really appreciate your participation in this study. As we are wrapping up, I would just 
like to get your feedback on how it felt to be a part of this group today. 
 
 How did you feel talking with others about your experiences? 
 What did you get out of today’s group? 
 Would you be interested in participating in future research projects? 
 
  




Draft of Qualitative Focus Group Protocol 
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QUALITATIVE FOCUS GROUP PROCEDURES 
 
I. INFORMED CONSENT 
 
 A. OVERVIEW OF CONSENT INFORMATION 
 
 A participant who gives their informed consent to participate in the focus group 
discussion should fully understand the nature of the research study, the purpose and 
pertinent procedures for the study, potential risks and benefits of participating, 
confidentiality and steps taken by research team to ensure confidentiality, and how the 
data will be used and stored.   
 
 B. FOCUS GROUP CONFIDENTIALITY CONCERNS 
 
Although a number of steps are taken to ensure confidentiality for every 
participant, the nature of a discussion group limits our ability to ensure that who attends 
and what is said in the focus group remains confidential.  Breach of confidentiality may 
occur if other group members choose to directly or indirectly disclose information 
regarding the identity of group members or the content of what is shared to people 
outside of the group.  The facilitator of the focus group directly addresses this risk during 
the introduction.  Specifically, she states that, “What is said here should stay here. Please 
respect the privacy of group members by not repeating what is said today outside of the 
group.” 
 
 C. PARTICIPANT CONSENT 
 
 After a brief introduction, the focus group facilitator leads the group through the 
informed consent form, highlighting the most important aspects of informed consent.  
The following outline illustrates the content that is verbally expressed by the facilitator 
during this process:  
 WHO:  The project directors for this study are Jessie Heath, M.S., a clinical 
psychology doctoral student at Syracuse University and Dr. Peter Vanable, an 
associate professor of psychology at Syracuse University and an adjunct assistant 
professor of medicine at SUNY Upstate Medical University. 
  PURPOSE & PROCEDURE:  You are being asked to participate in a research 
study designed to learn more about effects of positive and negative treatment 
experiences of persons living with HIV. Our goal is to identify what medical 
provider behaviors are viewed as stigmatizing by HIV+ patients and gain a better 
understanding of how stigmatizing behaviors of medical care providers can affect 
the HIV+ patients they treat. We will use the information obtained in this study to 
inform the development of strategies to reduce the stigmatization of HIV+ 
patients in medical care settings. 
 TIME & COMPENSATION:  Your participation involves a group discussion 
and filling out a short questionnaire, a total of 2 hours. You will receive $20 for 
your time. 
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 RISKS/BENEFITS:   
o Embarrassment or discomfort:  Some of the things we will talk about in 
the group discussion involved sensitive, private information.  You are 
invited to share as much or as little information as you desire, you can 
refuse to answer any question you feel is too personal. 
o Breach of confidentiality:  Because we will be meeting in a group, there is 
the potential for other group members to tell other people what you say 
during the discussion.  We will try to prevent this from happening by 
asking group members to keep everything that is said in the group 
discussion confidential.   
o Benefits:  You may learn more about your feelings and become aware of 
how your medical treatment experiences have affected you.  In addition, 
because the information you provide assists in the development of stigma 
reducing strategies, your participation could benefit others living with 
HIV. 
 CONFIDENTIALITY and HIPPA 
o If you decide to participate, any information that you give us is strictly 
confidential. We will keep your information private, except under 2 
circumstances.   
 First, if you tell us that you’re planning to hurt yourself or 
someone else we would have to disclose that information.  
 Second, if officials were concerned that the research team was 
acting inappropriately, the research records might be audited to 
make sure the research was being conducted ethically; however, 
the auditors would be required to protect your privacy. 
 PROTECTION OF CONFIDENTIALITY  
o All project staff receive extensive training and supervision on 
confidentiality procedures.   
o Your survey is given an identification number and only authorized 
research staff has access to the key that connects your information to your 
name.  Your identity will not be included on the audiotapes and the tapes 
will be erased once we are finished with the project. 
o Certificate of Confidentiality from the Department of Health and Human 
services, which states that the investigators cannot be forced to release 
your information (for example, by subpoena) to any federal, state, or local, 
civil, criminal, administrative, legislative, or other proceedings.  This 
Certificate does NOT prevent you or your family from voluntarily 
disclosing information about yourself or your involvement in this research.   
 PARTICIPATION IS VOLUNTARY:  You may refuse to participate or 
discontinue your participation at any time without penalty or loss of benefits. 
 PERMISSION TO BE RECONTACTED: The participants are then asked to 
sign and date one copy of the consent form and keep a second copy for their own 
records.  Participants are also given a copy of University Hospital’s Privacy 
Practices Policy and asked to keep it for their records.  
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D. STORAGE OF CONSENT FORMS 
 
After pertinent information from the completed consent forms has been entered 
into the secure Excel patient database, the completed focus group consent forms will be 
stored in a locked filing cabinet in the UPH office. 
 
 
II.  QUANTITATIVE DEMOGRAPHIC SURVEY ADMINISTRATION 
 
 A. ASSIGNMENT OF PARTICIPANT NUMBER 
 
After participants consent to and complete the quantitative demographic 
questionnaire, they will be assigned a participant ID number.  
 
 B. SURVEY ADMINISTRATION 
  
 The quantitative demographic survey is administered following the informed 
consent.  The participants are given clipboards to increase privacy in the group settings 
and are asked to complete the survey as accurately and honestly as possible.  When 
everyone has completed the survey, the surveys are collected and the discussion portion 
of the focus group begins.   
 
C. DATA ENTRY 
 
Data from the completed quantitative questionnaire will be entered by the 
principle investigator into SPSS.  The PI will then verify the accuracy of the initial data 
entry by double entering the data.   
 
 D. DATA STORAGE 
 
 Completed questionnaires will be stored in a locked filing cabinet in the UPH lab 
space in the CNY Medical Building.  No identifying information will be on the 
completed questionnaire.   
 
 
III.   PROTOCOL FOR FOCUS GROUP ADMINISTRATION 
 
 A. RECORDING PROCEDURE 
 
During the focus group, two handheld cassette recorders will be used to record the 
session.  Prior to each focus group, the tape recorders will be tested to ensure that there 
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B. FOCUS GROUP SCRIPT 
 
 The PC/focus group facilitator will follow the focus group script when leading 
focus group discussions. 
 
  
 C. PARTICIPANT REIMBURSEMENT 
 
 The PI will retrieve reimbursement funds from Sean Kelley prior to the start of 
the focus group.  Participants will be reimbursed $20 for their two hours of participation 
in the focus groups.  After participants have received their reimbursement, the PI will 
complete a reimbursement receipt including only the participant’s ID number and file it 
in the UPH filing cabinet under non-reconciled payment receipts.  The original 
reimbursement form will then be turned in to Sean Kelley.  A photocopy will be stored in 
the UPH filing cabinet under reconciled payment receipts.   
 
 D. STORAGE OF FOCUS GROUP TAPES 
 
 All focus group tapes will be labeled with the tape type (Master vs. Back-up), 
focus group date, interviewer’s initials, and focus group number.  Back-up tapes for each 
group will be stored in a locked filing cabinet in the UPH office. 
 
 E. FOCUS GROUP TRANSCRIPTS 
 
 The focus group tape will be transcribed, verbatim, by the facilitator.  Once the 
focus group transcripts are completed, an electronic copy will be stored on the UPH 
computer.  A paper copy will be stored in the locked UPH filing cabinet in the folder 
created specifically for that focus group. 
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Appendix D 
Draft of Qualitative Focus Group Informed Consent Form 
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SUNY UPSTATE MEDICAL UNIVERSITY AND  
SYRACUSE UNIVERSITY 
Consent/Authorization Form 




You are invited to participate in a research study designed to gain a better understanding 
of how the behaviors of medical care providers can affect the HIV+ patients they treat. 
We will use the information obtained in this study to inform the development of 
strategies to improve patient-provider relationships and the quality of medical care 
received HIV+ patients. The project directors for this study are Jessie Heath, M.S., a 
clinical psychology doctoral student at Syracuse University and Dr. Peter Vanable, an 
Associate Professor of Psychology at Syracuse University and an adjunct assistant 
professor of medicine at SUNY Upstate Medical University.  Other trained research staff 
will also be involved, and will be supervised by Dr. Peter Vanable of Syracuse 
University.  We are asking approximately 20 patients from this clinic to participate in the 
study. 
 
You will be given enough time to read and understand the information provided in this 
consent and authorization form. Please ask the study staff to explain any words or 
information that you do not understand. You may keep an unsigned copy of this consent 
and authorization form to think about your decision or discuss with your family, friends, 




If you decide to take part, you will be asked to share some of your positive and negative 
medical treatment experiences in a small discussion group that includes other individuals 
who are HIV+. In the discussion group, we will seek your input about what provider 
behaviors are seen as stigmatizing to HIV+ individuals and how the experience of 
stigmatization in medical settings may have affected you. The discussion group will also 
include questions regarding your suggestions on how HIV care could be improved.  
 
The discussion group will be tape recorded so that we can review all the suggestions and 
feedback provided by you and other participants. However, your identity will not be 
included on the audiotapes and the tapes will be erased once we are finished with the 
project. The discussion group will take approximately 2 hours to complete.  
 
If you agree to participate in the study, you will also be asked to complete a brief survey 
with questions about your background and health information, including medical 
appointment attendance, hospitalizations, and recent indicators of health status (CD4 
count, viral load).  




The risks of participating in this study include the possibility of experiencing 
uncomfortable feelings or distress when discussing your past treatment experiences.  
These risks will be minimized but not eliminated by our providing you with the 
opportunity to discuss any concerns that arise after completing the focus group.  There is 
also a risk that information that you provide during this study could be inadvertently 
disclosed to others, or that a breach in confidentially could occur regarding your 
involvement in the study. For example, other individuals who participate in the 
discussion group may tell other people what you say during the discussion group.  
However, we will try to prevent this from happening by asking group members not to 




The potential benefit to you is that may learn more about your feelings and become aware 
of how your medical treatment experiences have affected you.  In addition, because the 
information you provide may assist in educating health care providers about the best 
approaches to interacting with patients, your participation could benefit others living with 
HIV. 
 
Voluntary Participation:  
 
Your participation in this study is entirely voluntary and you may refuse to participate or 
discontinue participation at any time without penalty or loss of benefits to which you 
would be normally entitled.  Your decision about whether or not to participate in the 




If you decide not to participate in this research study, you will continue to receive your 




There are no costs to you and/or your insurance carrier for participating in this study.  
You will receive $20 for your participation.   
 
If you choose to stop participating in the study before all study requirements are 
completed, you will be paid $10 for each hour of time you devote to the study. 
 
In addition, by accepting payment for participating in this study, certain identifying 
information about you may be made available to professional auditors to satisfy audit and 
Federal reporting requirements, but confidentiality will be preserved. Please note that if 
you earn $600 or over in a calendar year as a research subject, you may have to pay taxes 
on these earnings. 




If you have any questions about the research, please contact Ms. Jessie Heath (315) 443-
1052 or Dr. Peter Vanable at (315) 443-2024.  If you have any questions about your 
rights as a research subject, please contact the SUNY Upstate Medical University 
Institutional Review Board Office at (315) 464-4317 or the Syracuse University 
Institutional Review Board Office at (315) 443-3013. 
 
Confidentiality of Records and Authorization to Use/Share Protected Health 
Information for Research: 
If you agree to participate in this research, identifiable health information about you 
will be used and shared with others involved in this research. For you to be in this 
research we need your permission to collect and share this information. Federal law 
protects your right to privacy concerning this information.  
 
When you sign this consent form at the end, it means that you have read this section and 
authorize the use and/or sharing of your protected health information as explained below. 
Your signature also means you have received a copy of Upstate’s Notice of Privacy 
Practices. 
 
Individually identifiable health information under the federal privacy law is considered to 
be any information from your medical record, or obtained from this study, that can be 
associated with you, and relates to your past, present, or future physical or mental health 
or condition. This is referred to as protected health information. 
 
Your protected health information will be kept confidential. Research staff will not share 
the information you provide during the discussion group with your doctor or nurse here in 
the clinic. Further, you will not be identified in any publication or presentation resulting 
from this study. Several steps have been taken to protect the confidentiality of your 
responses and involvement in this research.  Project staff has participated in extensive 
training and supervision regarding the importance of maintaining participant 
confidentiality.  In addition, an identification number will be assigned to your focus 
group responses, and only the directors of this research (Jessie Heath, M.S., and Dr. 
Vanable) will have access to the key that indicates which number belongs to which 
participant. The master list linking the participant ID number to the participant’s 
identifying information will be maintained in a separate, secure computer database, and 
will be destroyed at the conclusion of the study.   
 
To help us further protect your privacy, the investigators have received a Confidentiality 
Certificate from the Department of Health and Human Services.  With this Certificate, 
the investigators cannot be forced (for example by court subpoena) to disclose research 
information that may identify you in any Federal, State, or local, civil, criminal, 
administrative, legislative, or other proceedings. The researchers will use the Certificate 
to resist any demands for information that would identify you, except as explained below. 
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The Certificate cannot be used to resist a request for information from personnel of the 
United States Department of Health and Human Services that is used for auditing or 
evaluation of federally funded projects. 
In addition, the Confidentiality Certificate does not prevent you or a member of your 
family from voluntarily releasing information about yourself or your involvement in this 
research. Note however, that if an insurer or employer learns about your participation, 
and obtains your consent to receive research information, then the investigator may not 
use the Certificate of Confidentiality to withhold this information. This means that you 
and your family must also actively protect your own privacy.  
 
Why is it necessary to use/share your protected health information with 
others? 
The main reason to use and share your health information is to conduct the research 
as described in this consent form. Your information may also be shared with people 
and organizations that make sure the research is being done correctly, and to report 
unexpected or bad side effects you may have.  In addition, we would be required to 
release protected health if you tell us of your intent to harm yourself or others. 
 
What protected health information about you will be used or shared with others as 
part of this research?  
We may use and share the results of the interviews. We will only collect information 
that is needed for the research. 
 
Who will be authorized to use and/or share your protected health 
information?  
The researchers, their staff and the staff of Upstate Medical University participating 
in the research will use your protected health information for this research study. In 
addition, the Upstate Institutional Review Board (IRB), a committee responsible for 
protecting the rights of research subjects, and other Upstate Medical University or 
University Hospital staff who supervise the way the research is done, may have 
access to your protected health information.  
 
The researchers and their staff will determine if your protected health information 
will be used or shared with others outside of Upstate Medical University for 
purposes directly related to the conduct of the research.  
 
With whom would the protected health information be shared?  
Your protected health information may be shared with: 
 
 Federal agencies that supervise the way the research is conducted, such as the 
Department of Health and Human Services’ Office for Human Research 
Protections, the National Institutes of Health, or other governmental offices as 
required by law.   
 
 Researchers from Syracuse University assisting in the study. 
 
  167    
 
 The Syracuse University Institutional Review Board (a committee responsible for 
protecting the rights of research subjects). 
 
All reasonable efforts will be used to protect the confidentiality of your protected 
health information. However, not all individuals or groups have to comply with the 
Federal privacy law. Therefore, once your protected health information is disclosed 
(leaves Upstate Medical University), the Federal privacy law may not protect it.   
 
For how long will your protected health information be used or shared with 
others? 
There is no scheduled date at which this information will be destroyed or no longer used. 
This is because information that is collected for research purposes continues to be used 
and analyzed for many years and it is not possible to determine when this will be 
complete. 
 
Can you withdraw your authorization to collect/use/share your protected 
health information? 
You always have the right to withdraw your permission (revoke authorization) for 
us to use and share your health information, by putting your request in writing to 
the investigator in charge of the study.  This means that no further private health 
information will be collected. Once authorization is revoked, you may no longer 
participate in this research activity, but standard medical care and any other benefits to 
which you are entitled will not be affected. Revoking your authorization only affects 
uses and sharing of information obtained after your written request has been 
received, but not information obtained prior to that time.  
 
Even after you withdraw your permission, Upstate Medical University may continue 
to use and share information needed for the integrity of the study; for example, 
information about an unexpected or bad side effect you experienced related to the 
study.  
 
Can you have access to your health information? 
At the end of the study, you have the right to see and copy health information about 
you in accordance with the SUNY Upstate Medical University policies; however, your 
access may be limited while the study is in progress.  
 
Permission To Re-contact For Follow-Up Research 
We may conduct additional research on this important topic.  May we contact you about 
participation in future studies?  Indicating you are willing to be contacted does not 
obligate you to participate in any other study, nor does it affect your participation in this 
study.  
 
  No, I prefer not to be contacted about future studies.  
  Yes, I am willing to be contacted about future studies.  
 
Phone: _______________ Mailing Address: ________________________________ 
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Consent To Participate In Research & Authorization To Use And Share Personal 
Health Information: 
 
I hereby give my consent to participate in this research study and agree that my personal 
health information can be collected, used and shared by the researchers and staff for the 
research study described in this form. I will receive a signed copy of this consent form. 
  
______________________________________   __________________ 




Printed Name of Research Participant 
 
 
__________________________________________  __________________ 
Signature of Person Obtaining Consent/Authorization  Date 
 
 
_______________________________________________   
Printed Name of Person Obtaining Consent/Authorization 
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Receipt: Treatment Experiences of HIV+ Patients Study 







 Focus Group     Validity          Experimental 
 
          
 











___________________________  ___________ 











___________________________   
Printed Name    
 
___________________________  ___________ 
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Appendix F 
Validity Sub-study Questionnaire 
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Validity Sub-study Questionnaire 
 
*Please answer the following items after each segment of the medical care visit is 
presented to you. 
 
Vignette Segment 1. 
 
a. Please imagine that you are the patient portrayed in this vignette. Now rate how you 
feel interacting with this provider in terms of feeling: Comfort, At Ease, Relaxed, Secure, 
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b. Please imagine that you are the patient portrayed in this vignette and rate how much 










1. I felt 
devalued by 
this provider. 
1 2 3 4 5 6 7 






1 2 3 4 5 6 7 
3. I believe 
this provider 
treated me 
like an equal. 
1 2 3 4 5 6 7 
4. I believe 
this provider 
would prefer 
not to treat 
me. 
1 2 3 4 5 6 7 
5. I believe 
this provider 
treated me the 
same as he 
treats his 
other patients. 
1 2 3 4 5 6 7 
6. I believe 
this provider 
thought I was 
a bad person. 
1 2 3 4 5 6 7 




1 2 3 4 5 
6 7 





1 2 3 4 5 6 7 




1 2 3 4 5 6 7 
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Vignette Segment 2. 
 
a. Please imagine that you are the patient portrayed in this vignette. Now rate how you 
feel interacting with this provider in terms of feeling: Comfort, At Ease, Relaxed, Secure, 










































































































































































b. Please imagine that you are the patient portrayed in this vignette and rate how much 














1 2 3 4 5 6 7 






1 2 3 4 5 6 7 
3. I believe 
this provider 
treated me 
1 2 3 4 5 6 7 




4. I believe 
this provider 
would prefer 
not to treat 
me. 
1 2 3 4 5 6 7 
5. I believe 
this provider 
treated me 
the same as 
he treats his 
other 
patients. 
1 2 3 4 5 6 7 
6. I believe 
this provider 
thought I 
was a bad 
person. 
1 2 3 4 5 6 7 




1 2 3 4 5 6 7 





1 2 3 4 5 6 7 
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Vignette Segment 3. 
 
a. Please imagine that you are the patient portrayed in this vignette. Now rate how you 
feel interacting with this provider in terms of feeling: Comfort, At Ease, Relaxed, Secure, 











































































































































































b. Please imagine that you are the patient portrayed in this vignette and rate how much 














1 2 3 4 5 6 7 






1 2 3 4 5 6 7 
3. I believe 
this provider 
treated me 
1 2 3 4 5 6 7 




4. I believe 
this provider 
would prefer 
not to treat 
me. 
1 2 3 4 5 6 7 
5. I believe 
this provider 
treated me 
the same as 
he treats his 
other 
patients. 
1 2 3 4 5 6 7 
6. I believe 
this provider 
thought I 
was a bad 
person. 
1 2 3 4 5 6 7 




1 2 3 4 5 6 7 





1 2 3 4 5 6 7 

















a. Please imagine that you are the patient portrayed in this vignette. Now rate how 
you feel interacting with this provider in terms of feeling: Comfort, At Ease, 










































































































































































b. Please imagine that you are the patient portrayed in this vignette and rate how much 














1 2 3 4 5 6 7 






1 2 3 4 5 6 7 




1 2 3 4 5 6 7 
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equal. 
4. I believe 
this provider 
would prefer 
not to treat 
me. 
1 2 3 4 5 6 7 
5. I believe 
this provider 
treated me 
the same as 
he treats his 
other 
patients. 
1 2 3 4 5 6 7 
6. I believe 
this provider 
thought I 
was a bad 
person. 
1 2 3 4 5 6 7 




1 2 3 4 5 6 7 





1 2 3 4 5 6 7 




1 2 3 4 5 6 7 
 
 
c. Taking into consideration this entire treatment experience, how comfortable would you 






































d. Taking into consideration this entire treatment experience, how comfortable would you 


































e. Taking into consideration this entire treatment experience, how comfortable would you 



































****Thank you! Please ring bell for research assistant.  
 




Draft of Validity Phase Protocol 
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VALIDITY STUDY PROCEDURES 
 
I. INFORMED CONSENT 
 
 A. OVERVIEW OF CONSENT INFORMATION 
 
 A participant who gives their informed consent to participate in the study should 
fully understand the nature of the research study, the purpose and pertinent procedures for 
the study, potential risks and benefits of participating, confidentiality and steps taken by 
research team to ensure confidentiality, and how the data will be used and stored.   
 
 B. PARTICIPANT CONSENT 
 
 After a brief introduction, the principle investigator (PI) leads the participant 
through the informed consent form, highlighting the most important aspects of informed 
consent.  The following outline illustrates the content that is verbally expressed by the PI 
during this process:  
 WHO:  The project directors for this study are Jessie Heath, M.S., a clinical 
psychology doctoral student at Syracuse University and Dr. Peter Vanable, an 
associate professor of psychology at Syracuse University and an adjunct assistant 
professor of medicine at SUNY Upstate Medical University. 
  PURPOSE & PROCEDURE:  You are being asked to participate in a research 
study designed to learn more about how aspects of patient-provider relationships 
can affect the medical treatment of persons living with HIV. Our goal is to gain a 
better understanding of how the behaviors of medical care providers within 
medical appointments can affect the HIV+ patients they treat. We will use the 
information obtained in this study to inform the development of strategies to 
improve patient-provider relationships and the quality of medical care received 
HIV+ patients. 
 TIME & COMPENSATION:  Your participation involves viewing two 
vignettes of  hypothetical medical care visits, responding to questions using an 
interactive computer program, and briefly discussing your opinions with a 
research assistant. The study takes approximately one half hour, and you will 
receive $10 for you time. 
 RISKS/BENEFITS:   
o Risks: There are three risks associated with this study. First, you may feel 
uncomfortable answering personal questions. If this occurs, you may 
choose not to answer any question. Second, you may find some aspects of 
the vignette mildly upsetting. A third risk involves the risk of disclosing 
private information to our research team. However, all information that 
you share with members of our team is considered strictly confidential, 
and we are obligated to protect your privacy. 
o Benefits:  You may learn more about your feelings and become aware of 
how aspects of medical treatment experiences can affect you.  In addition, 
because the information you provide assists in the development of 
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strategies to improve patient-provider relationships, your participation 
could benefit others living with HIV. 
 
 CONFIDENTIALITY and HIPPA 
o If you decide to participate, any information that you give us is strictly 
confidential. We will keep your information private, except under 2 
circumstances.   
 First, if you tell us that you’re planning to hurt yourself or 
someone else we would have to disclose that information.  
 Second, if officials were concerned that the research team was 
acting inappropriately, the research records might be audited to 
make sure the research was being conducted ethically; however, 
the auditors would be required to protect your privacy. 
 PROTECTION OF CONFIDENTIALITY  
o All project staff receive extensive training and supervision on 
confidentiality procedures.   
o Your survey is given an identification number and only authorized 
research staff has access to the key that connects your information to your 
name.  Your identity will not be included on the audiotapes and the tapes 
will be erased once we are finished with the project. 
o Certificate of Confidentiality from the Department of Health and Human 
services, which states that the investigators cannot be forced to release 
your information (for example, by subpoena) to any federal, state, or local, 
civil, criminal, administrative, legislative, or other proceedings.  This 
Certificate does NOT prevent you or your family from voluntarily 
disclosing information about yourself or your involvement in this research.   
 PARTICIPATION IS VOLUNTARY:  You may refuse to participate or 
discontinue your participation at any time without penalty or loss of benefits. 
 PERMISSION TO BE RECONTACTED: The participants are then asked to 
sign and date one copy of the consent form and keep a second copy for their own 
records.  Participants are also given a copy of University Hospital’s Privacy 
Practices Policy and asked to keep it for their records.  
 
 C. STORAGE OF CONSENT FORMS 
 
After pertinent information from the completed consent forms has been entered 
into the Excel patient database, the completed focus group consent forms will be stored in 
a locked filing cabinet in the UPH office. 
 
II.  VALIDITY STUDY PROTOCOL ADMINISTRATION 
 
 A. ASSIGNMENT OF PARTICIPANT NUMBER AND CONDITION 
 
After participants consent, they will be assigned a participant ID number and 
randomized to a view either the “high stigma” or “no stigma” study condition first using 
a random number generator. 




B. VIGNETTE AND SURVEY ADMINISTRATION 
  
 The quantitative survey is administered following the informed consent.  The 
participants will be seated in front of a computer, where the PI will introduce the 
computerized study protocol and briefly describe how the computer program works. The 
PI will answer any questions the participant has and ensure the participant’s ability to 
successfully interact with the computer program.  For participants with limited computer 
exposure, the principle investigator will provide additional instruction on the use of the 
mouse and keyboard as necessary.  Participants will also be instructed that if they have 
any difficulties with the computer program to ring a bell on the desk and the principle 
investigator will assist them. Participants will then follow the audio instructions on the 
ACASI program to complete the small battery of self-report assessments and respond to 
the visual and audio treatment vignettes. The ordering of the protocol will be as follows: 
(1) reporting of background and health information, (2) step-by-step presentation of 
treatment vignettes with ratings of comfort and stigmatization assessed at several points 
throughout the presented patient-provider interaction, and (3) a brief discussion with the 
research assistant to elicit feedback about the vignettes. 
 
C. DATA ENTRY AND STORAGE 
 
Data from the ACASI program will be automatically stored upon completion of 
the protocol and then transformed into an SPSS format for analyses. There will be no 
hard copies of data in the experimental phase of the study and no identifying information 
will present in the ACASI or SPSS files.   
 
 D. PARTICIPANT REIMBURSEMENT 
 
 The PI will retrieve reimbursement funds from Sean Kelley prior to the start of 
the focus group.  Participants will be reimbursed $10 for their one half hour of 
participation in the focus groups.  After participants have received their reimbursement, 
the PI will complete a reimbursement receipt including only the participant’s ID number 
and file it in the UPH filing cabinet under non-reconciled payment receipts.  The original 
reimbursement form will then be turned in to Sean Kelley.  A photocopy will be stored in 








Draft of Validity Phase Informed Consent Form 
 
  186    
 
SUNY UPSTATE MEDICAL UNIVERSITY AND 
SYRACUSE UNIVERSITY 
Consent/Authorization Form 




You are invited to participate in a research study designed to learn more about how 
aspects of patient-provider relationships can affect the medical treatment of persons 
living with HIV. Our goal is to gain a better understanding of how the behaviors of 
medical care providers can affect the HIV+ patients they treat. We will use the 
information obtained in this study to inform the development of strategies to improve 
patient-provider relationships and the quality of medical care received HIV+ patients. 
The directors of this study are Jessie Heath, M.S., a clinical psychology doctoral student 
and Dr. Peter Vanable, an Associate Professor of Psychology at Syracuse University and 
an Adjunct Assistant Professor of Medicine at SUNY Upstate Medical University.  Other 
trained research staff will also be involved, and will be supervised by Drs. Peter Vanable 
of Syracuse University. We are asking approximately 20 patients to participate in the 
study. 
 
You will be given enough time to read and understand the information provided in this 
consent and authorization form. Please ask the study staff to explain any words or 
information that you do not understand. You may keep an unsigned copy of this consent 
and authorization form to think about your decision or discuss with your family, friends, 




If you decide to take part in this study, you will listen and respond to information that is 
presented individually to you on a computer. You will view two vignettes representing 
typical, first-time medical care visits of an HIV+ patient. On the computer, you will hear 
audio descriptions of the medical visits, conversations between the hypothetical patient 
and provider, and also view pictures of the interaction. Throughout the presentation of the 
vignettes, you will answer questions presented on the computer screen regarding your 
feelings and opinions about what you are viewing. Following the presentation of the 
vignettes, you will give verbal feedback to a research assistant about your experience in 
the study and suggestions for improving the vignettes. The study takes approximately one 
half hour to complete, and your participation is completely voluntary. 
 
If you agree to participate in the study, you will also be asked to complete a brief survey 
with questions about your background and health information, including medical 
appointment attendance, hospitalizations, and recent indicators of health status (CD4 








There are three risks associated with this study. First, you may feel uncomfortable 
answering personal questions. If this occurs, you may choose not to answer any question. 
Second, you may find some aspects of the treatment vignette mildly upsetting. A third 
risk involves the risk of disclosing private information to our research team. However, all 
information that you share with members of our team is considered strictly confidential, 




The potential benefits are that you may learn more about your feelings and become aware 
of how aspects of medical treatment experiences can affect you.  In addition, because the 
information you provide assists in the development of strategies to improve patient-
provider relationships, your participation could benefit others living with HIV. 
 
Voluntary Participation:  
 
Your participation in this study is entirely voluntary and you may refuse to participate or 
stop participation at any time without penalty or loss of benefits to which you would 
normally be entitled.  Your decision about whether or not to participate in the study will 




If you decide not to participate in this research study, you will continue to receive your 




There are no costs to you and/or your insurance carrier for participating in this study. 
After completing the study, you will receive $10 to offset your expenses and to thank you 
for your time. 
 
If you choose to stop participating in the study before all study requirements are 
completed, you will be paid $5 for each ¼ hour of time you devote to the study. 
 
In addition, by accepting payment for participating in this study, certain identifying 
information about you may be made available to professional auditors to satisfy audit and 
Federal reporting requirements, but confidentiality will be preserved. Please note that if 
you earn $600 or over in a calendar year as a research subject, you may have to pay taxes 









If you have any questions about the research, please contact Ms. Jessie Heath at (315) 
443-1052 or Dr. Peter Vanable at (315) 443-2024.  If you have any questions about your 
rights as a research subject, please contact the SUNY Upstate Medical University 
Institutional Review Board Office at (315) 464-4317 or the Syracuse University 
Institutional Review Board Office at (315) 443-3013. 
Confidentiality of Records and Authorization to Use/Share Protected Health 
Information for Research: 
 
If you agree to participate in this research, identifiable health information about you 
will be used and shared with others involved in this research. For you to be in this 
research we need your permission to collect and share this information. Federal law 
protects your right to privacy concerning this information.  
 
When you sign this consent form at the end, it means that you have read this section and 
authorize the use and/or sharing of your protected health information as explained below. 
Your signature also means you have received a copy of Upstate’s Notice of Privacy 
Practices. 
 
Individually identifiable health information under the federal privacy law is considered to 
be any information from your medical record, or obtained from this study, that can be 
associated with you, and relates to your past, present, or future physical or mental health 
or condition. This is referred to as protected health information. 
 
Your protected health information will be kept confidential. Research staff will not share 
the information you provide during the discussion group and on the survey with your 
doctor or nurse here in the clinic. Further, you will not be identified in any publication or 
presentation resulting from this study. Several steps have been taken to protect the 
confidentiality of your responses and involvement in this research.  Project staff has 
participated in extensive training and supervision regarding the importance of 
maintaining participant confidentiality.  In addition, an identification number will be 
assigned to your survey, and only the directors of this research (Jessie Heath, M.S. and 
Dr. Vanable) will have access to the key that indicates which number belongs to which 
participant. The master list linking the participant ID number to the participant’s 
identifying information will be maintained in a separate, secure computer database, and 
will be destroyed at the conclusion of the study.  Your name or other identifying 
information will not be kept with your survey, and your survey information will be stored 
in a secure computer database.  
 
To help us further protect your privacy, the investigators have received a Confidentiality 
Certificate from the Department of Health and Human Services.  With this Certificate, 
the investigators cannot be forced (for example by court subpoena) to disclose research 
information that may identify you in any Federal, State, or local, civil, criminal, 
administrative, legislative, or other proceedings. The researchers will use the Certificate 
to resist any demands for information that would identify you, except as explained below. 
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The Certificate cannot be used to resist a request for information from personnel of the 
United States Department of Health and Human Services that is used for auditing or 
evaluation of federally funded projects. 
 
In addition, the Confidentiality Certificate does not prevent you or a member of your 
family from voluntarily releasing information about yourself or your involvement in this 
research. Note however, that if an insurer or employer learns about your participation, 
and obtains your consent to receive research information, then the investigator may not 
use the Certificate of Confidentiality to withhold this information. This means that you 
and your family must also actively protect your own privacy.  
 
Why is it necessary to use/share your protected health information with 
others? The main reason to use and share your health information is to conduct the 
research as described in this consent form. Your information may also be shared 
with people and organizations that make sure the research is being done correctly, 
and to report unexpected or bad side effects you may have. In addition, we will 
release protected health information about you if we learn about your intent to harm 
yourself or others. 
 
What protected health information about you will be used or shared with others as 
part of this research? We may use and share the results of tests, questionnaires, and 
interviews. We will only collect information that is needed for the research. 
 
Who will be authorized to use and/or share your protected health 
information? The researchers, their staff and the staff of Upstate Medical University 
participating in the research will use your protected health information for this 
research study. In addition, the Upstate Medical University and Syracuse University 
Institutional Review Boards (IRB), committees responsible for protecting the rights 
of research subjects, and other Upstate Medical University, Syracuse University, or 
University Hospital staff who supervise the way the research is done, may have 
access to your protected health information.  
 
The researchers and their staff will determine if your protected health information 
will be used or shared with others outside of Upstate Medical University and 
Syracuse University for purposes directly related to the conduct of the research.  
 
With whom would the protected health information be shared? Your protected 
health information may be shared with: 
 
 Federal agencies that supervise the way the research is conducted, such as the 
Department of Health and Human Services’ Office for Human Research 
Protections or the National Institutes of Health.  
 
 Researchers from Syracuse University assisting in the study. 
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 The Syracuse University Institutional Review Board (a committee responsible for 
protecting the rights of research subjects). 
 
All reasonable efforts will be used to protect the confidentiality of your protected 
health information. However, not all individuals or groups have to comply with the 
Federal privacy law. Therefore, once your protected health information is disclosed 
(leaves Upstate Medical University), the Federal privacy law may not protect it.    
 
For how long will your protected health information be used or shared with 
others? There is no scheduled date at which this information will be destroyed or no 
longer used. This is because information that is collected for research purposes continues 
to be used and analyzed for many years and it is not possible to determine when this will 
be complete. 
 
Can you withdraw your authorization to collect/use/share your protected 
health information? You always have the right to withdraw your permission 
(revoke authorization) for us to use and share your health information, by putting 
your request in writing to the investigator in charge of the study.  This means that 
no further private health information will be collected. Once authorization is 
revoked, you may no longer participate in this research activity, but standard medical 
care and any other benefits to which you are entitled will not be affected. Revoking 
your authorization only affects uses and sharing of information obtained after your 
written request has been received, but not information obtained prior to that time.  
 
Even after you withdraw your permission, Upstate Medical University may continue 
to use and share information needed for the integrity of the study; for example, 
information about an unexpected or bad side effect you experienced related to the 
study.  
 
Can you have access to your health information? At the end of the study, you have 
the right to see and copy health information about you in accordance with the SUNY 
Upstate Medical University policies; however, your access may be limited while the 
study is in progress.  
 
Permission To Contact For Follow-Up Research 
We may conduct additional research on this important topic.  May we contact you about 
participation in future studies?  Indicating you are willing to be contacted does not 
obligate you to participate in any other study, nor does it affect your participation in this 
study.  
 
  No, I prefer not to be contacted about future studies.  
  Yes, I am willing to be contacted about future studies.  
 
Phone: _______________  
 
Mailing Address: _______________________________________ 
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Consent To Participate In Research & Authorization To Use And Share Personal 
Health Information: 
 
I hereby give my consent to participate in this research study and agree that my personal 
health information can be collected, used and shared by the researchers and staff for the 
research study described in this form. I will receive a signed copy of this consent form. 
  
 
______________________________________   __________________ 




Printed Name of Research Participant 
 
 
___________________________________________  __________________ 
Signature of Person Obtaining Consent/Authorization  Date 
 
 
___________________________________________   
Printed Name of Person Obtaining Consent/Authorization 
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Appendix I 
Experiences of HIV-related Stigmatization in Healthcare 
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Experiences of HIV-related Stigmatization in Healthcare 
 
Directions: Please indicate the extent to which you have experienced these behaviors 





A healthcare provider . . .  
 








1. has refused to treat me because I am 
HIV+ 
0 1 2 3 4 
2. has appeared angry or irritated while 
treating me 
0 1 2 3 4 
3. has avoided touching me because I am 
HIV+ 
0 1 2 3 4 
4. has rushed me through an 
appointment because I am HIV+ 
0 1 2 3 4 
5. has blamed me for my infection 
because of my lifestyle 
0 1 2 3 4 
6. has given me a lower quality of care 
because I am HIV+ 
0 1 2 3 4 
7. would not maintain eye contact with 
me because I am HIV+ 
0 1 2 3 4 
8. has sat/stood very far away from me 
in the treatment room because I am 
HIV+ 
0 1 2 3 4 
9. has made me wait longer for care than 
other patients because I am HIV+ 
0 1 2 3 4 
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10. has appeared nervous or 
uncomfortable while treating me 
0 1 2 3 4 
11. has treated me rudely or 
disrespectfully because I am HIV+ 
0 1 2 3 4 
12. has told me that I deserved to 
become infected 
0 1 2 3 4 
13. referred me to another provider 
because I am HIV+ 
0 1 2 3 4 
14. has worn extra gloves to examine me 
when  it was unnecessary 
0 1 2 3 4 
15. has told me or acted as if I was a 
waste of his/her time because I am HIV+ 
0 1 2 3 4 
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Appendix J 
Patient Comfort Measure 
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Patient Comfort Measure 
 
 
1. Please imagine that you are the patient portrayed in this vignette. Now rate how you 
feel interacting with this provider in terms of feeling: Comfort, At Ease, Relaxed, Secure, 










































































































































































2. How comfortable would you feel having a conversation about risky sexual behaviors 
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3. How comfortable would you feel having a conversation about alcohol and substance 
































4. How comfortable would you feel having a conversation about HIV medication 
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Appendix K 
Perceptions of Stigmatization within the Patient-Provider Interaction 
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Perceptions of Stigmatization within the Patient-Provider Interaction 
 
 
Directions: Please indicate the extent to which you agree or disagree with each of the 















1 2 3 4 5 6 7 






1 2 3 4 5 6 7 





1 2 3 4 5 6 7 
4. I believe 
this provider 
would prefer 
not to treat 
me. 
1 2 3 4 5 6 7 
5. I believe 
this provider 
treated me 
the same as 
he treats his 
other 
patients. 
1 2 3 4 5 6 7 
6. I believe 
this provider 
thought I 
was a bad 
person. 
1 2 3 4 5 6 7 




1 2 3 4 5 6 7 





1 2 3 4 5 6 7 




1 2 3 4 5 6 7 















10. I believe this 
provider would 
listen to me. 
1 2 3 4 5 6 7 
11. I believe this 
provider would 
care about me. 
1 2 3 4 5 6 7 




1 2 3 4 5 6 7 
13. I believe this 
provider would 
spend enough 
time with me. 
1 2 3 4 5 6 7 
14. I believe this 
provider would 
involve me in 
treatment 
decisions. 
1 2 3 4 5 6 7 




1 2 3 4 5 6 7 





1 2 3 4 5 6 7 
17. I believe this 
provider would 
engage me in my 
care. 
1 2 3 4 5 6 7 
18. I believe this 
provider would be 
helpful to me. 
1 2 3 4 5 6 7 
19. I believe this 
provider would 
respect me. 
1 2 3 4 5 6 7 




1 2 3 4 5 6 7 
21. I believe this 
provider would 
see me when I 
ask. 
1 2 3 4 5 6 7 
22. I believe this 
provider would 
give me important 
information. 
1 2 3 4 5 6 7 
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Appendix L 
Engagement in Care Measure 
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Engagement in Care Measures 
 
 
A. Intentions to Remain in HIV Care Measure 
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B. Intentions to Discuss Sexual Risk Behavior Measure 
 
*Please answer the following questions as if you have had unprotected anal or 
vaginal sex since becoming HIV+. In other words, even if you have not had 
unprotected sex since becoming HIV+, please imagine that you have when you are 
answering these next questions. 
 
1. If the provider shown in the computer program asked, how likely is it that you would 




































1 2 3 4 5 6 7 
 
2. If the provider shown in the computer program asked, how likely is it that you would 























1 2 3 4 5 6 7 





1 2 3 4 5 6 7 
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3. In the event that you were having difficulties achieving and maintaining safer sex 

































C. Intentions to Discuss Substance Use Risk Behavior Measure 
 
*Please answer the following questions as if you have drank alcohol or used drugs 
(not prescribed to you) since becoming HIV+. In other words, even if you have not 
drank alcohol or used drugs since becoming HIV+, please imagine that you have 
when you are answering these next questions. 
 
1. If the provider shown in the computer program asked, how likely is it that you would 






















1 2 3 4 5 6 7 




1 2 3 4 5 6 7 






1 2 3 4 5 6 7 






1 2 3 4 5 6 7 
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2. If the provider shown in the computer program asked, how likely is it that you would 























1 2 3 4 5 6 7 





1 2 3 4 5 6 7 







1 2 3 4 5 6 7 







1 2 3 4 5 6 7 
 
 
3. In the event that you were SHARING NEEDLES during drug use, and the provider 
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4. In the event that you were interested in receiving alcohol or substance abuse treatment, 
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D. Intentions to Discuss Medication Adherence Difficulties Measure 
 
*Please answer the following questions as if you are taking HIV MEDICATIONS 
and HAVE NOT had perfect 100% adherence. In other words, even if you are not 
on HIV medications or have never missed a dose, please imagine that you have when 
you are answering these next questions. 
 
1. If the provider shown in the computer program asked, how likely is it that you would 
tell them that you had UNINTENTIONALLY missed doses of your HIV medications 
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2. If the provider shown in the computer program asked, how likely is it that you would 
tell them you had INTENTIONALLY missed doses of your HIV medications 
(examples: purposely skipping doses, medication vacations, taking meds not as 
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3. In the event that you were having difficulties with medication adherence (not taking 
your meds exactly how you are supposed to), how likely is it that you would start a 
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E. Disclosure of Personal Risk Behaviors Measure  
 
*For these next questions, please imagine that you are at a clinic appointment with 
Dr. XXX, the provider previously shown on the computer. You are sitting on the 
exam table when Dr. XXX enters the room and states that he will be asking you a 
series of questions regarding sensitive health behaviors such sexual activities, 
alcohol and drug use, and HIV medication adherence. Please answer the provider 
based on your own actual, real life experiences. 
 
 















Some of the 
Time 
50%  
Half of the 
Time 
75%  











1-2 days 3-4 days 5-6 days 7 days 
 
 
5. Thinking of times when you have drank in the past three months, how many alcoholic 





1-2 drinks 3-4 drinks 5-6 drinks 
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Yes, but only a 
few times. 
Yes, I have 
used drugs 
frequently but 
did not have 
problems 
related to my 
use. 














Once or Twice 




























I have not 
taken any of 
my meds. 
 
10% 20% 30% 40% 50% 60% 70% 80% 90% 
100% 
I have taken all 
the doses of my 
meds. 
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Non-Stigma Vignette Female 
1. Segment 1:  
Narrator: Dr. Everheart knocked on the door before entering into the room. He 
approached Ms. Johnson and shook her hand while introducing himself.  
Actor 1 (provider): Hello Ms. Johnson my name is Dr. Actor 1 (provider) Everheart and 
I’ll be your primary physician here at the clinic. I understand that you are new to the area. 
I hope you are enjoying our lovely city. How are you doing? 
Narrator: Dr. Everheart takes a seat in a chair near the exam table where Ms. Johnson is 
sitting and begins reviewing her chart. 
Actor 2 (patient): Pretty good, I’m feeling healthy. I’m just a little stressed with having to 
start all over at a new clinic with new doctors. 
Actor 1 (provider): Well that’s understandable, we’ll try to make the process as easy as 
possible for you. Basically all we are going to be doing today is going over your medical 
history, completing a physical exam, and discussing any questions or concerns that you 
or I might have about your health. I like to be thorough with all my new patients, and 
double check some of the information in their files just to be sure it’s up to date and 
correct. Your last treatment center sent us your file yesterday, I just have few pieces of 
information that I would like to confirm with you. 
Actor 2 (patient): ok 
Actor 1 (provider): Your chart says that you tested positive for HIV about five years ago 
in February of 2006. 
Actor 2 (patient): Yeah, that’s the story. 
Actor 1 (provider): It says that you most likely became infected from sexual activity with 
men, and more specifically your boyfriend at the time. 
Actor 2 (patient): Yeah. He didn’t realize that he was positive and after 5 or 6 months 
together we weren’t as strict about using condoms all the time. One day he found out one 
of his past hook-ups was positive and we both went in and got tested. Both of us found 
out that we were positive. We’re still together though and he moved here with me.  
Actor 1 (provider): It seems like you have really been there for each other. You know, it’s 
so common for people to not know that they are positive. It seems like both of you got 
blind-sided in that situation. It’s really good that you both decided to come in and get 
tested when you did.  
Actor 2 (patient): Thanks. 
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2. Segment 2:  
Actor 1 (provider): So it also says that you began taking anti-retroviral medications pretty 
soon after you received your diagnosis. 
Actor 2 (patient): Yeah it was within a few months. 
Actor 1 (provider): And other than a couple bouts of pneumonia in 2007 and 2008, you 
have been pretty healthy. Looks like your viral load and CD4 counts have been pretty 
stable ever since you started taking meds, except for the summer of last year when your 
viral load became detectable again and your CD4 count dropped by 30%. Do you 
remember what was going on around that time that caused these changes? 
Actor 2 (patient): Yeah, my last doctors tried to switch my meds because they were 
making me nauseas and tired throughout the day. The new combination didn’t work, so 
they put me back on the old meds after a few months. I was actually upset about it 
because physically I felt really great on the new meds. I mean is it really that big of deal 
if my numbers change a little? 
Actor 1 (provider): You know it can often be a fairly complicated process to find the right 
combination of meds for patients. We try to balance out the experience of side effects 
with the effectiveness of the medications, and every patient responds a bit differently. 
Unfortunately, it is a big deal if your viral load and CD4 count change. Those are our best 
indicators of how the HIV virus is progressing in your body, and they can even be better 
indicators then how your body is physically feeling. I actually have a great brochure 
about some of the important information about viral load and CD4 counts. Would you 
like me to go over some of it with you? 
Actor 2 (patient): That would actually be really helpful. 
Narrator: Dr. Everheart stood up from his chair and grabbed a brochure. After walking 
over to the exam table, Dr. Everheart pointed out the key points of the brochure to Ms. 
Johnson and answered any remaining questions that she had.  
Actor 2 (patient): Ok, so I get now why they took me off the new meds, but is there 
anything that you can do to help with the side effects. I can’t be feeling sick all day at my 
new job. I don’t want to make that type of impression. 
Actor 1 (provider): For now, there are a few prescriptions to lessen your symptoms that 
haven’t been tried by your last doctors. And after I get some more detailed results from 
your blood draw today, I will look into the possibility of other medication regimens that 
might be as effective as your current meds but with less side effects. I don’t know if the 
new HIV medications on market will turn out to be a good fit for you, but we can 
definitely look into the possibility. 
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Actor 2 (patient): Ok, fair enough. 
3. Segment 3: 
Narrator: Dr. Everheart handed the brochure to Ms. Johnson and explained that he would 
now be performing a physical examination. 
Actor 1 (provider): Alright, well I am now going to give you a brief physical examination 
to check your heart rate, blood pressure, breathing, and also check out your throat, ears, 
and eyes for normal functioning. 
Narrator: Dr. Everheart approached Ms. Johnson, placing the stethoscope in his ears. He 
stood close to Ms. Johnson, placed the stethoscope on her chest, and listened to her 
breathing for approximately 10 seconds. He then placed the stethoscope on his back and 
listened for another 10 seconds. Dr. Everheart removed the stethoscope from her ears, 
reached for the blood pressure cuff, and placed it on Ms. Johnson’s arm. After taking Ms. 
Johnson’s blood pressure, Dr. Everheart, stood up and walked to the supply cabinet in the 
exam room. Dr. Everheart returned with a tongue depressor and asked Ms. Johnson to 
open her mouth. Dr. Everheart leaned towards Ms. Johnson and examined the inside of 
her throat thoroughly. Dr. Everheart then felt her lymph nodes on the side of her neck for 
a few moments before returning to his seat near the exam table.  
4. Segment 4:  
Actor 1 (provider): Well everything looks good as far as blood pressure and heart rate. 
And no signs of temperature or cold symptoms. How have you been feeling recently? 
Actor 2 (patient): Pretty good, but I’ve been having a lot of headaches lately.  
Actor 1 (provider): Has anything happened recently to trigger these headaches? Any 
changes in medication, diet, activity level? 
Actor 2 (patient): Not really. 
Actor 1 (provider): Have you been experiencing a lot of stress lately? Everything been 
going ok with friends/family? 
Actor 2 (patient): You know I have been stressed out a lot due to the move, but I really 
don’t think it’s just that. They’re pretty bad. I get shooting pains right behind my eyes, 
and it’s happening at least twice a week. 
Actor 1 (provider): Ok, well I have some ideas for what might be causing these types 
headaches. Those pain symptoms are pretty common for a lot of people especially those 
with a family history of migraines. I’ll check to see if we have some medication samples 
to for you take home and see if they help. They shouldn’t interact with any of your HIV 
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meds, just make sure to take them with food. If after a week you’re still having problems 
we can do some more extensive tests to see what’s going on. Sound okay to you?  
Actor 2 (patient): Sounds good. 
Actor 1 (provider): Great. Well I’m going to go grab those medication samples.  
Narrator: Dr. Everheart left the exam room and returned in several minutes with the 
medication samples. 
Actor 1 (provider): Well we’re just about finished with today’s appointment. But before 
you leave, I’d like to chat with you a little about your current sexual practices and also 
any previous or current alcohol or drug use. I know these types of topics are sensitive in 
nature and can seem a little out of the blue for a regular medical appointment. Basically 
new national standards of medical practice have been created, calling for health care 
providers to assess these types of things at all medical care visits to improve prevention 
of new infections and also to allow for the best care possible for current HIV+ patients. 
It’s important to me that you feel comfortable, so is it okay for me to ask you a few 
questions? 
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Stigma Vignette Female 
1. Segment 1:  
Narrator: Dr. Everheart knocked on the door before entering into the room. He walked 
through door looking at Ms. Johnson’s file and did not look up while introducing himself.  
Actor 1 (provider): Hello Ms. Johnson my name is Dr. Everheart and I’ll be your primary 
physician here at the clinic. How are you doing? 
Narrator: Dr. Everheart takes a seat in a chair on the far side of the room from where Ms. 
Johnson is sitting and begins reviewing her chart. 
Actor 2 (patient): Pretty good, I’m feeling healthy. I’m just a little stressed with having to 
start all over at a new clinic with new doctors. 
Narrator: Dr. Everheart continues to look down at Ms. Johnson’s chart as he speaks.  
Actor 1 (provider): Well, nothing to worry about. Basically all we are going to be doing 
today is going over your medical history and completing a physical exam. I like to be 
thorough with all my new patients, and double check some of the information in their 
files. Your last treatment center sent us your file yesterday, I just have few pieces of 
information that I would like to confirm with you. 
Actor 2 (patient): ok 
Actor 1 (provider): Your chart says that you tested positive for HIV about five years ago 
in February of 2006. 
Actor 2 (patient): Yeah, that’s the story. 
Actor 1 (provider): It says that you most likely became infected from having sex with 
HIV+ men. Hopefully becoming positive has motivated you to be more careful with 
reducing your number of sexual partners, using condoms, and staying away from drugs. 
Oh wait, I see here that you were infected by your boyfriend at the time. 
Actor 2 (patient): Yeah. He didn’t realize that he was positive and after 5 or 6 months 
together we weren’t as strict about using condoms all the time. One day he found out one 
of his past hook-ups was positive and we both went in and got tested. Both of us found 
out that we were positive. We’re still together though and he moved here with me.  
Actor 1 (provider): That’s surprising. You really don’t see that nowadays. But, I guess 
you learned your lesson, and at least you both decided to come in and get tested when 
you did.  
Actor 2 (patient): Thanks. 
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2. Segment 2:  
Actor 1 (provider): So it also says that you began taking anti-retroviral medications pretty 
soon after you received your diagnosis. 
Actor 2 (patient): Yeah it was within a few months. 
Actor 1 (provider): And other than a couple bouts of pneumonia in 2007 and 2008, you 
have been pretty healthy. Looks like your viral load and CD4 counts have been pretty 
stable ever since you started taking meds. That is except for the summer of last year when 
your viral load became detectable again and your CD4 count dropped by 30%. Did you 
stop taking your meds? 
Actor 2 (patient): No, actually my last doctors tried to switch my meds because they were 
making me nauseas and tired throughout the day. The new combination didn’t work, so 
they put me back on the old meds after a few months. I was actually upset about it 
because physically I felt really great on the new meds. I mean is it really that big of deal 
if my numbers change a little? 
Actor 1 (provider): Unfortunately, Ms. Johnson it is a big deal if your viral load and CD4 
count change. Those are our best indicators of how the HIV virus is progressing in your 
body. You’ve been positive a while, I assumed you knew all this.  I think I have a 
brochure that can explain viral load and CD4 counts to you. Let me grab it. 
Narrator: Dr. Everheart rose from his chair and grabbed a brochure. Without approaching 
the exam table, he leaned over to hand the brochure to Ms. Johnson. 
Actor 1 (provider): I strongly suggest you review this material. 
Actor 2 (patient): I’ll check this out later, but is there anything that you can do to help 
with the side effects. I can’t be feeling sick all day at my new job. I don’t want to make 
that type of impression. 
Actor 1 (provider): For now, there are a few prescriptions to lessen your symptoms that 
haven’t been tried by your last doctors.  
Actor 2 (patient): What about changing my HIV meds? Can we try something new? I’ve 
been reading a lot about a one-a-day pill. Could we try that? 
Actor 1 (provider): I really don’t think that’s necessary at this point. Your current meds 
are working great, other than a few side effects. But if it’s that important to you, after I 
get some more detailed results from your blood draw today, I will look into the 
possibility of other medication regimens.  
Actor 2 (patient): Ok. 
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3. Segment 3: 
Narrator: Dr. Everheart explained that he would now be performing a physical 
examination. 
Actor 1 (provider): Alright, well I am now going to give you a brief physical examination 
to check your heart rate, blood pressure, breathing, and also check out your throat, ears, 
and eyes for normal functioning. 
Narrator: Dr. Everheart walked to the supply cabinet and grabbed two pairs of latex 
gloves. He put them on his hands and approached Ms. Johnson, placing the stethoscope 
in his ears. He maintained an arm’s length distance from Ms. Johnson, having to stretch 
his arm to place the stethoscope on her chest. Leaning away from Ms. Johnson, he 
listened to his breathing for a few seconds, and then placed the stethoscope on her back 
and listened for another couple seconds. Dr. Everheart removed the stethoscope from his 
ears, reached for the blood pressure cuff, and asked Ms. Johnson’s to place it on her own 
arm. After taking Ms. Johnson’s blood pressure, Dr. Everheart, stood up and again 
walked to the supply cabinet in the exam room. Dr. Everheart returned with a tongue 
depressor and asked Ms. Johnson to open her mouth. Dr. Everheart again maintained an 
arm’s length distance from Ms. Johnson and had a strained look on his face while 
examining the inside of her throat. Dr. Everheart then felt her lymph nodes on the side of 
her neck for a few moments before returning to his seat on the far side of the exam room.  
4. Segment 4:  
Actor 1 (provider): Well everything looks good as far as blood pressure and heart rate. 
And no signs of temperature or cold symptoms. How have you been feeling recently? 
Actor 2 (patient): Pretty good, but I’ve been having a lot of headaches lately.  
Actor 1 (provider): Has anything happened recently to trigger these headaches? Any 
changes in medication, diet, activity level? 
Actor 2 (patient): Not really. 
Actor 1 (provider): Then it’s probably just HIV-related. 
Actor 2 (patient): Well maybe. But they’re pretty bad. I get shooting pains right behind 
my eyes, and it’s happening at least twice a week. 
Actor 1 (provider): Ok, well it sounds like you might be experiencing migraines. I think 
we have some med samples here in the clinic that you could try out, but I’m not really 
sure if migraine medications with interact negatively with your HIV medications. Let me 
check with your nurse practitioner.  
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Narrator: Dr. Everheart walked to the door and opened it far enough to stick his head out 
into the hall. In a moderately loud voice, he called for Ms. Johnson’s nurse practitioner.  
Actor 1 (provider): Christine, will Imitrex interact with Ms. Regina Johnson’s HIV 
regimen? 
Narrator: After Dr. Everheart talked with Christine, he closed the door and turned to face 
Ms. Johnson. 
Actor 1 (provider): Ok, well they shouldn’t interact with any of your HIV meds, just 
make sure to take them with food. If after a week you’re still having problems we can do 
some more extensive tests to see what else might be going on. Sound okay to you? 
Actor 2 (patient): Sounds good. 
Actor 1 (provider): Great. Well I’m going to go grab those medication samples.  
Narrator: Dr. Everheart left the exam room and returned in 15 minutes with the 
medication samples. 
Actor 1 (provider): Well we’re just about finished with today’s appointment. But before 
you leave, I need to ask you a series of questions about your current sexual practices and 
also any previous or current alcohol or drug use.  
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Non-Stigma Vignette Male 
1. Segment 1:  
Narrator: Dr. Everheart knocked on the door before entering into the room. He 
approached Mr. Johnson and shook his hand while introducing himself.  
Actor 1 (provider): Hello Mr. Johnson my name is Dr. Actor 1 (provider) Everheart and 
I’ll be your primary physician here at the clinic. I understand that you are new to the area. 
I hope you are enjoying our lovely city. How are you doing? 
Narrator: Dr. Everheart takes a seat in a chair near the exam table where Mr. Johnson is 
sitting and begins reviewing his chart. 
Actor 2 (patient): Pretty good, I’m feeling healthy. I’m just a little stressed with having to 
start all over at a new clinic with new doctors. 
Actor 1 (provider): Well that’s understandable, we’ll try to make the process as easy as 
possible for you. Basically all we are going to be doing today is going over your medical 
history, completing a physical exam, and discussing any questions or concerns that you 
or I might have about your health. I like to be thorough with all my new patients, and 
double check some of the information in their files just to be sure it’s up to date and 
correct. Your last treatment center sent us your file yesterday, I just have few pieces of 
information that I would like to confirm with you. 
Actor 2 (patient): ok 
Actor 1 (provider): Your chart says that you tested positive for HIV about five years ago 
in February of 2006. 
Actor 2 (patient): Yeah, that’s the story. 
Actor 1 (provider): It says that you most likely became infected from sexual activity with 
men, and more specifically your partner at the time. 
Actor 2 (patient): Yeah. He didn’t realize that he was positive and after 5 or 6 months 
together we weren’t as strict about using condoms all the time. One day he found out one 
of his past hook-ups was positive and we both went in and got tested. Both of us found 
out that we were positive. We’re still together though and he moved here with me.  
Actor 1 (provider): It seems like you have really been there for each other. You know, it’s 
so common for people to not know that they are positive. It seems like both of you got 
blind-sided in that situation. It’s really good that you both decided to come in and get 
tested when you did.  
Actor 2 (patient): Thanks. 
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2. Segment 2:  
Actor 1 (provider): So it also says that you began taking anti-retroviral medications pretty 
soon after you received your diagnosis. 
Actor 2 (patient): Yeah it was within a few months. 
Actor 1 (provider): And other than a couple bouts of pneumonia in 2007 and 2008, you 
have been pretty healthy. Looks like your viral load and CD4 counts have been pretty 
stable ever since you started taking meds, except for the summer of last year when your 
viral load became detectable again and your CD4 count dropped by 30%. Do you 
remember what was going on around that time that caused these changes? 
Actor 2 (patient): Yeah, my last doctors tried to switch my meds because they were 
making me nauseas and tired throughout the day. The new combination didn’t work, so 
they put me back on the old meds after a few months. I was actually upset about it 
because physically I felt really great on the new meds. I mean is it really that big of deal 
if my numbers change a little? 
Actor 1 (provider): You know it can often be a fairly complicated process to find the right 
combination of meds for patients. We try to balance out the experience of side effects 
with the effectiveness of the medications, and every patient responds a bit differently. 
Unfortunately, it is a big deal if your viral load and CD4 count change. Those are our best 
indicators of how the HIV virus is progressing in your body, and they can even be better 
indicators then how your body is physically feeling. I actually have a great brochure 
about some of the important information about viral load and CD4 counts. Would you 
like me to go over some of it with you? 
Actor 2 (patient): That would actually be really helpful. 
Narrator: Dr. Everheart stood up from his chair and grabbed a brochure. After walking 
over to the exam table, Dr. Everheart pointed out the key points of the brochure to Mr. 
Johnson and answered any remaining questions that he had.  
Actor 2 (patient): Ok, so I get now why they took me off the new meds, but is there 
anything that you can do to help with the side effects. I can’t be feeling sick all day at my 
new job. I don’t want to make that type of impression. 
Actor 1 (provider): For now, there are a few prescriptions to lessen your symptoms that 
haven’t been tried by your last doctors. And after I get some more detailed results from 
your blood draw today, I will look into the possibility of other medication regimens that 
might be as effective as your current meds but with less side effects. I don’t know if the 
new HIV medications on market will turn out to be a good fit for you, but we can 
definitely look into the possibility. 
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Actor 2 (patient): Ok, fair enough. 
3. Segment 3: 
Narrator: Dr. Everheart handed the brochure to Mr. Johnson and explained that he would 
now be performing a physical examination. 
Actor 1 (provider): Alright, well I am now going to give you a brief physical examination 
to check your heart rate, blood pressure, breathing, and also check out your throat, ears, 
and eyes for normal functioning. 
Narrator: Dr. Everheart approached Mr. Johnson, placing the stethoscope in his ears. He 
stood close to Mr. Johnson, placed the stethoscope on his chest, and listened to his 
breathing for approximately 10 seconds. He then placed the stethoscope on his back and 
listened for another 10 seconds. Dr. Everheart removed the stethoscope from his ears, 
reached for the blood pressure cuff, and placed it on Mr. Johnson’s arm. After taking Mr. 
Johnson’s blood pressure, Dr. Everheart, stood up and walked to the supply cabinet in  the 
exam room. Dr. Everheart returned with a tongue depressor and asked Mr. Johnson to 
open his mouth. Dr. Everheart leaned towards Mr. Johnson and examined the inside of 
his throat thoroughly. Dr. Everheart then felt his lymph nodes on the side of his neck for 
a few moments before returning to his seat near the exam table.  
4. Segment 4:  
Actor 1 (provider): Well everything looks good as far as blood pressure and heart rate. 
And no signs of temperature or cold symptoms. How have you been feeling recently? 
Actor 2 (patient): Pretty good, but I’ve been having a lot of headaches lately.  
Actor 1 (provider): Has anything happened recently to trigger these headaches? Any 
changes in medication, diet, activity level? 
Actor 2 (patient): Not really. 
Actor 1 (provider): Have you been experiencing a lot of stress lately? Everything been 
going ok with friends/family? 
Actor 2 (patient): You know I have been stressed out a lot due to the move, but I really 
don’t think it’s just that. They’re pretty bad. I get shooting pains right behind my eyes, 
and it’s happening at least twice a week. 
Actor 1 (provider): Ok, well I have some ideas for what might be causing these types 
headaches. Those pain symptoms are pretty common for a lot of people especially those 
with a family history of migraines. I’ll check to see if we have some medication samples 
to for you take home and see if they help. They shouldn’t interact with any of your HIV 
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meds, just make sure to take them with food. If after a week you’re still having problems 
we can do some more extensive tests to see what’s going on. Sound okay to you?  
Actor 2 (patient): Sounds good. 
Actor 1 (provider): Great. Well I’m going to go grab those medication samples.  
Narrator: Dr. Everheart left the exam room and returned in several minutes with the 
medication samples. 
Actor 1 (provider): Well we’re just about finished with today’s appointment. But before 
you leave, I’d like to chat with you a little about your current sexual practices and also 
any previous or current alcohol or drug use. I know these types of topics are sensitive in 
nature and can seem a little out of the blue for a regular medical appointment. Basically 
new national standards of medical practice have been created, calling for health care 
providers to assess these types of things at all medical care visits to improve prevention 
of new infections and also to allow for the best care possible for current HIV+ patients. 
It’s important to me that you feel comfortable, so is it okay for me to ask you a few 
questions? 
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Stigma Vignette Male 
1. Segment 1:  
Narrator: Dr. Everheart knocked on the door before entering into the room. He walked 
through door looking at Mr. Johnson’s file and did not look up while introducing himself.  
Actor 1 (provider): Hello Mr. Johnson my name is Dr. Everheart and I’ll be your primary 
physician here at the clinic. How are you doing? 
Narrator: Dr. Everheart takes a seat in a chair on the far side of the room from where Mr. 
Johnson is sitting and begins reviewing his chart. 
Actor 2 (patient): Pretty good, I’m feeling healthy. I’m just a little stressed with having to 
start all over at a new clinic with new doctors. 
Narrator: Dr. Everheart continues to look down at Mr. Johnson’s chart as he speaks.  
Actor 1 (provider): Well, nothing to worry about. Basically all we are going to be doing 
today is going over your medical history and completing a physical exam. I like to be 
thorough with all my new patients, and double check some of the information in their 
files. Your last treatment center sent us your file yesterday, I just have few pieces of 
information that I would like to confirm with you. 
Actor 2 (patient): ok 
Actor 1 (provider): Your chart says that you tested positive for HIV about five years ago 
in February of 2006. 
Actor 2 (patient): Yeah, that’s the story. 
Actor 1 (provider): It says that you most likely became infected from having sex with 
other men. Hopefully becoming positive has motivated you to be more careful with 
reducing your number of sexual partners and using condoms. Oh wait, I see here that you 
were infected by your partner at the time. 
Actor 2 (patient): Yeah. He didn’t realize that he was positive and after 5 or 6 months 
together we weren’t as strict about using condoms all the time. One day he found out one 
of his past hook-ups was positive and we both went in and got tested. Both of us found 
out that we were positive. We’re still together though and he moved here with me.  
Actor 1 (provider): That’s surprising. You really don’t see that nowadays. But, I guess 
you learned your lesson, and at least you both decided to come in and get tested when 
you did.  
Actor 2 (patient): Thanks. 
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2. Segment 2:  
Actor 1 (provider): So it also says that you began taking anti-retroviral medications pretty 
soon after you received your diagnosis. 
Actor 2 (patient): Yeah it was within a few months. 
Actor 1 (provider): And other than a couple bouts of pneumonia in 2007 and 2008, you 
have been pretty healthy. Looks like your viral load and CD4 counts have been pretty 
stable ever since you started taking meds. That is except for the summer of last year when 
your viral load became detectable again and your CD4 count dropped by 30%. Did you 
stop taking your meds? 
Actor 2 (patient): No, actually my last doctors tried to switch my meds because they were 
making me nauseas and tired throughout the day. The new combination didn’t work, so 
they put me back on the old meds after a few months. I was actually upset about it 
because physically I felt really great on the new meds. I mean is it really that big of deal 
if my numbers change a little? 
Actor 1 (provider): Unfortunately, Mr. Johnson it is a big deal if your viral load and CD4 
count change. Those are our best indicators of how the HIV virus is progressing in your 
body. You’ve been positive a while, I assumed you knew all this.  I think I have a 
brochure that can explain viral load and CD4 counts to you. Let me grab it. 
Narrator: Dr. Everheart rose from his chair and grabbed a brochure. Without approaching 
the exam table, he leaned over to hand the brochure to Mr. Johnson. 
Actor 1 (provider): I strongly suggest you review this material. 
Actor 2 (patient): I’ll check this out later, but is there anything that you can do to help 
with the side effects. I can’t be feeling sick all day at my new job. I don’t want to make 
that type of impression. 
Actor 1 (provider): For now, there are a few prescriptions to lessen your symptoms that 
haven’t been tried by your last doctors.  
Actor 2 (patient): What about changing my HIV meds? Can we try something new? I’ve 
been reading a lot about a one-a-day pill. Could we try that? 
Actor 1 (provider): I really don’t think that’s necessary at this point. Your current meds 
are working great, other than a few side effects. But if it’s that important to you, after I 
get some more detailed results from your blood draw today, I will look into the 
possibility of other medication regimens.  
Actor 2 (patient): Ok. 
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3. Segment 3: 
Narrator: Dr. Everheart explained that he would now be performing a physical 
examination. 
Actor 1 (provider): Alright, well I am now going to give you a brief physical examination 
to check your heart rate, blood pressure, breathing, and also check out your throat, ears, 
and eyes for normal functioning. 
Narrator: Dr. Everheart walked to the supply cabinet and grabbed two pairs of latex 
gloves. He put them on his hands and approached Mr. Johnson, placing the stethoscope in 
his ears. He maintained an arm’s length distance from Mr. Johnson, having to stretch his 
arm to place the stethoscope on his chest. Leaning away from Mr. Johnson, he listened to 
his breathing for a few seconds, and then placed the stethoscope on his back and listened 
for another couple seconds. Dr. Everheart removed the stethoscope from his ears, reached 
for the blood pressure cuff, and asked Mr. Johnson’s to place it on his own arm. After 
taking Mr. Johnson’s blood pressure, Dr. Everheart, stood up and again walked to the 
supply cabinet in the exam room. Dr. Everheart returned with a tongue depressor and 
asked Mr. Johnson to open his mouth. Dr. Everheart again maintained an arm’s length 
distance from Mr. Johnson and had a strained look on his face while examining the inside 
of his throat. Dr. Everheart then felt his lymph nodes on the side of his neck for a few 
moments before returning to his seat on the far side of the exam room.  
4. Segment 4:  
Actor 1 (provider): Well everything looks good as far as blood pressure and heart rate. 
And no signs of temperature or cold symptoms. How have you been feeling recently? 
Actor 2 (patient): Pretty good, but I’ve been having a lot of headaches lately.  
Actor 1 (provider): Has anything happened recently to trigger these headaches? Any 
changes in medication, diet, activity level? 
Actor 2 (patient): Not really. 
Actor 1 (provider): Then it’s probably just HIV-related. 
Actor 2 (patient): Well maybe. But they’re pretty bad. I get shooting pains right behind 
my eyes, and it’s happening at least twice a week. 
Actor 1 (provider): Ok, well it sounds like you might be experiencing migraines. I think 
we have some med samples here in the clinic that you could try out, but I’m not really 
sure if migraine medications with interact negatively with your HIV medications. Let me 
check with your nurse practitioner.  
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Narrator: Dr. Everheart walked to the door and opened it far enough to stick his head out 
into the hall. In a moderately loud voice, he called for Mr. Johnson’s nurse practitioner.  
Actor 1 (provider): Christine, will Imitrex interact with Mr. Robert Johnson’s HIV 
regimen? 
Narrator: After Dr. Everheart talked with Christine, he closed the door and turned to face 
Mr. Johnson. 
Actor 1 (provider): Ok, well they shouldn’t interact with any of your HIV meds, just 
make sure to take them with food. If after a week you’re still having problems we can do 
some more extensive tests to see what else might be going on. Sound okay to you? 
Actor 2 (patient): Sounds good. 
Actor 1 (provider): Great. Well I’m going to go grab those medication samples.  
Narrator: Dr. Everheart left the exam room and returned in 15 minutes with the 
medication samples. 
Actor 1 (provider): Well we’re just about finished with today’s appointment. But before 
you leave, I need to ask you a series of questions about your current sexual practices and 
also any previous or current alcohol or drug use.  
 




Draft of Experimental Phase Protocol 
 




I. INFORMED CONSENT 
 
 A. OVERVIEW OF CONSENT INFORMATION 
 
 A participant who gives their informed consent to participate in the study should 
fully understand the nature of the research study, the purpose and pertinent procedures for 
the study, potential risks and benefits of participating, confidentiality and steps taken by 
research team to ensure confidentiality, and how the data will be used and stored.   
 
 B. PARTICIPANT CONSENT 
 
 After a brief introduction, the principle investigator (PI) leads the participant 
through the informed consent form, highlighting the most important aspects of informed 
consent.  The following outline illustrates the content that is verbally expressed by the PI 
during this process:  
 WHO:  The project directors for this study are Jessie Heath, M.S., a clinical 
psychology doctoral student at Syracuse University and Dr. Peter Vanable, an 
associate professor of psychology at Syracuse University and an adjunct assistant 
professor of medicine at SUNY Upstate Medical University. 
  PURPOSE & PROCEDURE:  You are being asked to participate in a research 
study designed to learn more about how aspects of patient-provider relationships 
can affect the medical treatment of persons living with HIV. Our goal is to gain a 
better understanding of how the behaviors of medical care providers within 
medical appointments can affect the HIV+ patients they treat. We will use the 
information obtained in this study to inform the development of strategies to 
improve patient-provider relationships and the quality of medical care received 
HIV+ patients. 
 TIME & COMPENSATION:  Your participation involves viewing a vignette of 
a hypothetical medical care visit and responding to questions using an interactive 
computer program.  The study takes approximately one hour, and you will receive 
$20 for you time. 
 RISKS/BENEFITS:   
o Risks: There are three risks associated with this study. First, you may feel 
uncomfortable answering personal questions. If this occurs, you may 
choose not to answer any question. Second, you may find some aspects of 
the vignette mildly upsetting. A third risk involves the risk of disclosing 
private information to our research team. However, all information that 
you share with members of our team is considered strictly confidential, 
and we are obligated to protect your privacy. 
o Benefits:  You may learn more about your feelings and become aware of 
how aspects of medical treatment experiences can affect you.  In addition, 
because the information you provide assists in the development of 
strategies to improve patient-provider relationships, your participation 
could benefit others living with HIV. 





 CONFIDENTIALITY and HIPPA 
o If you decide to participate, any information that you give us is strictly 
confidential. We will keep your information private, except under 2 
circumstances.   
 First, if you tell us that you’re planning to hurt yourself or 
someone else we would have to disclose that information.  
 Second, if officials were concerned that the research team was 
acting inappropriately, the research records might be audited to 
make sure the research was being conducted ethically; however, 
the auditors would be required to protect your privacy. 
 PROTECTION OF CONFIDENTIALITY  
o All project staff receive extensive training and supervision on 
confidentiality procedures.   
o Your survey is given an identification number and only authorized 
research staff has access to the key that connects your information to your 
name.  Your identity will not be included on the audiotapes and the tapes 
will be erased once we are finished with the project. 
o Certificate of Confidentiality from the Department of Health and Human 
services, which states that the investigators cannot be forced to release 
your information (for example, by subpoena) to any federal, state, or local, 
civil, criminal, administrative, legislative, or other proceedings.  This 
Certificate does NOT prevent you or your family from voluntarily 
disclosing information about yourself or your involvement in this research.   
 PARTICIPATION IS VOLUNTARY:  You may refuse to participate or 
discontinue your participation at any time without penalty or loss of benefits. 
 PERMISSION TO BE RECONTACTED: The participants are then asked to 
sign and date one copy of the consent form and keep a second copy for their own 
records.  Participants are also given a copy of University Hospital’s Privacy 
Practices Policy and asked to keep it for their records.  
 
 C. STORAGE OF CONSENT FORMS 
 
After pertinent information from the completed consent forms has been entered 
into the Excel patient database, the completed focus group consent forms will be stored in 
a locked filing cabinet in the UPH office. 
 
II.  EXPERIMENTAL PROTOCOL ADMINISTRATION 
 
 A. ASSIGNMENT OF PARTICIPANT NUMBER AND CONDITION 
 
After participants consent, they will be assigned a participant ID number and 
randomized to a “high stigma,” “moderate stigma,” or “no stigma” study condition using 
a random number generator. 




B. VIGNETTE AND SURVEY ADMINISTRATION 
  
 The quantitative survey is administered following the informed consent.  The 
participants will be seated in front of a computer, where the PI will introduce the 
computerized study protocol and briefly describe how the computer program works. The 
PI will answer any questions the participant has and ensure the participant’s ability to 
successfully interact with the computer program.  For participants with limited computer 
exposure, the principle investigator will provide additional instruction on the use of the 
mouse and keyboard as necessary.  Participants will also be instructed that if they have 
any difficulties with the computer program to ring a bell on the desk and the principle 
investigator will assist them. Participants will then follow the audio instructions on the 
ACASI program to complete the small battery of self-report assessments and respond to 
the visual and audio treatment vignettes. The ordering of the protocol will be as follows: 
(1) reporting of background and health information, (2) step-by-step presentation of 
treatment vignette with ratings of comfort assessed at several points throughout the 
presented patient-provider interaction, (3) ratings on the Perceptions of Stigmatization 
within the Patient-Provider Interaction scale, (4) ratings on measures assessing intentions 
to engage in care, and (5) ratings on the Experiences of HIV-related Stigmatization in 
Healthcare Settings measure.  
 
C. DATA ENTRY AND STORAGE 
 
Data from the ACASI program will be automatically stored upon completion of 
the protocol and then transformed into an SPSS format for analyses. There will be no 
hard copies of data in the experimental phase of the study and no identifying information 
will present in the ACASI or SPSS files.   
 
 D. PARTICIPANT REIMBURSEMENT 
 
 The PI will retrieve reimbursement funds from Sean Kelley prior to the start of 
the focus group.  Participants will be reimbursed $20 for their one hour of participation in 
the focus groups.  After participants have received their reimbursement, the PI will 
complete a reimbursement receipt including only the participant’s ID number and file it 
in the UPH filing cabinet under non-reconciled payment receipts.  The original 
reimbursement form will then be turned in to Sean Kelley.  A photocopy will be stored in 
the UPH filing cabinet under reconciled payment receipts.   
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SUNY UPSTATE MEDICAL UNIVERSITY AND 
SYRACUSE UNIVERSITY 
Consent/Authorization Form 




You are invited to participate in a research study designed to learn more about how 
aspects of patient-provider relationships can affect the medical treatment of persons 
living with HIV. Our goal is to gain a better understanding of how the behaviors of 
medical care providers within medical appointments can affect the HIV+ patients they 
treat. We will use the information obtained in this study to inform the development of 
strategies to improve patient-provider relationships and the quality of medical care 
provided to persons living with HIV. The directors of this study are Jessie Heath, M.S., a 
clinical psychology doctoral student and Dr. Peter Vanable, an Associate Professor of 
Psychology at Syracuse University and an Adjunct Assistant Professor of Medicine at 
SUNY Upstate Medical University.  Other trained research staff will also be involved, 
and will be supervised by Drs. Peter Vanable of Syracuse University. We are asking 
approximately 150 patients to participate in the study. 
 
You will be given enough time to read and understand the information provided in this 
consent and authorization form. Please ask the study staff to explain any words or 
information that you do not understand. You may keep an unsigned copy of this consent 
and authorization form to think about your decision or discuss with your family, friends, 




If you decide to take part in this study, you will listen and respond to information that is 
presented individually to you on a computer. You will be randomly assigned to view one 
of two vignettes representing a typical, first-time medical care visit of an HIV+ patient. 
On the computer, you will hear audio descriptions of the medical visit, conversations 
between the hypothetical patient and provider, and also view pictures of the interaction.  
Throughout, and following the presentation of the vignette, you will answer questions 
presented on the computer screen regarding your feelings and opinions about what you 
are viewing. You will then respond to questions related to health, sexual behavior, and 
substance use. The study takes approximately one hour to complete, and your 
participation is completely voluntary. 
 
If you agree to participate in the study, you will also be asked to complete a brief survey 
with questions about your background and health information, including medical 
appointment attendance, hospitalizations, and recent indicators of health status (CD4 
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There are three risks associated with this study. First, you may feel uncomfortable 
answering personal questions. If this occurs, you may choose not to answer any question. 
Second, you may find some aspects of the vignette mildly upsetting. A third risk involves 
the risk of disclosing private information to our research team. However, all information 
that you share with members of our team is considered strictly confidential, and we are 




The potential benefits are that you may learn more about your feelings and become aware 
of how aspects of medical treatment experiences can affect you.  In addition, because the 
information you provide assists in the development of strategies to improve patient-
provider relationships, your participation could benefit others living with HIV. 
 
Voluntary Participation:  
 
Your participation in this study is entirely voluntary and you may refuse to participate or 
stop participation at any time without penalty or loss of benefits to which you would 
normally be entitled.  Your decision about whether or not to participate in the study will 




If you decide not to participate in this research study, you will continue to receive your 




There are no costs to you and/or your insurance carrier for participating in this study. 
After completing the study, you will receive $20 to offset your expenses and to thank you 
for your time. 
 
If you choose to stop participating in the study before all study requirements are 
completed, you will be paid $10 for each ½ hour of time you devote to the study. 
 
In addition, by accepting payment for participating in this study, certain identifying 
information about you may be made available to professional auditors to satisfy audit and 
Federal reporting requirements, but confidentiality will be preserved. Please note that if 
you earn $600 or over in a calendar year as a research subject, you may have to pay taxes 




If you have any questions about the research, please contact Ms. Jessie Heath at (315) 
443-1052 or Dr. Peter Vanable at (315) 443-2024.  If you have any questions about your 
rights as a research subject, please contact the SUNY Upstate Medical University 
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Institutional Review Board Office at (315) 464-4317 or the Syracuse University 
Institutional Review Board Office at (315) 443-3013. 
 
Confidentiality of Records and Authorization to Use/Share Protected Health 
Information for Research: 
 
If you agree to participate in this research, identifiable health information about you 
will be used and shared with others involved in this research. For you to be in this 
research we need your permission to collect and share this information. Federal law 
protects your right to privacy concerning this information.  
 
When you sign this consent form at the end, it means that you have read this section and 
authorize the use and/or sharing of your protected health information as explained below. 
Your signature also means you have received a copy of Upstate’s Notice of Privacy 
Practices. 
 
Individually identifiable health information under the federal privacy law is considered to 
be any information from your medical record, or obtained from this study, that can be 
associated with you, and relates to your past, present, or future physical or mental health 
or condition. This is referred to as protected health information. 
 
Your protected health information will be kept confidential. Research staff will not share 
the information you provide during the discussion group and on the survey with your 
doctor or nurse here in the clinic. Further, you will not be identified in any publication or 
presentation resulting from this study. Several steps have been taken to protect the 
confidentiality of your responses and involvement in this research.  Project staff has 
participated in extensive training and supervision regarding the importance of 
maintaining participant confidentiality.  In addition, an identification number will be 
assigned to your survey, and only the directors of this research (Jessie Heath, M.S. and 
Dr. Vanable) will have access to the key that indicates which number belongs to which 
participant. The master list linking the participant ID number to the participant’s 
identifying information will be maintained in a separate, secure computer database, and 
will be destroyed at the conclusion of the study.  Your name or other identifying 
information will not be kept with your survey, and your survey information will be stored 
in a secure computer database.  
 
To help us further protect your privacy, the investigators have received a Confidentiality 
Certificate from the Department of Health and Human Services.  With this Certificate, 
the investigators cannot be forced (for example by court subpoena) to disclose research 
information that may identify you in any Federal, State, or local, civil, criminal, 
administrative, legislative, or other proceedings. The researchers will use the Certificate 
to resist any demands for information that would identify you, except as explained below. 
 
The Certificate cannot be used to resist a request for information from personnel of the 
United States Department of Health and Human Services that is used for auditing or 
evaluation of federally funded projects. 
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In addition, the Confidentiality Certificate does not prevent you or a member of your 
family from voluntarily releasing information about yourself or your involvement in this 
research. Note however, that if an insurer or employer learns about your participation, 
and obtains your consent to receive research information, then the investigator may not 
use the Certificate of Confidentiality to withhold this information. This means that you 
and your family must also actively protect your own privacy.  
 
Why is it necessary to use/share your protected health information with 
others? The main reason to use and share your health information is to conduct the 
research as described in this consent form. Your information may also be shared 
with people and organizations that make sure the research is being done correctly, 
and to report unexpected or bad side effects you may have. In addition, we will 
release protected health information about you if we learn about your intent to harm 
yourself or others. 
 
What protected health information about you will be used or shared with others as 
part of this research? We may use and share the results of tests, questionnaires, and 
interviews. We will only collect information that is needed for the research. 
 
Who will be authorized to use and/or share your protected health 
information? The researchers, their staff and the staff of Upstate Medical University 
participating in the research will use your protected health information for this 
research study. In addition, the Upstate Medical University and Syracuse University 
Institutional Review Boards (IRB), committees responsible for protecting the rights 
of research subjects, and other Upstate Medical University, Syracuse University, or 
University Hospital staff who supervise the way the research is done, may have 
access to your protected health information.  
 
The researchers and their staff will determine if your protected health information 
will be used or shared with others outside of Upstate Medical University and 
Syracuse University for purposes directly related to the conduct of the research.  
 
With whom would the protected health information be shared? Your protected 
health information may be shared with: 
 
 Federal agencies that supervise the way the research is conducted, such as the 
Department of Health and Human Services’ Office for Human Research 
Protections or the National Institutes of Health.  
 
 Researchers from Syracuse University assisting in the study. 
 
 The Syracuse University Institutional Review Board (a committee responsible for 
protecting the rights of research subjects). 
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All reasonable efforts will be used to protect the confidentiality of your protected 
health information. However, not all individuals or groups have to comply with the 
Federal privacy law. Therefore, once your protected health information is disclosed 
(leaves Upstate Medical University), the Federal privacy law may not protect it.   
 
For how long will your protected health information be used or shared with 
others? There is no scheduled date at which this information will be destroyed or no 
longer used. This is because information that is collected for research purposes continues 
to be used and analyzed for many years and it is not possible to determine when this will 
be complete. 
 
Can you withdraw your authorization to collect/use/share your protected 
health information? You always have the right to withdraw your permission 
(revoke authorization) for us to use and share your health information, by putting 
your request in writing to the investigator in charge of the study.  This means that 
no further private health information will be collected. Once authorization is 
revoked, you may no longer participate in this research activity, but standard medical 
care and any other benefits to which you are entitled will not be affected. Revoking 
your authorization only affects uses and sharing of information obtained after your 
written request has been received, but not information obtained prior to that time.  
 
Even after you withdraw your permission, Upstate Medical University may continue 
to use and share information needed for the integrity of the study; for example, 
information about an unexpected or bad side effect you experienced related to the 
study.  
 
Can you have access to your health information? At the end of the study, you have 
the right to see and copy health information about you in accordance with the SUNY 
Upstate Medical University policies; however, your access may be limited while the 
study is in progress.  
 
Permission To Contact For Follow-Up Research 
We may conduct additional research on this important topic.  May we contact you about 
participation in future studies?  Indicating you are willing to be contacted does not 
obligate you to participate in any other study, nor does it affect your participation in this 
study.  
 
  No, I prefer not to be contacted about future studies.  
  Yes, I am willing to be contacted about future studies.  
 
Phone: _______________  
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Consent To Participate In Research & Authorization To Use And Share Personal 
Health Information: 
 
I hereby give my consent to participate in this research study and agree that my personal 
health information can be collected, used and shared by the researchers and staff for the 
research study described in this form. I will receive a signed copy of this consent form. 
  
 
______________________________________   __________________ 




Printed Name of Research Participant 
 
 
___________________________________________  __________________ 
Signature of Person Obtaining Consent/Authorization  Date 
 
 
___________________________________________   
Printed Name of Person Obtaining Consent/Authorization 
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 Role: Principle Investigator 
 Co-Investigator: Peter A. Vanable, Ph.D. 
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Syracuse University Psychology Department Dissertation Research Award. 
 Funded by the Psychology Department of Syracuse University. 
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Syracuse Veterans Affairs Medical Center  
Supervisors: Kyle Possemato, Ph.D. and Paige Ouimette, Ph.D. 
 NIAAA R03 Grant: Assessing Naturalistic Course of PTSD Among Patients with 
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- Principal Investigator: Paige Ouimette, Ph.D. (Syracuse VAMC, 
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- Member of a health psychology laboratory specializing in the study of 
Posttraumatic Stress Disorder and Substance Dependence. 
- Performed structured clinical interviews for three longitudinal studies 
assessing the presence of current and lifetime posttraumatic stress 
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symptoms (Clinician Administered PTSD Scale) and substance use 
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persons receiving care at chemical dependency treatment centers. 
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Michael First, Ph.D.), CAPS, LIFE, and Time-line Follow-back 
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Syracuse University 
Supervisor: Peter A. Vanable, Ph.D.  
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- Principal Investigator: Peter A. Vanable, Ph.D. (Syracuse University)  
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American adolescents.  
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collection, data entry, data analysis, and manuscript preparation. 
- Assisted in managing intervention workshops for HIV+ MSM and co-
facilitated focus groups pertaining to stress management strategies 
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Research Assistant: Alcohol Research Lab          2009-2010 
Syracuse University 
Supervisor: Stephen Maisto, Ph.D. 
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- Principal Investigator: Stephen A. Maisto, Ph.D. (Syracuse University)  
 Experiences: 
- Member of a health psychology laboratory studying risk behaviors 
related to substance use and HIV transmission among MSM. 
- Participation in experimental data collection involving alcohol 
administration, data entry, data analysis, and manuscript drafting. 
- Experience with participant recruitment and screening via telephone 
interviews and outreach events with the LGBT community.  
 
Undergraduate Research Assistant: HIV Research Group         2003-2005 
University of Missouri-KC 
Advisor and Principle Investigator: Kathy Goggin, Ph.D.  
 Experiences: 
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- Research assistant in an active health psychology lab studying risk 
behaviors related to HIV transmission, HIV medication adherence, and 
alcohol and condom use among at-risk populations. 
- Completed interviews with clients at the Kansas City Free Health 
Clinic regarding their experience with the HIV Counseling and Testing 
program at the clinic.  Reported findings in quarterly evaluations. 
 
Teaching and Training Experience 
 
PTSD and Substance-related Disorders Assessment Training       2011 
Syracuse VAMC-Center for Integrated Health 
 Supervisor of Clinical Assessment Training for Research Staff 
- Organized content and developed the structure of a 4 day seminar to 
train new research staff in the clinical assessment of PTSD and 
substance-related disorders. 
- Trained staff on the background and implementation of the Clinician 
Administered PTSD Scale (CAPS) and Substance Use Disorders SCID 
module using verbal instruction, training videos, role plays, and step-
by-step analysis of audio recordings of actual clinical interviews. 
 
Psychology 395: Abnormal Psychology            2008-2009 
Syracuse University  
Supervised by Peter A. Vanable, Ph.D.            
 Teaching Assistant: Primary Instructor       
- Organized content and developed the structure of an advanced level 
undergraduate course. 
- Taught classes of 60-80 students using PowerPoint presentations, class 
discussions and activities, and video representations of mental health 




Psychology 470: Experience Credit               2007-2008, 2010-2011 
Syracuse University  
Supervised by Peter A. Vanable, Ph.D.    
 Graduate Student Mentor  
- Mentored two undergraduates in carrying out experimental research 
protocol. 
- Trained students in data collection and analysis procedures and also 
supervised the development of several poster presentations.  
 
Syracuse University Summer PRIDE (Psychology Research and        2010, 2011 
Diversity Enhancement) Program             
Supervised by Peter A. Vanable, Ph.D. 
 Graduate Student Mentor 
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- Mentored two undergraduates from ethnically diverse backgrounds in 
data collection and analysis procedures and also supervised the 
development of oral presentations.  
 
Program Evaluation Services 
 
SUNY Upstate Medical University Infectious Disease Clinic, Syracuse, New York  
 Consultant 
- Conducted focus groups and analyzed data from patient feedback 
surveys regarding mental health, case management, and treatment 
adherence services provided to HIV+ patients through funding from 
Ryan White Care grants. 
- Created reports informing clinic staff of patients’ perceptions of 
quality of care, impact of services received, and suggestions for further 
improvement. 
- Completed phone interviews with young (17-25), HIV+ men who have 
sex with men regarding current sexual practices, partner seeking 
behaviors, and condom use to create a qualitative report for New York 
Department of Health.  
 
Awards and Honors 
 
APA Division 38 Student Research Award                    2010 
Summa Cum Laude, University of Missouri-Kansas City                        2004 
Graduation with Honors, University of Missouri-Kansas City                 2004 
Excellence in Research Award – SEARCH 1
st
 place (UMKC)         2004 
University of Missouri – Kansas City Honors College Scholar             2004 
University of Missouri – Kansas City Honors Student                    2002-2004 
Dean’s List at University of Missouri – Kansas City          2002-2004 
Dean’s List at University of Miami            2001-2002 
President’s and Provost’s Honor Roll at University of Miami                   2001-2002 
Bank of America Joe Martin Scholarship           2001-2004 
Hersch Norman Memorial Scholarship                    2001 
Wal-Mart All American Scholarship                    2001 




Society of Behavioral Medicine (SBM)               
American Psychological Association (APA)             
 Division 38, Health Psychology  
Association of Behavior and Cognitive Therapies (ABCT) 
         
Honorary Memberships 
 
The National Honor Society in Psychology (Psi Chi)      
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Golden Key International Honor Society       




Ad-hoc reviewer: Journal of Social and Clinical Psychology  
Ad-hoc reviewer: BioMedCentral  
Ad-hoc reviewer: Archives of Women’s Health 









Kansas City Free Health Clinic, Kansas City, MO         2004-2005 
Supervised by: Jamie Stevens, MA 
 Certified Counselor in HIV Testing 
- Received state certification for HIV Counseling and Testing in June of 
2004. 
- Conducted psycho-education counseling sessions with persons being 
tested for HIV by assessing client’s risk level, creating personalized 
risk reduction plans, and educating clients about HIV and sexually 
transmitted diseases 
- Administered Orasure HIV tests. 
 
Metropolitan Organization to Counter Sexual Assault     2004 
Kansas City, MO  
 Support Group Facilitator 
- Facilitated a support group for adult survivors of childhood sexual 
abuse entitled Survivors United Reaching Empowerment (SURE).  
- Received training in supportive counseling techniques, emergency 
response intervention, and in giving community education 
presentations regarding sexual abuse and assault. 
 
 
 
 
